Clinical Development
Afinitor®/Votubia® (everolimus)
Clinical Trial Protocol CRAD001M2304 / [STUDY_ID_REMOVED]
A three -arm, randomized, double -blind, placebo -controlled 
study of the efficacy
 and safety of two trough- ranges of 
everolimus as adjunctiv e therapy in patients w ith tuberous 
sclerosis complex (TSC) w ho hav e refractor y partial -onset 
seizures
Authors
Document type Amended Protocol Version
EUDRACT number 2011 -000860 -90
Version number 03 (Clean )
Development phase III
Document status Final
Release date 25-Mar-2016
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]

[COMPANY_001] Confidential Page 2
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table of contents
Table of contents ................................................................................................................. [ADDRESS_760837] of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 10
Amendment 3 (25 -Mar-2016) ........................................................................................... 11
Summary  of previous amendments ................................................................................... 13
Protocol summary .............................................................................................................. 23
1Background ........................................................................................................................ 25
1.1 Overview of Tuberous Sclerosis and current treatment options ............................ 25
1.1.1 Epi[INVESTIGATOR_579097] h TSC ............................................................... 25
1.1.2 Role of mTOR in TSC and epi[INVESTIGATOR_58753].......................................... 26
1.1.3 Rapamy cin and everolimus (RAD001) in TSC -epi[INVESTIGATOR_002] ...................... 29
1.2 Introduction to investigational treatment(s) and other study  treatment(s) ............. 32
1.2.1 Overview of everolimus (RAD001) ...................................................... [ADDRESS_760838] Extension Phase ............................................................................. 46
4.1.5 Definition of end of the study ............................................................... 47
4.2 Early study termination .......................................................................................... 47
5Population .......................................................................................................................... 47
5.1 Patient population .................................................................................................. 47
5.2 Inclusion criteria .................................................................................................... 47
5.3 Exclusion criteria ................................................................................................... 51
6Treatment ........................................................................................................................... 53
6.1 Study  treatment ...................................................................................................... 53
6.1.1 Dosing Regimen .................................................................................... 53

[COMPANY_001] Confidential Page 3
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
6.1.2 Rescue medication ................................................................................ 57
6.1.3 Treatment duration ................................................................................ 57
6.2 Dose modification guidelines ................................................................................ 58
6.2.1 Starting dose rationale ........................................................................... 58
6.2.2 Dose Titration ........................................................................................ 59
6.2.3 Rounding of doses ................................................................................. 60
6.2.4 Dose reduction or delay ........................................................................ 61
6.2.5 Management of specific toxicity ........................................................... 63
6.3 Concomitant medications ...................................................................................... 68
6.3.1 Permitted concomitant therap y requiring caution and/or action ........... [ADDRESS_760839] Extension phase ............................................................................. 91
7.1.6 End of treatment visit and premature withdrawal ................................. 91
7.1.7 Follow up/Study  completion ................................................................. 93
7.2 Assessment ty pes................................................................................................... 94
7.2.1 Eligibility  assessments .......................................................................... 94
7.2.2 Efficacy  assessments ............................................................................. 95
7.2.3 Safety  and tolerability  assessments ....................................................... 95
7.2.4 Pharmacokinetics ................................................................................ 104
7.2.5 Patient reported outcomes ................................................................... 111

[COMPANY_001] Confidential Page 4
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
8Safety  monitoring and reporting ...................................................................................... [ADDRESS_760840] ....................................................... 113
8.2 Serious adverse events ......................................................................................... 113
8.2.1 Definitions........................................................................................... 113
8.2.2 Reporting............................................................................................. 114
8.3 Emergency  unblinding of treatment assignment ................................................. 115
8.4 Pregnancies .......................................................................................................... 115
8.5 Warnings and precautions .................................................................................... 116
8.6 Data Monitoring Committee ................................................................................ 116
8.7 Steering Committee ............................................................................................. 116
9Data collection and management ..................................................................................... 116
9.1 Data confidentiality ............................................................................................. 116
9.2 Site monitoring .................................................................................................... 117
9.3 Data collection..................................................................................................... 117
9.4 Database management and quality  control .......................................................... 118
10Statistical methods and data anal ysis.............................................................................. 119
10.1 Analy sis sets ........................................................................................................ 119
10.1.1 Full Anal ysis Set ................................................................................. 119
10.1.2 Safety  Set ............................................................................................ 119
10.1.3 Per- Protocol Set .................................................................................. 120
10.1.4 Long -Term Evaluation Set .................................................................. 120
10.2 Patient demographics/other baseline characteristics ........................................... 120
10.3 Treatments (stud y treatment, concomitant therapi[INVESTIGATOR_014]) .......................................... 120
10.3.1 Study  medication ................................................................................. 120
10.3.2 Concomitant medication ..................................................................... 121
10.4 Primary  objective ................................................................................................. 121
10.4.1 Variable ............................................................................................... 121
10.4.2 Statistical hy pothesis, model, and method of analy sis........................ 122
10.4.3 Handling of missing values/censoring/discontinuations ..................... 123
10.4.4 Supportive and sensitivity anal yses.................................................... 123
10.5 Secondary  objectives ........................................................................................... 124
10.5.1 Efficacy  objectives .............................................................................. 124
10.5.2 Safety  objectives ................................................................................. 126

[COMPANY_001] Confidential Page 5
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
10.5.3 Pharmacokinetics ................................................................................ 128
10.5.4 Patient- reported outcomes ................................................................... 129
129
129
129
10.7 Interim anal ysis.................................................................................................... 130
10.8 Sample size calculation........................................................................................ 130
11Ethical considerations and administrative procedures .................................................... 131
11.1 Regulatory  and ethical complianc e...................................................................... 131
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... [ADDRESS_760841] keepi[INVESTIGATOR_5304]..................... 132
11.7 Confidentiality  of study documents and patient records ..................................... 133
11.8 Audits and inspections......................................................................................... 133
11.9 Financial disclosures ............................................................................................ 133
12Protocol adherence .......................................................................................................... 134
12.1 Amendments to the protocol ................................................................................ 134
13References (available upon request) ................................................................................ 135
14Appendix A: Using Diffusion Tensor Imaging (DTI) with Tractograph y to Measure 
the Treatment Effect of Everolimus in Tuberous Sclerosis Complex (TSC) Patients 
with Epi[INVESTIGATOR_002] : An EX IST-[ADDRESS_760842] ..................................................................................................... 148
14.4.5 Analy sis of Benefit and Risk for DTI Sub -study  Participation ........... 148

[COMPANY_001] Confidential Page 6
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
List of figures
[ADDRESS_760843] of tables
Table 1 -1 Everolimus – Drug Substance ............................................................... 33
Table 3 -1 Objectives and related endpoints .......................................................... 38
Table 4 -1 PK sampling and dose titration events during Core phase.................... 43
Table 4 -2 PK sampling and dose titration events during Extension phase ........... 44
Table 4 -3 Dose transition of everolimus to 6 -10 ng/ml beginning at Week 26 ....46
Table 5 -1 Diagnostic Criteria for Tuberous Sclerosis Complex ........................... 48
Table 6 -1 Dose and Treatment Sche dule............................................................... 53
Table 6 -2 Starting dose .......................................................................................... 56
Table 6 -3 Predicted pre -dose concentrations in patients of different age 
groups after the per protocol starting dose ............................................ 59
Table 6 -4 Examples for how to dose a patient ...................................................... 60
Table 6 -5 Everolimus dose modification guidelines for non -hematologic 
toxicities ................................................................................................ 62
Table 6 -6 Dosing guidelines for study  drug -related hematologic toxicities ......... 63
Table 6 -7 Management of non -infectious pneumonitis ......................................... 66
Table 6 -8 Action to be taken based on screening hepatitis B results .................... 67
Table 6 -9 Guidelines for the management of hepatitis B reactivation .................. 67
Table 6 -10 Guidelines for the management of hepatitis C flare .............................. 68
Table 6 -11 Clinically  relevant drug interactions: inducers, and inhibitors of 
isoenzy me CYP3A4 .............................................................................. 70
Table 6 -12 Clinically  relevant drug inter actions: substrates, inducers, 
inhibitors of PgP and PgP/CYP3A4 dual inhibitors ............................. [ADDRESS_760844] Extension Phase Treatment ........................................................... 75
Table 7 -1 Visit evaluation schedule ...................................................................... 77

[COMPANY_001] Confidential Page 7
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7 -2 Visit Evaluation Schedule: Post Extension Phase ................................. 84
Table 7 -3 Central Clini cal laboratory parameters collection plan ....................... 101
Table 7 -4 Everolimus/Placebo PK Sample L og Table for Study  core phase, 
Visits 0 -11(777) .................................................................................. [ADDRESS_760845] -Extension phase ..106
Table 7 -7 PK Sample L og Table for Carbamazepi[INVESTIGATOR_050] .......................................... 107
Table 7 -8 PK Sample L og Table for Oxcarbazepi[INVESTIGATOR_050] .......................................... 107
Table 7 -9 PK Sample L og Table for Clonazepam .............................................. 107
Table 7 -10 PK Sample L og Table for Diazepam .................................................. 107
Table 7 -11 PK Sam ple L og Table for Clobazam .................................................. 108
Table 7 -12 PK Sample L og Table for Felbamate .................................................. 108
Table 7 -13 PK Sample L og Table for Phenobarbital ............................................ 108
Table 7 -14 PK Sample L og Table for Pheny toin.................................................. 109
Table 7 -15 PK Sample L og Table for Primidone .................................................. 109
Table 7 -16 PK Sample L og Table for Topi[INVESTIGATOR_052] ................................................ 109
Table 7 -17 PK Sample L og Table for Valproic acid ............................................. 110
Table 7 -18 PKSample L og Table for Zonisamide................................................ 110
Table 10 -1 Supportive and sensitivity anal yses for primary  objective ................. 124
Table 10 -2 Sample size and power for primary  objective ..................................... 130

[COMPANY_001] Confidential Page 8
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
List of abbreviations
AE Adverse Ev ent
AED Anti-epi[INVESTIGATOR_579098]/glutamic pyruvic transaminase/GPT
AMH Anti-Mullerian Hormone
ANC Absolute neutrophil count
ANCOVA Analysis of covariance
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
BSA Body surface area
CI Confidence interval
CMH Cochran -Mantel -Haenszel
Cmin Minimum (trough) pre -dose concentration
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
C-SSRS Columbia Suicide Severity Reporting Scale
CTCAE Common Terminology Criteria for Adverse Events
CYP3A4 Human cytochrome P450 3A4
DDI Drug -drug interaction
DMC Data Monitoring Committee
DMPK/BA Drug Metabolism and Pharmacokinetics / Bioanalytics
ECG Electrocardiogram
eCRF Electronic Case Report/Record Form
EEG Electroencephalogram
EIAED Enzyme inducing anti -epi[INVESTIGATOR_579099] B Virus
HCV Hepatitis C Virus
HDL High Density Lipoprotein
HIV Human Immunodeficiency Virus
HRQoL Health Related Quality of Life
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
IUD Intrauterine Device
IUS Intrauterine System
LDL Low Density Lipoprotein
mTOR mammalian Target Of Rapamycin
PgP P-glycoprotein
PK Pharmacokinetics
PPS Per Protocol Set
QOL Quality of life
QOLCE Quality of Life in Childhood Epi[INVESTIGATOR_579100] -31-P Quality of Life in Epi[INVESTIGATOR_261379] -31-Problems

[COMPANY_001] Confidential Page 9
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
QOLIE -AD-[ADDRESS_760846] Upper limit of normal
VABS -II Vineland Adaptive Behavior Scales 2ndEdition
VEGF Vascular endothelial growth factor
VNS Vagal nerve stimulator
WBC White blood cell
WNV Wechsler Non -Verbal Scale of Ability

[COMPANY_001] Confidential Page 10
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_339548] (total daily or weekly etc .) 
Enrollment Point/time of patient randomization into the study; informed consent must be obtained 
prior to screening (i.e. prior to starting any of the procedures described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with “investigational new 
drug.”
Investigational 
treatmentDrug whose properties are being test ed in the study as well as their associated placebo 
and active treatment controls (when applicable). This also includes approved drugs 
used outside of their indication/approved dosage, or that are tested in a fixed 
combination. Inv estigational treatment generally does not include other study 
treatments administered as concomitant background therapy required or allowed by [CONTACT_348404]/dosage
Medication number A unique identifier on the label o f each study treatment package which is linked to one 
of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures that was 
not included in the investigational treatment
Patient number A unique identifying number assigned to each patient /subject /healthy volunteer who 
enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening, baseline, titration, washout, etc.
Premature patient 
withdrawalPoint/time when the patient exits from the study prior to the planned completion of all 
study treatment administration and/or assessments; at this time all study treatment 
administration is discontinued and no further assessme nts are planned, unless the 
patient will be followed for progression and/or survival
Randomization number A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the patient 
(subject) as part of the required study procedures, including placebo and active drug 
run-ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason; may 
or may not also be the point/time of premature patient with drawal
Treatment group A treatment group defines the dose and regimen or the combination , and may consist 
of 1 or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified time points

[COMPANY_001] Confidential Page 11
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Amendment 3 (25-Mar-2016)
Amendment rationale
As of February  26, 2016, [ADDRESS_760847] been randomized, 87 patients discontinued 
treatment and 279patients arestill ongoing in the Extension phase .
In December 2015, the primary  analysis of study  data (data cutoff: October 2, 2015) was 
performed. The primary endpoint of the study  was met when a clinically  and statisticall y 
significant reduction in seizure frequency  and increase in response rate, durin g the 
maintenance period of the Core Phase, was observed among patients randomized to the high 
everolimus Cmin range treatment arm (HT) and to patients randomized to the low everolimus 
Cmin range arm (LT) , when compared to patients randomized to placebo. Safety  for the 3 
treatment arms was also assessed. The Study  Steering Committee assessed the results and 
concluded that everolimus treatment offered study  patients a positive and compelling 
Benefit/Risk.
Protocol Amendment 3 to this Study  has been prepared for the following reasons:
Major changes
1.To create a new phase of the study  (Post -Extension phase) that will permit the opportunity  
for patients remaining in the study  to receive ongoing treatment with everolimus and for 
the study  to extend the monitoring and collection of everolimus exposure, as well as safet y 
measures during this longer study  participation and drug exposure phase .
As patients were receiving a benefit from participation in the study , it w as decided to 
extend the End of the Study  until a date when either, everolimus could be 
commerciall y available to study participants or until it would be reasonable to expect 
that a roll over protocol could be opened at stud y sites, so that patients benefi ting 
from continued treatment with everolimus, prior to the commercial availability  of the 
drug, could exit this study , and enter the rollover protocol (as referenced in Sections 
4.1.3 and 4.1.4). This strategy  will allow closure of this study  by [CONTACT_37112] 3 0, 2017 
(approximately  [ADDRESS_760848] been the end of study , had the study  
been c losed at the completion of the E xtension phase), and the creation of a final CSR.
To permit the completion of the Extension Phase and the generation of a Clin ical 
Study  Report covering E xtension phase , as originally  envisioned.
2.To provide investigators with independent control of patient dosing ,targeting a trough 
level within 5 -15 ng/ml, subject to safety and tolerability. This allows for more 
personalized and clinically  relevant increases or decreases in dose titrations to more 
rapi[INVESTIGATOR_579101] y permit titration of the everolimus dose to a level that creates a 
desired Cmin.
Minor changes
1.While making the necessary  changes in the protocol to facilitate th e objectives described 
above, some additional clarify ing language was included.
2.To clarify  protocol text
3.To update pregnancy section based on the revised pregnancy  follow up language .

[COMPANY_001] Confidential Page 12
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
4.To update the DTI sub -study  to take account of the fact that onl y about [ADDRESS_760849] been simplified to descriptive analy ses onl y, 
and no attempt will now be made to correlate findings with the primary  outcome measure 
of seizure frequency .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Major changes
Changes due to the addition of the Post Extension phase and continued monitoring of 
dosing, exposure, and safety  as a result of the extension of treatment
Protocol summary , Section 2.2, 4.1, 4.1.3, 4.1.4, 4.1.5, 6.1.1, 6.1.2, 6.1.3, 6.2.2, 6.2.4, 
6.5.2, 7.1, 7.1.5, 7.1.6, [IP_ADDRESS], 7.2.3, [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS] , 
[IP_ADDRESS].1, [IP_ADDRESS].2, [IP_ADDRESS].3, [IP_ADDRESS].4, [IP_ADDRESS].6, 7.2.4, 10, 10.1.4, Figure 4 -1,
Table 7 -1, Table 7 -2, Table 7 -5, Table 7 -6
Updates to allow Investigators to request more personalized and clinically  relevant dosing
Section 4.1.4, 6.1.1, 6.2.2, 6.2.4, 7.1.5
Minor changes
Corrections made related to clarify  protocol text
Glossary  of terms, Section 4.1, 4.1.3, 6.2.3, [IP_ADDRESS], 7.1.2, 7.1.4, [IP_ADDRESS], [IP_ADDRESS], 
[IP_ADDRESS].6, [IP_ADDRESS], 7.2.4, 7.2.5, 8.6 , Table 6 -11, Table 6 -12
Updates to pregnancy language
Section [IP_ADDRESS].6
Corrections made to update the DTI sub -study  to take account of the lower than expected 
sample size (n ≈15 instead of n=50)
Appendix A, Section 14.1, 14.2, 14.3.1, [IP_ADDRESS], [IP_ADDRESS]
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protoco l amendment.

[COMPANY_001] Confidential Page 13
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Summary  of previous amendments
Amendment [ADDRESS_760850] been randomized, 3 patients discontinued 
treatment and with 36patients still in the baseline phase.
Amendment 2 has been prepared for the following reasons.
Major Changes
1. To include an additional 10 patients to the everolimus 9 to 15 ng/ml trough range arm, to 
account for a potential loss in power
A human error was identified resulting in the failure of the IRT s ystem to perform 
dose tit rations in the presence of C minvalues outside the targeted trough ranges for 
patients randomized to everolimus (high trough range: 9-15ng/ml and low trough 
range: 3 -7ng/ml). The error was corrected, but it is estimated that some patients 
randomized to the high trough range may  not have achieved the targeted exposure to 
everolimus. As a result, it was decided to increase the sample size in the everolimus 9 
to 15 ng/ml trough range arm by  [ADDRESS_760851] of the study .
2.Inclusion criteria 3 updated to expand the definition of partial onset seizures (POS) and 
include sensory  seizures as the sole seizure t ype if confirmed to be partial onset by [CONTACT_579216]
Associated eligibility  criteria are updated as a result of this change which include the 
updated definition of partial onset seizures for Inclusion criteria 4 and the removal of 
Exclusion criteria 2
Sensory  seizures had been excluded from the counti ng of partial onset seizures. The 
intent f or this exclusion was to limit seizure counting to objectivel y assessable 
seizures (i.e., motor events that can be observed by  [CONTACT_19015]). Yet, investigators 
have noted that sensory  events confirmed to be seizures by  [CONTACT_579217] 
a seizur e as least as “probable” as a motor event, not confirmed by  [CONTACT_579218]. As a 
consequence, this amendment includes the expansion of the definition of partial onset 
seizures suitable for counting in this study , to include sensory  seizures confirmed by  
[CONTACT_579218]. By [CONTACT_579219], it has become necessary  to 
expand the definition of sensory  seizures to two subcategories (those confirmed by  
[CONTACT_579220] b y EEG).

[COMPANY_001] Confidential Page 14
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
3. Exclusion criteria 4 clarifie d to exclude patients < 2 y ears of age with untreated infantile 
spasms
It has been recognized over the course of the trial that many  patients with epi[INVESTIGATOR_579102], following effective treatment for infantile spasms, may  be inadvertently  
excluded from the study , based on the exclusion criteria of “infantile spasms” 
Therefore, the exclusion is herein modified to “untreated infantile spasms”. This 
modification will clarify  the eligibility  of patients with residual epi[INVESTIGATOR_579103] ,as originall y intended .
4. A ddition of Exclusion criteria 26 related to patients on a ketogenic diet defined as < 40g 
of carboh ydrate a day
The amendment adds ketogenic diet, defined as “< 40 g of carboh ydrate/day”.
Ketogenic diet, a t ype of anti -epi[INVESTIGATOR_30989] y therapy, may mediate its effect through mTOR 
inhibition. Because the potential interaction of similarly  acting therapi[INVESTIGATOR_579104], it was determined that treatment with a low carboh ydrate ketogenic 
diet should be an exclusion criterion .
5. Allowing investigator discretion to manage everolimus titrations in the extension phase.
The modifications preserve blinding of the Core Phase randomization among patients, 
investigators and the sponsor, and provide freedom for dose adjustments that 
neurologists are t ypi[INVESTIGATOR_1306] y accustomed to (in the extension phase of multi -dose vs 
placebo randomized trials of anti -epi[INVESTIGATOR_006]).
Investigators have expressed a desire to know the everolimus Cmin values of their 
patients after the Core phase of the stu dy, and to be permitted to make dose 
adjustments (increases or decreases), during the Extension phase. To accomplish this, 
patients are first transitioned towards an everolimus trough concentration range of 6 -
10 ng/ml, which preserves the blinding of the o riginal randomization. After this 
transition (week 26 for newly  enrolled patients) Cmin values will be revealed to 
investigators who will have the option to modify  the dose of study  drug. If 
investigators choose not to modify  dosing, the dose will be deter mined by  [CONTACT_941] I RT to 
maintain the everolimus trough concentration range between 3 -15 ng/ml for all 
patients .
6.Updates to Exclusion Criteria 25 and additional assessment of self-injury  and mood and /or
behavior changes
The study  requires patients 13 y ears and over to complete the eC -SSRS themselves 
and for caregivers to complete the eC- SSRS on behalf of patients under the age of 13
or patients with cognitive impairment . The amendment now requires that the 
investigator discuss epi[INVESTIGATOR_480912] -injury  and changes in the patient’s mood and /or
behavior with the patient and caregiver ,forallpatients .For patients ≥13 years of age 
who do not complete the scale via IRT, the investigator will proactivel y assess the 
patient for the presence of suicidality .These chang es help ensure a relevant mental 
safet y assessment has been performed on behalf of patients for whom the eC -SSRS 
has not been completed .The exclusion criteria was also updated to harmonize with 
the guidance provided throughout the protocol, namely  that a score of 4 or 5 could be 
addressed in a discussion with a healthcare professional.

[COMPANY_001] Confidential Page 15
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
7.Updates to Data collection, Data management and quality  control
The Vineland scale raw scores would be collected in a separate database and not in 
clinical OC -RDC database. This is the first protocol amendment since the final license 
agreement for the Vineland scale, therefore additional information regarding the 
collection of the Vineland data has been included in this amendment .
8.Correction to definition of Safet y Population
The Safet y Population in the original protocol was planned to be defined using actual 
Cmin values, however that approach has since been recognized as inappropriate. That 
is, there will be no attempt to reassign patients from one everolimus arm to the othe r 
everolimus arm based on observed everolimus concentrations during the Core phase. 
This is because increases in the dose of everolimus would have been recommended 
during the Core phase in order to reach the targeted trough range of 9 -15 ng/ml, and 
any associated toxicity  should therefore be attributed to the 9 -15 ng/ml arm and not 
the 3 -7 ng/ml arm.
Minor Changes
1.To provide corrections to protocol text
2.To include clarifications related to Study  Procedures, Timing of Visits and Assessments, 
updated Referenc e list and other ty pographical Errors
3.To include anti -Mullerian Hormone (AMH) in all newly  enrolled female patients ≥10 
years of age
AMH is a gonadotrophin independent, paracrine hormone, involved in the recruitment 
of primordial follicles. It measures ova rian function and may  be useful in assessing 
conditions such as poly cystic ovary  syndrome and premature ovarian failure. One of 
the noted risk factors of everolimus is amenorrhea, and whether amenorrhea 
represents a consequence of endocrine dy sfunction rel ated to everolimus, remains 
unclear. It has been suggested that patients with tuberous sclerosis may  have, as a 
consequence of mTOR over -activation, a higher rate of primordial follicle recruitment, 
with premature ovarian failure leading to amenorrhea. In short, it is unclear whether 
amenorrhea is a comorbid condition associated with TSC or a conseq uence of 
everolimus treatment. The measurement of AMH before and during treatment with 
everolimus, in female patients near puberty  can help address this question .Only  
female patients ≥[ADDRESS_760852] -treatment levels in TSC patients near pubert y until 
menopause .
Changes to the Protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
Major Changes
Sample size increase of 10 additional patients
Section 5.1, 6.4.2, 10.8

[COMPANY_001] Confidential Page 16
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Updates to Inclusion criteria 3 and 4
Section 5.2
Updates to Exclusion criteria 2, 4 and 26
Section 5.3
Investigator -led titration
Section 4.1, 4.1.3, 4.1.4, Fig. 4 -1,Table 4 -3,6.1.1, 6.2.2, 6.5.2, Table 6 -14, Table 7 -1, 
7.1.4 , Table 7 -4
Updates to Exclusion criteria 25 and additional assessment of self -injury and mood 
and/orbehavior changes
Section 5.3 and [IP_ADDRESS]
To include Data collection and Database management language relating to the paper 
component of the trial
Section 9.3, 9.4
Correction to definition of Safety Population
Section 10.1.2
Minor Changes
Corrections related to Protocol Text
Section 6.1.3, [IP_ADDRESS], 7.1.1, 7.1.2, 7.1.3, 7.1.4, 7.1.6, [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS].6, 7.2.4, 
[IP_ADDRESS], 10.1.3, 10.5.1, [IP_ADDRESS], Table 7 -2
Clarifications related to Study Procedures , Timing of Visits and Assessments and 
updated Reference list
Section 2.2, 4.1.1, 4.1.3, 4.1.5, 5.2, 5.3, [IP_ADDRESS], , 6.2.2, [IP_ADDRESS], 6.3, 6.3.1, 6.4.3, 6.5.1, 
[IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS].2, 7.2.5, 
8.1.3, [IP_ADDRESS], 13, 14, Table 6 -5, Table 6 -6, Table 6 -7, Table 7 -1, Table 7-3, Table 7 -
4
To include anti -Mullerian Hormone (AMH) in all newly enrolled female patients ≥10 
years of age
Section [IP_ADDRESS].7, Table 7 -1, Tabl e 7-2
Corrections of typographical errors
Figure 1 -1, Fig 1 -3, Table 3 -1, Table 7 -6, and throughout the protocol
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent th at takes into account 
the changes described in this amended protocol.

[COMPANY_001] Confidential Page 17
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Amendment [ADDRESS_760853]. The changes 
identified in this protocol amendment address feedback to the protocol provided by [CONTACT_23357] 
(European Medicines Agency ) and FDA, and includes clarifications of instructions and 
corrections of ty pographical errors. The rationale for the major changes are as follows:
The exclusion criterion regarding Lennox Gastaut Syndrome (LGS) isremoved. Patients with 
TSC may have multiple seizure types that must include partial onset seizure to be enrolled in 
the study .The diagnosis of LGS includes multiples seizure types, intellectual disability  and a 
slow -spi[INVESTIGATOR_579105]. Therefore, because patients carry ing the diagnosis of TSC 
and LGS are viewed as patients with TSC whose disease has progressed to cause intellectual 
disabil ity and a characteristic LGS EEG wave pattern, there is no reason to exclude patients 
who have LGS as long as they  have an underly ing diagnosis of TSC and partial onset seizures.
The volume of blood drawn in the study  was reviewed and modified tomake it compliant 
with the“ETHI CAL CONSIDERATIONS FOR CLIN ICAL TRIALS ON MEDI CINAL 
PRODUCTS CONDUCTED WITH THE PAEDIATRI C POPULATION: Recommendations 
of the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC 
relating to good clinical practice in the conduct of clinical trials on medicinal products for 
human use” The volume of blood collected from pediatric patients during all phases of the is 
now limited to ensure that not more than 1% of the patient’s total blood volume (i.e.,
0.8mL/kg) is collected on any visit,and not more than 3% of the patients total blood volume 
(i.e.,2.4mL /kg is collected in any 3 week period. To accomplish this two changes are 
incorporated :
Patients weighing less than [ADDRESS_760854] adequate volumes of blood to monitor their safet y and evaluate PK
Patients weighing 12 to 20 kg will not be required to provide PK AED and it will be 
recommended that TSC1/[ADDRESS_760855] group is1 to <6.
FDA specifically  requested a sensitivity  analysis of the primary  endpoint where seizure 
frequency  is determined across the entire Core phase (i.e., titration period as well as 
maintenance period). This analysis is alread y included in Section 10.4.4 of the protocol, 
however the wording is improved to make it more explicit.
In order to ensure that patients remain in their target trough range, clarification was made that 
titration may occur during both the Core and the Extension Phases. Language is added to 
Section 4.1.3, and rows in Tables 4-1 and 4-2 to indicate that titrati on may occur outside a 
‘scheduled’ time, and what actions must happen if this occurs.

[COMPANY_001] Confidential Page 18
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Missing information about whether or not patients may take rescue medication during the 
Baseline Phase isupdated in the exclusion criteria, and in withdrawal criteria.
To improve internal consistency  in the protocol the dosing age gr oup for the >18 is changed to 
≥ 18.
Clarifications on the inclusion criteria have been added. These focus primaril y on the 
definition of partial onset seizures. Seizures in patients with TSC a re focal in origin, due to the 
underly ing pathophy siology  of the disease which drives neuronal hyperexcitability  in or near 
tubers and possibl y other areas of the brain. Therefore, for the purpose of this study  being 
conducted in patients with TSC, any  seizure with a motor component is deemed to be a partial 
onset seizure, unless that seizure type is demonstrated to be a primary  generalized seizures on 
an ictal EEG. Clarification to the definition of partial onset seizures have been captured in 
Inclusion Criteria 3.Additionally , further subcategories to categories IB (Complex partial 
seizures) and IC (secondarily  generalized partial seizures) were added in order to capture the 
different clinical presentations of this seizure ty pe.
Three items areadded unde r criteria for premature withdrawal ([IP_ADDRESS]) to ensure that patients 
who should no longer be included in the study  are removed. 1) an interruption from study 
drug that lasts for more than 28 days;2) an interruption of one or more of the concomitant 
AEDs for more than 7 days;3) In patients who have their dose interrupted for toxicity , if 
restarting study  drug upon resolution of the toxicity  requires dose reduction, and that 
reduction results in instruction to take [ADDRESS_760856] of Abbreviations and Glossary of Term s
Abbreviations updated to reflect deletion of C -SSRS.
Terms updated to clarify  patient number.
2. Changes to Study Design (Protocol section 4)
Figure 4 -1:Footnote changed to clarify  that after the titration period, patients are 
maintained on their treatment for 12 weeks.
Section 4.1.1: Randomization stratification updated to include patients s tarting at age 
1.
Section 4.1.2: Description of titration and PK sampling updated for clarity . The 
volumes of PK blood samples per age group were also added to this section.
Table 4 -1: Table on PK sampling and dose titration updated to reflect the possibil ity 
of additional PK sampling and potential for titrations.

[COMPANY_001] Confidential Page 19
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Section 4.1.3: Text regarding length of extension phase clarified.
Section 4.1.3: Description of titration and PK sampling in the extension phase 
updated for clarit y. Blood volume to be taken was clarified and a sentence was added 
to specify  that patients weighing 12-20 kgwould not be required to provide blood 
samples for PK AED testing.
Table 4 -2: Table on PK sampling and dose titration in extension phase updated to 
reflect the possibility  of additional PK sampling and potential for titrations .
Table 4 -2: The heading of “table” is changed to “week” .
3.Changes to Patient Population ( Protocol section 5)
Section 5.1: Patient population was changed to include patients starting at age [ADDRESS_760857] of world.
Section 5.2: Inclusion criteria number [ADDRESS_760858] of world.
Section 5.2: Inclusion Criterion #1, the minimum number of pedia tric patients to be 
randomized in the age group 1 to <6 y ears has changed to 40 patients, in the age 
group 6 to <12 years has changed to 40 patients, and in the age group 12 to <18 y ears
has changed to 40 patients.
Section 5.2: Inclusion Criterion #7, t he requirement for sexually  active males to use a 
condom during intercourse has been increased to 8 weeks after stoppi[INVESTIGATOR_577461].
Section 5.3: The exclusion criteria have been modified to exclude patients who 
require rescue medication during the Basel ine Phase for 7 or more consecutive day s 
or 7 or more cumulative day s.
Section 5.3: The exclusion criteria regarding Lennox Gastaut Syndrome (LGS) has 
been removed.
Section 5.3: Additional exclusion criteria was added stating that patients who weigh 
less t han 12kg cannot be enrolled.
4. Changes to Treatment (Protocol section 6)
Section 6.1.1: The change allows for clarification regarding color coding of the study  
medication in order to maintain the blind.
Section 6.1.1: Packaging of medication boxes clarified as color labeled boxes will be 
provided separatel y and not as a “kit”.
Table 6 -2: The age of the patients that receive a starting dose of 5.0 mg/m2/day  has 
been changed to patients aged 10 to less than (<) 18 and age of patients receiving a 
starting dose of 3.0 mg/m2/day has been modified to greater than or equal to ( ≥) 18 
years.
Section 6.1.2: Clarification added to rescue medication section that they are only  
allowed for a period that does not exceed 6 day s during the baseline period.
Section 6.1.3: Dose reduction due to toxicity  to zero tablets during the core phase and 
pregnancy  were added to possible reasons for treatment withdrawal.

[COMPANY_001] Confidential Page 20
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 6 -3: The changes allow for clarification on the age group of patients whose pre-
dose concentrations have been predicted after the per protocol starting dose. The 
middle age group was changed to 10 to less than (<) 18 years age group and ≥ [ADDRESS_760859] age group.
Section 6.2.3: Under titration the change allows for further clarification on the 
different age groups listed in table 6-4.
Section 6.2.4: Reason of interruption of study  drug for more than 28 day s was added 
as a possible reason for treatment withdrawal.
Tables 6 -5, 6-6, 6- 7, and 6 -9: Clarificati on on the guidelines for Everolimus dose 
modification for patients that do, or do not take CYP3A4 inducers.
Section [IP_ADDRESS]: Additional section was added for the management of amenorrhea.
Table 6 -10: The guideline for the management of hepatitis C flare has changed to the 
patient being excluded from the study .
Section 6.4.2: Randomization stratification updated to include patients starting at age 
1.
Section 6.5.2: Packaging of medication boxes clarified as color labeled boxes will be 
provided separatel y and not as a “kit”.
Table 6 -13 and Table 6- 14: Packaging of medication boxes clarified as color labeled 
boxes will be provided separatel y and not as a “kit”. Additional option added for low 
trough range group.
5.Changes to Visit Schedule and Assessments (Protoc ol Section 7)
Table 7 -1: In the visit evaluation schedule, the inclusion and exclusion criteria that 
will be recorded, has been changed to category  “D” indicating that this data will be 
entered into the database .
Table 7 -1: Seizure history  has been added t o the visit evaluation schedule to be 
performed at screening.
Table 7 -1: Further clarification in the form of a footnote was added for timing of 
WNV, Vineland, and QOL after the end of core visit.
Table 7 -1: Assessment for endocrine tests at EOT Core was a dded.
Table 7 -1: Clarification added to study  drug administration assessment.
Table 7 -1: A footnote was added to give the option for patients between 12-[ADDRESS_760860] the TSC 1/2 genetic sampling on visit 4, to decrease the blood collection amount 
on visit 2. This information is also included in section 7.1.2 under the description of 
the baseline visit.
Table 7 -1: AED PK sampling was added at the screening visit.
Section 7.1.1: The section on screening has been amended to further clarify  the 
requirements for certain procedures, collection of patient data, and the methods of 
maintaining and recording this data, including IRT procedures.
Section 7.1.1: The statement on permitting reassessment of screening criteria has been 
moved from the sub -heading of screening for hepatitis C to the main heading of 
screening.

[COMPANY_001] Confidential Page 21
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Section 7.1.2: The baseline phase and baseline visit has been amended to further 
clarify  the requirements during this phase, especially  seizure diaries, the use of rescue 
medication, data recording and collection, requirements for determining eligibility , 
IRT procedures and MRI sub- study  details.
Section 7.1.2: The paragraph detailing the screening visit has been removed from the 
baseline phase section as the details are covered under section 7.1.1.
Section 7.1.3: The core phase section has been amended to further clarify  the 
requirements during this phase, including procedures performed during this phase.
Section 7.1.4: The extension phase section has been amended to further clarify  the 
requirements dur ing this phase, including procedures performed during this phase.
Section 7.1.5: The end of treatment section has been amended to further clarify  the 
requirements during this visit.
Section [IP_ADDRESS]: Three additional criteria for premature withdrawal of the patient from 
the study  have been added -An interruption of study  drug that lasts for more than [ADDRESS_760861] their dose interrupted for toxicity , if restarti ng study  drug 
upon resolution of the toxicity  requires dose reduction, and that reduction results in 
instruction to take 0 tablets for placebo patients during the core phase, or 0 mg of 
everolimus for active drug patients in the Core phase, or 0 mg everoli mus for all 
patients in the Extension phase .
Section [IP_ADDRESS]: Seizure history  and TSC history  added to patient history  description.
Section [IP_ADDRESS]: Clarifications made to descriptions of neurobehavioral, 
neurodevelopmental, and neurocognitive assessments.
Section [IP_ADDRESS]: The tanner staging section regarding pubic hair stages has been 
amended to provide further clarity  on this assessment.
Section [IP_ADDRESS]: Pregnancy  history , menstrual history  and monitoring section was 
updated to include description of the menstruation diaries and how data will be 
collected.
Section [IP_ADDRESS]: Clarification was added for collection of pre- baseline height and 
weight and collection of parental height.
Section [IP_ADDRESS]: I nstructions for who completed the eC- SSRS was clarified.
Table [IP_ADDRESS]: The table detailing the central clinical laboratory  parameters 
collection plan and the following test -categories have been amended to accuratel y list 
all the laboratory  evaluations that are required.
Section [IP_ADDRESS].2: Description of clinica l chemistry  was amended to reflect the 
laboratory  evaluations to be performed.
Section [IP_ADDRESS].5: Description of urinaly sis was amended to reflect the laboratory  
evaluations to be performed.
Section [IP_ADDRESS].6. Timing and procedures for monthly  pregnancy  tests were clarified.

[COMPANY_001] Confidential Page 22
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Section 7.2.4: The pharmacokinetic section was updated to include blood sample 
clarifications for pediatric patients , and to define the timing of a trough sample
Section 7.2.5: Clarification statement was added indicating that the par ent/caregiver 
of patients <10 years old will be completing the three qualit y of life questionnaires on 
behalf of the patient.
6. Changes to Statistical Methods and Data Analysis (Protocol section 10)
Section 10.4.1: Changed the word supportive to sensitivity  when describing the 
analysis of the primary  outcome.
Section [IP_ADDRESS]: The change to the EMA primary  variable: response rate includes the 
change of “exclusion criteria” to “inclusion criteria” as the criteria where counting of 
partial -onset seizures is defined.
Section 10.4.4: “Supportive anal yses” has been changed to “Sensitivity  analy ses”.
7. Changes to R eferences (Protocol section 13)
Changes to this section include re -formatting of all the reference articles.
8.Changes to Appendix A (Protocol section 14)
Changes were made to Appendix A to include EEGs and clarifications were made to 
the MRI  section .
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into acco unt 
the changes described in this amended protocol.

[COMPANY_001] Confidential Page 23
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Protocol summary
Study title: A three- arm, randomized, double -blind, placebo -controlled study of the efficacy  and safety 
of two trough -ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex 
(TSC) who have refractory partial -onset seizures
Study phase : III
Study objectives :
Primary objective: To compare the reduction in frequency of partial -onset seizures on each of two 
trough ranges of everolimus (3 -7 ng/mL and 9 -15 ng/mL) v ersus placebo in patients with TSC who are 
taking one to three AEDs.
Key secondary objective: To compare each of the two everolimus trough ranges versus placebo with 
respect to:
1.Ability to completely suppress partial -onset seizures.
2.Proportion of patients with ≥ 25% reduction from baseline in average weekly frequency of 
partial -onset seizures.
3.Distribution of reduction from baseline in seizure frequency
4.Seizure- free days
5.Treatment duration
6.Quality of life
Study population: The target population is comprised of approximately [ADDRESS_760862] refractory partial -onset seizures. Patients between ages of 1 and 65 years will be 
enrolled.
Number of patients :355
Overview of study design: This is a three -arm, randomized, double -blind, p lacebo -controlled study  to 
evaluate the efficacy  and safety  of two trough -ranges of everolim us given as adjunctive therapy in 
patients with tuberous sclerosis complex (TSC) who have refractory partial -onset seizures.
The study consists of 4phases for each patient [Baseline phase: From Screening Week -8 (V1) to 
randomization visit at W eek 0 (V2)], Core phase [Double -blind, placebo -controlled, from randomization 
at Week 0 (V2) to Week 18 (V11)], Extension phase [All patients receiving everolimus from Week 18
(V11) until [ADDRESS_760863] patient has completed the core phase] , and Post Extension Phase 
[after the end of the Extension phase until October 30, 2017].
Eligibility criteria will be assessed subsequently at the end of the baseline phase (V2, W eek 0), prior to 
randomization. All patients who continue to meet eligibility criteria, including demonstrating the 
minimum seizure frequency during the 8-week baseline phase (see Section 5.2and 5.3), will be 
randomized in a 1:1:1.09 ratio to one of the three treatment arms as described in Section 6.1. 
Randomization will be stratified by [CONTACT_579221]: 1 to <6 years; (ii) 6 to 
<12 years; (iii) 12 to <18 years; and (iv) ≥ 18 y ears.
Statistical considerations: The data cut-off date for the primary efficacy  and safety analyses will be 
when all patients have completed the Core phase or have discontinued early. At that time, alldata 
from the Core phase will be available as will a part of the Extension phase data. The analyses for the 
reports will thus cover both periods:
The main focus will be on descriptive and inferential comparisons of both everolimus arms 
versus placebo on e fficacy  and safety in the Core phase.
Descriptive efficacy  and safety analy ses on Extension phase data will also be conducted in 
order to explore the longer term effects of everolimus.

[COMPANY_001] Confidential Page 24
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
The second data cut-off will be at the end of the extension phase, which is planned [ADDRESS_760864] Extension phase ( October 30, 2017).

[COMPANY_001] Confidential Page 25
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
1 Background
1.1 Overview of Tuberous Sclerosis and current treatment options
TSC is an autosomal dominant genetic disorder caused by [CONTACT_579222]1
or TSC2 genes, with a prevalence ranging from 1 in 6000 to 1 in 25,000 (Morrison 2009 , 
Crino 2006 , Osborne 1991 ).TSC affects approximately  1  m illion people worldwide (Anon 
2010 ).Clinical disease spectrum is highl y variable, with manifestations ranging from mild 
skin findings to seizures (which affect up to 90% of patients), learning disabilities (38% to 
80%), mental retardation (50% to 70%), autism (20% to 60%), and fatal renal, cardiac, or 
pulmo nary disease (Curatolo et 
al 2002 , Levine et al 2006 ). Despi[INVESTIGATOR_579106], a limited number of features are responsible for the decreased life 
expectancy  associated with the disease. These include neurologic disorders (SEGAs and 
seizures), renal disease (angiomy olipomas and renal cell carcinoma [RCC ]), pulmonary 
disease (lymphangioleiomy omatosis), and cardiovascular disease (rhabdomy oma) (Goh et al 
2004 ).
1.1.[ADDRESS_760865] common genetic causes of epi[INVESTIGATOR_002] . Eight y to 90% of 
individuals with TSC are affected by  [CONTACT_14198][INVESTIGATOR_579107]. In a retrospective study  of 291 TSC patients treated at [LOCATION_005] General 
Hospi[INVESTIGATOR_307], 84.5% of the patients developed epi[INVESTIGATOR_30989] y (Chu- Shore et al 201 0).
Seizures with partial -onset are observed in most TSC patients. A variety  of seizure ty pes have 
been reported including infantile spasms, simple partial, complex partial and generalized 
tonic -clonic seizures (Holmes 2007 ; Wong 2010 ; Orlova and Crino 2010 ). In the 
[LOCATION_005] General Hospi[INVESTIGATOR_579108], the most 
common seizures observed were complex partial seizures (86.9%, including those with 
secondary  generalization) and infantile spasms (46.4%) ( Chu
-Shore et al 2010 ).
Patients with seizure onset before the age of [ADDRESS_760866] a substantially  increase d risk of subsequent mental 
retardation or autism. In a study that evaluated the intellectual abilities in 108 patients with 
TSC using standardized assessment tools and compared these with other features of TSC, 
including seizures, reported that infantile spasms and severe intractable seizures are highl y 
correlated with global intellectual impairment (Joinson et al 2003 ).Studies have also found a 
higher incidence of autism in children with TSC who have intractable epi[INVESTIGATOR_579109]
(Bolton et al 2002 ).Children with TSC are particularl y prone to epi[INVESTIGATOR_579110] -Gastaut syndrome. Goh evaluated intellectual outcomes in children with TSC 
and infantile spasms and found that the length of uncontrolled seizure activity  and poor 
control of other seizure types after infantile spasms were associated with increased risk of 
mental retardation (Goh et al 2005 ).
A retrospective chart review of all patients with TSC seen between January  2002 and October 
2008 by(Chu- Shore, et al 2010 ) reported that the onset of seizures typi[INVESTIGATOR_579111] (with 82% before 3 years of age); however, adults remain at risk. Notabl y, in 

[COMPANY_001] Confidential Page 26
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
this review 12% of adult patients with TSC without prior history  of seizure developed 
epi[INVESTIGATOR_579112] y, indicating that TSC patients are at an increased risk of epi[INVESTIGATOR_30989] y 
throug hout their lifetime.
Seizure control
Seizures may  be controlled by  [CONTACT_579223][INVESTIGATOR_006] (AEDs) or methods such 
as epi[INVESTIGATOR_30989] y surgery , vagal nerve stimulation (VNS) or ketogenic diet (Wong 2010 ; Jobst 
2009 ). However, between 20-60% of patients with TSC -associated epi[INVESTIGATOR_579113] (Franz 2000 ; Franz 
2001 ; Collins 2006 ). One study  found only 14% of epi[INVESTIGATOR_30989] y remission rate in its TSC 
population; furthermore, of these patients, about 25% relapsed after a mean follow -up of 5.5 
years (Sparagana 2003 ).
Refractory  seizures
Refractory  or intractable epi[INVESTIGATOR_30989] y is generally defined as failure to control partial -onset
seizures despi[INVESTIGATOR_579114] (Berg 2006 ;Chu
-Shore 2010 ;Kwan 2010 ).Many  patients with 
TSC continue to have intractable seizures with a poor response to both established and new 
anti-epi[INVESTIGATOR_579115]. In the (Chu- Shore study  2010),
155 out of 248 (62.5%) TSC patients 
with epi[INVESTIGATOR_579116] y. Furthermore, in patients with a history  of 
infantile spasms, 75.4% developed refractory  epi[INVESTIGATOR_579117] 39.8% in patients without 
a history  of infantile spasms (p < 0.0001).
Surgery  may constitute a valuable option for refractory seizures, however, surgery  is not 
feasible for all patients either because the removal of epi[INVESTIGATOR_579118] (for example when motor orlanguage areas are involved) or because of the multifocal 
origin of seizures (Granata 2009 ). Furthermore, it is reported that around one third of patients 
with TSC still experience seizures even after surgical treatment (Curatolo 2006 ; Jansen 2007 ; 
Napolioni 2009 ).
Attempts to determine why some TSC patients fail to respond to conventional AEDs and 
develop intractable epi[INVESTIGATOR_579119]
. One possible explanation is that the 
available AEDs target neuronal over -excitability through alteration in neurotransmitter release, 
receptor activation, or ion channel function ;therefore such AEDs act primarily  on the 
molecular mechanism that mediates the end stage of epi[INVESTIGATOR_30989] y(i.e.,seizures ). Such AEDs are 
considered “antiepi[INVESTIGATOR_23935]” therapi[INVESTIGATOR_579120] o nly, and 
not “antiepi[INVESTIGATOR_579121]” therapi[INVESTIGATOR_579122] c ause of epi[INVESTIGATOR_002] .
1.1.2 Role of mTOR in TSC and epi[INVESTIGATOR_579123] y are thought to be caused 
by [CONTACT_579224], which are present in over 80% of patients ( Crino, et al 2006 ).
However the relationship between tubers and seizures is not totally  well understood . Among 
other questions still unanswered, it is not known whether seizures originate within or near 
tubers, whether the pathophy siology  of seizures in TSC differs from other epi[INVESTIGATOR_579124], 
or how the development of tubers affects the maturation of brain circuits. Unresolved 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
questions also include how the specific gene mutation leads to tuber formation, the exact cells 
of tuber origin, and the factors that determine tuber location and number .
The protein products of the TSC1 (hamartin) and TSC2 (tuberin) genes are part of the 
PI3K/PKB(Akt)/S6K1 signaling pathway  that regulates cell growth and proliferation via the 
mammalian target of rapam ycin (mTOR) (Dan et al 2002 ; El-Hashemite et al 2003 ;
Goncharova et al 2002 ; Manning et al 2002) .A precise interaction between tuberin and 
hamartin appears to be critical at different stages of central nervous system development, 
including morphogenesis, cell adhesion/migration, and cell fate determination (Wong 2009 ).
In the brain, TSC1 and TSC2 messenger RNA (mRNA) and proteins have been detected in 
cerebral cortex, hippocampus, cerebellum, brainstem, choroid plexus epi[INVESTIGATOR_2130], and spi[INVESTIGATOR_579125] (Marcotte and Crino 2006 ).
mTOR exists as two complexes, designated mTORC1 (mammalian target of rapam ycin 
complex 1) and mTORC2 (mammalian target of rapam ycin complex 2).The hamartin/tuberin 
complex targets specifically  regula tion of mTORC1 through the inhibition of Ras homolog 
enriched in brain (Rheb) (Zhang et 
al 2003 ).Rheb is a small GTP -binding protein whose 
activation results in upregulation of mTORC1. Cortical tubers and other hamartomatous 
lesions found in patients with TSC demonstrate abnormal mTORC1 activation and 
upregulation of downstream targets including p70 S6 kinase (S6K1), 4E binding protein 
(4EBP1), and S6 ribosomal protein (Baybis et al 2004 ; Ma et al 2005 ).These proteins play a 
major role in the translational regulation of mRNAs in diverse processes, including proteins 
involved in G1-phase cell cycleprogression in many  different cell types (Huang et 
al 2008 ).
Less is known regarding the mTORC2 complex, but evidence suggests hamartin and tuberin 
have a role in mTORC2 -mediated signaling as well ( Huang et al 2008 ).
In addition to contribution to cortical tuber formation, emerging evidence suggests a major 
role of mTOR in neuronal function and neuronal disease pathogenesis. Widespread 
neuropatholog ical changes have been shown to be present in radiologicall y normal 
parench ymal structures in addition to TSC cerebral hamartomas (such as SEGA or 
subepend ymal nodules (SEN s)).mTOR is known to regulate cell size, arborization and 
function of dendritic spi [INVESTIGATOR_1651], as well as sy nthesis and density  of glutamate receptors ( Meikle et 
al 2007 ; Kwon et 
al 2006 ; Lenz 2005 ; Wiersma -Meems et al 2005 ).Tavazoie identified 
anatomic changes in dendritic spi[INVESTIGATOR_579126], more severe in homozy gous and less severe 
in heteroz ygous neurons for TSC mutations, indica ting a so-called genetic “dose effect” 
(Tavazoie et al 2005 ).This is relevant for the potential epi[INVESTIGATOR_579127]-tuberal 
cortex. Individual progenitor neurons sharing a common mutation in either TSC1 or TSC2 
give rise to cortical tubers. The process responsible for inactivation of the other copy of the 
TSC gene can differ for each neuronal progenitor cell, resulting in the markedl y different 
biologic activity  of various tubers, even within the same patient .
Nutrient deprivation , specificall y that of carboh ydrates, serves to inhibit mTOR and results in 
many of the same effects as treatment with rapamy cin (Peng et al 2002 ).This may be one of 
the mechanisms of action of the ketogenic diet, a therap y that is particularly  efficacious in 
TSC patients (
Kossoff et al 2005) .

[COMPANY_001] Confidential Page 28
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Neurotransmitter responses are also impacted by [CONTACT_3561] -dependent signaling in addition to 
morphological changes in neurons. TSC2+/ -rats exhibit edmemory  differences compared to 
wild-type controls and also more rapi[INVESTIGATOR_2478] y developed stage five seizures in one model of 
chemicall y-induced kindling (Waltereit et al 2006 ).Glutamatergic neurotransmission has been 
shown to enhance activity  of mTO R and S6K1 that serve to stimulate protein synthesis, 
including the synthesis of glutamate receptors (Gong et al 2006) .In another study , mTOR 
inhibition by [CONTACT_579225] y of 
cultured neurons and long-term consolidation of auditory  cortex -dependent memory  in gerbils 
(Tischmey er et al 2003
).Protein synthesis and microanatomic changes that underli e both 
synaptic long term potentiation and long term depression, processes thought to contribute to 
epi[INVESTIGATOR_579128] , are also regulated by [CONTACT_3561] (Ess 2006
).
Alterations in glutamatergic neurotransmission are associated with these changes, as is 
modulation of voltage -dependent potassium channels (Raab -Graham et al 2006 ).Additionally , 
glutamate itself can activate mTOR and S6K1 (Naray anan et 
al 2007) .In this way subclinical 
epi[INVESTIGATOR_41713], such as are 
those commonly  seen in TSC children, could cause 
epi[INVESTIGATOR_579129] a localized activation of mTOR independ ent of TSC1 or TSC2 
mutation. This is supported by [CONTACT_579226] (Zeng et al 2008
).Finall y, activation of mTOR is important in the 
development of chronic epi[INVESTIGATOR_579130] (Erlich et al 2007 ).
Apart from the direct effect of mTOR signaling on epi[INVESTIGATOR_58753], de Vrie s and Howe
proposed that the molecular disruption caused by [CONTACT_579227], given that many  of 
the upstream and downstream protein targets have key roles in the neurobiology  of learning 
and memory (de Vries and Howe 2007 ). As illustrated in the figure below (Napolioni et al 
2009) , the mutation of TSC genes, through downstream effect on neuronal and synaptic 
structures/neurotransmission, results in fundamental alterations in network properties as well 
as an imbalance in excitation and inhibition, acting as a common pathway  toward epi[INVESTIGATOR_30989] y, 
intellectual development, and autism.

[COMPANY_001] Confidential Page 29
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Impact of seizures on neurodevelopment and cognition is also well recognized. Poorly 
controlled seizures represent significant risk factors for adverse neurocognitive and 
neurodevelopmental outcome. Recent findings in an Eker Rat model of TSC2 showed an 
additive effect between molecular and seizure factors. In the study  by (Waltereit et al 2011) , 
Eker rats showed some specific social deficits, and gained additional social deficits through 
the onset of seizures. The combination of poorly  controlled seizures and TSC genot ype 
therefore represent sa significant risk factors for poor neurocognitive and neurodevelopmental 
outcomes in TSC. It is well known that the neuropsy chiatric manifestations of TSC (includi ng 
intellectual disability , autism and other neurocognitive deficits) represent some of the greatest 
contributions to the burden of care in TSC (Hunt et al 1983 ; de Vries 2010 ).
1.1.3 Rapamy cin and everolimus (RAD001) in TSC -epi[INVESTIGATOR_002]
[IP_ADDRESS] Nonclinical investigation
Nonclinical research using animal models, either due to genetic modification or treatment 
with seizure -inducing agents, has demonstrated a reduction in seizure activity  with mTOR 
inhibitors. For example, a neuronal -specific conditional knockout of TSC1 experienced 
spontaneous seizure activity  that caused death by [CONTACT_4475] 35 
(Figure 1-2). This could be 
completely  blocked by [CONTACT_579228] 
(RAD001), allowing survival to more th an 100 day s (Meikle 2007 and Meikle 2008 ).

[COMPANY_001] Confidential Page 30
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
 

[COMPANY_001] Confidential Page 31
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Zeng et al also reported that early  treatment with rapam ycin prevented the development of 
epi[INVESTIGATOR_579131]1GFAPCKO mice. Late treatment with 
rapam ycin suppressed seizures and prolonged survival in Tsc1GFAPCKO mice that had 
alread y developed epi[INVESTIGATOR_002]  (Zeng 2008 ).
In summary , the nonclinical research demonstrates that mTOR inhibi tors, rapam ycin and 
everolimus, have efficacy  for preventing seizures and prolonging survival in TSC mice. The 
effects of mTOR inhibition in mouse models of TSC are considered to be extremely  important 
as they are more consistent with an anti-epi[INVESTIGATOR_579132] (Wong 2010 ).
[IP_ADDRESS] Clinical experience in TSC
Everolimus has been investigated in one phase II study  (28 patients) in patients wi th TSC who 
have SEGA ([RAD001C2485 ]). Additionally  two phase III studies have been conducted in 
patients with TSC: study [RAD001M2301] in patients with TSC who have SEGA (117
patients) and study  [RAD001M2302] in patients with renal angiom yolipoma (118 patients), of 
which 113 had TSC .
Study RAD001C2485, an open -label phase II study  (Clinicaltrials.gov Identifier 
[STUDY_ID_REMOVED]) of everolimus in patients with TSC who have SEGA ,is ongoing at the 
 
Twenty -eight patients between the ages of [ADDRESS_760867] SEGA were enrolled between 07-Jan-2007 and 18-Dec-2008. The starting daily 
dose of everolimus was 3.0 mg/m2, with subsequent titration to attain a target trough level of 
5-15 ng/mL .The primary  efficacy  endpoint of the trial is reduction in SEGA volume. The 
effect of everolimus on seizure frequency  was assessed as a secondary endpoint (Krueger 
2010) .
A 24-hour video electroencephalogram (EEG) was performe d at baseline and at 24 weeks on 
all patients with uncontrolled epi[INVESTIGATOR_002]  (defined as those having at least one seizure per month 
prior to study  enrollment), and seizure frequency  was also assessed and followed using 
patient /caregiver report at study  visits.Neuro -psychometric function was assessed using a 
battery  of age appropriate tests. Eighteen out of the 28 enrolled patients (64%) had active 
seizures at baseline. Mean (median) number of seizures/24 hours (by  [CONTACT_98991] -EEG) was 6.3 (1.0) 
at baseline and 2.75 (0.0) at 6 months (median change: -0.99, P=0.022). Nine patients 
experienced decreases in seizure frequency  (across all types of seizure) relative to baseline. 
Furthermore, the proportion of patients experiencing seizures on a daily  basis (caregiver 
obser vation) improved from 27% at baseline to 8% at Month 6 (Krueger 2010 ).
Preliminary  data from another ongoing phase II trial that included 23 patients, [average age 
8.3 years (range 2-21)], has shown that everolimus can reduce seizure frequency  in TSC 
patients with medically -refractory  epi[INVESTIGATOR_30989] y,and may allow concurrent AEDs to be reduced or 
discontinued  
Clinicaltrials.gov I dentifier [STUDY_ID_REMOVED]).
Change in seizure frequency  using video EEG was evaluated as a secondary  endpoint in Study 
M2301, a randomized, double -blind, placebo -controlled trial of everolimus in [ADDRESS_760868] SEGA (median age 9.5 years; range 0.8 to 26.6) . Frequency  of seizures 

[COMPANY_001] Confidential Page 32
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
was measured at baseline and at Week 24 by  24-hour EEG. There was no observed difference 
between the two treatment arms in change from baseline in total seizure frequency .However, 
from a clinical viewpoint, analysis of the change in seizure frequency  was inconclusive, as 
seizure diary  was not used and a single 24-hour EEG did not appropriately  capture the high 
variability  in daily  seizure frequency .Although 103 patients (88%) were receivi ng AEDs at 
study  entry, only 40 patients (34.2%) were captured as having clinical or sub-clinical seizures 
using single 24 -hour EEG  Clintrials.gov Identifier [STUDY_ID_REMOVED]).
1.2 Introduction to investigational treatment(s) and other study  
treatmen t(s)
1.2.1 Overview  of everolimus (RA D001)
Everolimus (Afinitor®/Votubia®; RAD001) is a selective inhibitor of mTOR, specificall y 
targeting mTORC1. Everolimus was initially  developed to prevent allograft rejection 
following solid organ transplantation ,and is approved in more than 80countries worldwide 
for use in this indication (Certican®/Zortress®).
Everolimus was approved by [CONTACT_24623] (US) Food and Drug Administration (FDA) 
under the trade name [CONTACT_579298] l cell carcinoma 
(RCC) after failure of treatment with sunitinib or sorafenib ,and for the treatment of 
progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, 
locally  advanced or metastatic disease . The European Commis sion approved Afinitor for the 
treatment of patients with advanced RCC, whose disease has progressed on or after treatment 
with vascular endothelial growth factor -targeted therapy ,and for the treatment of unresectable 
or metastatic, well-or moderately-di fferentiated neuroendocrine tumors (NET) of pancreatic 
origin in adults with progressive disease.
More recentl y, an application was submitted for Afinitor in the treatment of patients with 
hormone receptor -positive advanced breast cancer in combination wit h an aromatase inhibitor, 
in postmenopausal women previously  treated with endocrine therapy . On 21-Jan-2012, 
Afinitor was approved in Argentina for this indication.
In addition, everolimus received accelerated approval for the treatment of patients with 
tuberous sclerosis (TSC) who have subependy malgiant cell astrocy toma (SEGA) who require 
therapeutic intervention but are not candidates for curative surgical resection (as Afinitor ) in 
the US,and received conditional approval in the EU (as Votubia) for t hetreatment of patients 
aged [ADDRESS_760869] been submitted for Afinitor/Votubia 
in the treatment of patients with TSC who have renal angiomy olipoma not requiring 
immediate surgery .

[COMPANY_001] Confidential Page 33
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 1-1 Everolimus –Drug Substance
Chemical name (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)- 1,18-dihydroxy- 12-
{(1R) -2-[(1S,3R,4R)-4- (2-hydroxyethoxy) -3-methoxycyclohexyl] -1-methylethyl} -19,30-
dimethoxy -15,17,21,23,29,35 -hexamethyl -11,36- dioxa -4-aza-
tricyclo[[IP_ADDRESS],9]hexatri aconta -16,24, 26,28 -tetraene -2,3,10,14,20 -pentaone
International non -
proprietary  nameEverolimus
Figure 1-4 Chemical Structure of Everolimus
[IP_ADDRESS] Non-clinical experience
Everolimus inhibits the proliferation of a range of human tumor cell lines in vitro including 
lines originating from lung, breast, prostate, colon, melanoma and glioblastoma. IC50s range 
from sub/low nM to µM. Everolimus also inhibits the proliferation of human umbilical vein 
endothelial cells (HUVECS) in vitro , with particular potency  against VEGF -induced 
proliferation suggesting that everolimus may also act as an anti-angiogenic agent. The anti-
angiogenic activit y of everolimus was confirmed in vivo. Everolimus selectivel y inhibited 
VEGF -dependent angiogenic response at well tolerated doses. Mice with primary  and 
metastatic tumors treated with everolimus showed a significant reduction in blood vessel 
density  when compared to controls.
Everolimus administered orall y daily was a potent inhibitor of tumor growth, at well tolerated 
doses, in11 different mouse xenograft models (including pancreatic, colon, epi[INVESTIGATOR_015], lung 
and melanoma) and two syngeneic models (rat pancreatic, mouse orthotopic melanoma). 
These models included tumor lines considered sensitive and “relativel y resistant” in vitro. In 
general, everolimus was better tolerated in mouse xenograft models than standard cytotoxic 
agents (i.e., doxorubicin and 5 -fluorouracil), while possessing similar anti- tumor activity .
In nonclinical models, the administration of everolimus is associ ated with reduction of protein 
phosphory lation in target proteins downstream of mTOR, notabl y phosphory lated S6 (p-S6) 
and p-4E- BP1, and occasionally  with an increase in phosphory lated AKT, a protein upstream 
of mTOR signaling pathway .

[COMPANY_001] Confidential Page 34
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
All significant adve rse events observed in toxicology  studies with everolimus in mice, rats, 
monkey s and mini -pi[INVESTIGATOR_89373] -
proliferative and immunosuppressant and at least in part reversible after a [ADDRESS_760870] notabl y 
testes.
Further details can be found in the everolimus [ Investigator’s Brochure ].
[IP_ADDRESS] Pharmacokinetics of RA D001 in patients with TSC
During Study  RAD001M2301, in patient s with TSC who have SEGA, pre-dose (Cmin) and 2-
hour post-dose (C2h) PK blood samples were collected at stead y-state. Age s of patients in the 
everolimus arm ofstudy ranged from 1 to 23.9 years. Patients in this study  received a starting 
dose of 4.5mg/m2daily  which was subsequently  titrated to a whole blood trough 
concentration of 5-15 ng/mL . This was the starting dose and trough range approved for this 
indication.
Everolimus C minwithin individual patients was approximately  dose-proportional (dose -
proportionality  coefficient = 1.107; 90% CI =  1 .03, 1.19). This was based on fitting the 
mixed -effect model to data in the dose range of 1.35 mg/m2-14.43 mg/m2.
The geometric mean Cminvalues normalized to mg/m2dose in patients of ages < 10 years and 
10-18 years were statistically  lower than that of adults (> 18 years), suggesting that 
everolimus clearance normalized to body  surface area w as higher in younger patients:
Geometric mean C min(for values not associated with co -administration of CYP3A4/PgP 
inhibitor and/or inducer):
18 years of age (A): 2.13 ng/mL per mg/m2dose (n=46)
10-18 years of age (B): 1.27 ng/mL per mg/m2dose (n=92)
< 10 y ears of age (C): 0.97 ng/mL per mg/m2dose (n= 194)
B:A geo -mean ratio [90% CI ] = 0.60 [0.38, 0.92]
C:A geo -mean ratio [90% CI ] = 0.46 [0.31, 0.68]
Co-administration of inducer of CYP3A4 decreased everolimus exposure as indicated by [CONTACT_579229]/m2dose in patients with TSC who have SEGA 
in different age groups:
Geometric mean computed out of C minassociated with co -administration of CYP3A4/PgP 
inducer (without inhibitor of CYP3A4 ):
18 years of age: 0.72 ng/mL  per mg/m2dose (n=7)
10-18 years of age: 0.80 ng/mL per mg/m2dose (n=118)
< 10 y ears of age: 0.61 ng/mL per mg/m2dose (n=122)
Results of a linear mixed model analy sis indicated that the relationship between absolute 
change from baseline in SEGA volume and Cminwas statistically  significant with a slope of -
0.304 (95%CI= -0.42, - 0.19), corresponding to a 0.211 cm3reduction in SEGA volume with a 
2-fold increase in Cmin. Results of another linear mixed model analy sis indicated that the 
relationship between percent change from baseline in SEGA lesion volume and Cminwas 
statistically  significant with a 12.98% (95% CI= 7.46%, 18.16 ) further tumor size reduction 

[COMPANY_001] Confidential Page 35
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
for a 2-fold Cminincrease. Subgroup analysis of selected AEs by [CONTACT_579230].
[ADDRESS_760871] partial -onset refractory  seizures. Such seizures (often 
“refractory ”) are known to be experienced commonly  in patients with TSC, as described in 
Section 1.1.1 .Epi[INVESTIGATOR_579133]. Asnoted above, the TSC1/TSC2 protein complex is a negative 
regulator of the mTOR pathway . Hence, mutation or loss of either of these gene products in 
nonclinical models is associated with increased mTOR pathway  activation and heightened 
sensitivity  to mTOR inhibitors (Astrinidis and Henske 2005 ; Inoki et al 2005 ; Kwiatkowski 
and Manning 2005 ).mTOR pathway  upregulation has also been observed in lesions derived 
from TSC patients ( Astrinidis and Henske 2005; Kwiatkowski and Manning 2005 ), and TSC1 
or TSC2 defective experimental animal models exist which recapi[INVESTIGATOR_579134] , 
behavioral and neurological aspects of the TSC disease (Onda et 
al 1999 ; Kwiatkowski and 
Manning 2005 ; Uhlmann et al 2002 ; Kenerson et al 2005 ) and are sensitive to mTOR 
inhibition (Kenerson et 
al 2005 ; Astrinidis and Henske 2005 ; Kwiatkowski and Manning 
2005 ).
Encouraging anti-epi[INVESTIGATOR_579135], nonclinical and preliminary  clinical 
evidence, discussed in Section 
1.1.3 , illustrates that two different mTOR targeting drugs 
(rapam ycin and everolimus), can limit the development of new onset seizures and increase 
survival in genetically  engineered models of TSC associated seizures. Rapam ycin has been 
shown to decrease the seizure frequency  after t he development of seizures in these animals. In 
the clinical setting, although the M2301 phase III findings were inconclusive, [ADDRESS_760872] in the primary  endpoint of the study .Finally , because epi[INVESTIGATOR_30989] y in TSC often seems to 
follow a progressive, intractable course, TSC patients with seizures are in high need of a 
novel type of intervention that is not only symptomatic “anti -seizure ” but may be “anti -
epi[INVESTIGATOR_579121]” by [CONTACT_579231][INVESTIGATOR_579136] ( Crino 2010 ; Wong 2010 ; Marcotte and Crino 2006 ). Taking all these data 
into account, there is strong rationale for evaluating the use of mTOR inhibitors such as 
everolimus for the treatment of refractory  partial -onset seizures associated with TSC.

[COMPANY_001] Confidential Page 36
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
2.[ADDRESS_760873] refractory  partial -onset seizures. This is a randomized, double -
blind, parallel -group study comparing two target trough concentration ranges of everolimus
versus placebo .
The use of placebo as the control arm is ethicall y acceptable because study treatment will be 
added to other anti-epi[INVESTIGATOR_579137] (1-3 AEDs). The 
presence of a placebo arm allows efficacy /safety  changes attributable to treatment to be 
differentiated from those attributable to underly ing disease, with any possible placebo effect 
being taken into account . Moreover, this design is consistent with clinical trial methodology  
used for evaluation of other AEDs as adjunctive treatment for refractory  partial onset seizures .
Therapeutic dose monitoring is being used since it is expected that most of the patients 
enrolled will be pediatric, with a broad age range, hence, it will allow to tailor the dose based 
on BSA and potential concomitant use of medications that interact with everolimus 
metabolism .
The use of two trough ranges of everolimus is based on the followi ng rational e: in a previous 
trial of everolimus in TSC patients (S tudy M2301), therapeutic drug monitoring was used to 
individualize the dose of everolimus to a targeted trough range of 5 to 15 ng/mL. However, 
results of this study  indicated that acceptabl e efficacy  (defined as >50% reduction in total 
target SEGA volume in at least 40% of patients) was obtained with trough levels as low as 3 
ng/mL below which efficacy  is not expected . Therefore, the lower limit of the trough range in 
the proposed study  is 3 ng/mL, with an upper limit of 15 ng/mL. In order to determine the 
most appropriate trough level range, and to gain insight into whether Cminvalues at the lower 
end of this range are as effective as higher values, this trial will assess two separate rang es (3-
7 ng/mL  and 9-15 ng/ mL).The primary  comparisons will be between each everolimus arm 
and placebo .
Additionally ,safet y will be presented by [CONTACT_579232].
The study  includes a prospective baseline phase during which patients complete a seizure 
diary  for a total of 8 weeks, which is considered long enough to provide reliable data on the 
baseline seizure frequency  of patients taking one to three AEDs . At the end of this baseline 
phase, if all eligibility  criteria arestillmet(lab results from the Screening visit), patients will 
continue their baseline phase AED medications and be randomized in a 1:1:1 .09fashion to 
receive adjunctive : 1) placebo; 2) everolimus to attain a trough level 3-7 ng/m L; or 3) 
everolimus to attain a trough level 9-15 ng/m L. Following rando mization, patients enter a 
core phase, which starts with a 6 week titration period during which up to 3 dose adjustments
could be made in order to reach the targeted everolimus trough range. This is followed by a 
maintenance period of 12 weeks’ duration, as recommended in the EMA guidance on anti-
epi[INVESTIGATOR_23698] (EMA 2010 ) as being long enough to establish efficacy . After completing the 
maintenance period, patients will be offered to continue in anextension phase; this extension 
phase will allow for longer -term safet y and efficacy  data to be obtained. Once the Extension 
phase is completed, patients deriving clinical benefit will be offered continued treatment in 

[COMPANY_001] Confidential Page 37
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
the Post Extension phase which will allow for additional long term safet y data to be obtained, 
while ensuring availability of everolimus.
For the primary  efficacy variable of this study , the regulatory  requirements differ between 
Europe and US, with EMA preferring response rate and FDA preferring perce ntage reduction 
in seizure frequency . Therefore ,both variables will be analy zed for the primary  objective, and 
without correction for multiplicity  since it is understood that each Agency will only use their 
preferred variable to make a decision on the primary  objective.
Both primary  efficacy  variables are based on the change from baseline in seizure frequency 
during the 12-week maintenance phase, with sensitivity  analyses included that count seizures 
over the entire core phase (titration period plus maintenance period) .
2.3 Rationale for dose and regimen selection
The starting dose in both Study C2485 and M2301 was based on the patients’ body  surface 
area (BSA). Therapeutic drug monitoring (TDM) of everolimus was used with a targeted 
trough concentration range in whole blood to determine the optimal therapeutic dose.
In Study M2301, an everolimus trough (Cmin)level of 3-15 ng/mL has shown superior 
efficacy  versus placebo in patients with TSC who have SEGA, with an acceptable safet y 
profile. In addition, there was a significant correlation between SEGA volume reduction and 
Cminwhile higher Cmindid not result in more adverse events. However, it is unknown if a C min
in the range of 3-15 ng/mL  will lead to a reduction in seizure frequency , or if a correlation 
between reduction in seizure frequency  and C minexists. Therefore, two trough levels, 3-7 
ng/mL (low) and 9 -15 ng/mL (high) , will be investigated .
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1below. Note that for the primary  
objective there are separate primary  variables and analy ses planned for EMA and FDA, in 
accordance with their differing preferen ces for demonstrating efficacy  of an anti-epi[INVESTIGATOR_24568]. See Section 10.4.1 for further details.
Also note that the analy ses provided in Table 3-1mainly  apply to data from the core phase of 
the trial, and at the data cutoff the extension phase will not be complete (see Section 10 ).

[COMPANY_001] Confidential Page 38
Amended Protocol Version 03 (Clean) Protocol No. C RAD001M2304
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary Refer to Section 10.4
To compare the reduction in frequency of partial -onset 
seizures on each of two trough ranges of everolimus 
(3-7 ng/mL and 9 -15 ng/mL) versus placebo in 
patients with TSC who are taking one to three AEDs.EMA: Response rate, where response means at least 
a 50% reduction from baseline in partial-onset seizure 
frequency during maintenance period of the core 
phase
FDA: Percentage reduction from baseline in partial 
onset seiz ure frequency during maintenance period of 
the core phaseEMA: Cochran -Mantel -Haenszel (CMH) chi-square 
tests
FDA: Rank analysis of covariance (ANCOVA )
Secondary Refer to Section 10.[ADDRESS_760874] to:
(1) Ability to completely suppress partial -onset 
seizures.
(2) Proportion of patients with ≥ 25% reduction from 
baseline in average weekly frequency of partial -onset 
seizures.
(3) Distribution of reduction from baseline in seizure 
frequency
(4) Seizure -free days
(5) Treatment duration
(6) Quality of life(1) Seizure -free rate, where seizure -free means a 
100% reduction in partial -onset seizure frequency 
during maintenance period o f the Core phase
(2) Proportion of patients with at least a 25% reduction 
from baseline in partial -onset seizure frequency during 
maintenance period of the core phase
(3) Categorical variable of six levels of reduction from 
baseline in partial -onset seiz ure frequency during 
maintenance period of the core phase ( ≤ -25% 
(exacerbation); > -25% to < 25% (no change); ≥ 25% 
to < 50%; ≥ 50% to < 75%; ≥ 75% to < 100%; 100% 
(seizure -freedom)).
(4) Frequency of seizure -free days during 
maintenance period of the Co re phase
(5) Time from randomization until treatment 
discontinuation in the Core phase
(6) Overall QOL global scores from th e 3 age -specific 
questionnairesDescriptive statistics

[COMPANY_001] Confidential Page 39
Amended Protocol Version 03 (Clean) Protocol No. C RAD001M2304
Objective Endpoint Anal ysis
To assess everolimus in relation to neurocognitive, 
neurobehavioral and neurodevelopmental measures
using the Vineland Adaptive Behavior Scales -II and 
the Wechsler Non -Verbal Scale of AbilityChange from baseline of sub -test scores Descriptive statistics
To assess the relationship between everolimus 
concentration and efficacy / safety endpointsPercentage reduction in seizure frequency / frequency 
of selected AEsMixed models and descriptive statistics
To evaluate the impact of everolimus on the pre -dose 
exposure of antiepi[INVESTIGATOR_579138]-dose concentrations of AEDs at Baseline (AEDs 
alone) and at post -Baseline (AED splus everolimus)Mixed models and descriptive statistics
To evaluate the effect of everolimus on long -term 
seizure reduction 50% response rate, percent reduction from Baseline 
and seizure free -days in partial onset seizure by [CONTACT_579233] / abnormal laboratory values Descriptive statistics
Toevaluate the impact of everoli mus on the risk of 
suicidality using the Columbia Suicide Severity Rating 
Scale (C-SSRS)Frequency C-SSRS outcomes, frequency of SAEs 
referring to a positive suicidal evaluationDescriptive statistics

[COMPANY_001] Confidential Page 40
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
4 Study  design
4.1 Description of study  design
This is a three -arm, randomized, double -blind, placebo- controlled study to evaluate the 
efficacy  and safety  of two trough -ranges of everolimus given as adjunctive therapy  in patients 
with tuberous sclerosis complex (TSC) who have refractory  partial -onset seizures .
The study  consists of 4 phases for each patient (see Figure 4-1 below) :
Baseline phase: From Screening Week -
8 (V1) to randomization visit at Week 0 (V2). For 
baseline seizure frequency  calculations, the 8 -week prospective pe riod counts will be 
totaled.
Core phase: Double-blind, placebo -controlled, from randomization at Week 0 (V2) to 
Week 18 (V11) .
Extension phase: From Week 18 ( V11) until [ADDRESS_760875] patient has completed 
the core phase , with all patients receivi ng everolimus .
Post Extension phase: From the end of the extension phase until everolimus is 
commerciall y available for the indication, a rollover protocol is available locally, or 
October 30, 2017, whichever occurs first (on a per patient basis) .

[COMPANY_001] Confidential Page 41
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Figure 4-1 Study Design
4.1.1 Baseline phase
The Baseline phase is 8 weeks/56 days (+ 2 weeks for scheduling purposes) and begins with 
the Screening Visit and ends with the Baseline Visit.Patients/caregivers will record seizure s 
in a seizure diary  beginning at the Screening Visit. The most recent [ADDRESS_760876] be used for determining eligibility.
Screening visit
During the Screening visit (V1, Week -8), the history  of prior seizure type and antiepi[INVESTIGATOR_579139] d.
The patient must provide a signed informed consent form (ICF) prior to any study related 
procedure.
Baseline visit
Patients who meet the eligibility  criteria will then enter a prospective , eight -week Baseline 
phase during which the seizure ty
pe and frequency  and anti epi[INVESTIGATOR_579140].
Patients are required to be on a stable dose of 1-3 AEDs (stable dose defined as no change for 
atleast 4 weeks prior to the screening visit and through the entire study ).Patients/caregivers 

[COMPANY_001] Confidential Page 42
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
will be instructed on how to count seizures and to complete a daily seizure diary for the entire 
eight -week Baseline phase.
Eligibility  criteria will be assessed subsequentl yat the end of the baseline phase (V2 , Week 0 ), 
prior to randomization. A ll patients who continue to meet eligibility criteria , including 
demonstrating the minimum seizure frequency  during the last 8-week s of thebaseline phase 
(see Section 5.1), will be randomized in a 1:1:1 .09ratio to one of the three treatment arms as 
described in Section 
6.1. Randomization will bestratified by [CONTACT_579234]: (i) 1 to <6 years; (ii) 6 to <12 years; (iii) 12 to <18 y ears; and (iv) ≥ 18 y ears.
4.1.2 Core phase
The Core phase of the study  includes both a titration period (V2, Week 0 to V8, Week 6) and 
a maintenance period ( V8, Week 6 toV11, Week 18) .
During the Core phase of the study , there will be visits at weeks 0 (V2), 1 (V3), 2 (V4) ,3 
(V5), 4 (V6), 5 (V7), 6 (V8), 10 (V9), 14 (V10), and 18 (V11).
Everolimus will be dosed based on TDM with dose titration to attain one of the two target 
Cminranges (3 to 7 ng/mL  or 9 to 15 ng/mL). Starting doses of study  drug are defined in 
Section [IP_ADDRESS].
During 
the 6 week titration period, three pre-dose PK blood samples (0.5 mL for 1 to < 2 
years of age; 1 mL for 2 to≤
6 years of age; and 2 mL for > 6 years of age) will be taken for 
potential dose adjustments as described in Table 4-1. The high frequency  of visits during the 
beginning of the Core phase is essential t o ensure that titration is being performed effectivel y, 
and also helps to ensure that seizures are being counted properly , and provides an opportunity 
to remind patients of the importance of good compliance
.
The titrations are implemented as follows. A local lab (at the treating center) will collect the 
blood samples and send them to a central laboratory  for determination of everolimus 
concentrations. The site will receive recommendations from the central Interactive Response 
Technology  (IRT) on dose adjust ment (to maintain, increase or decrease the number of the 2-
mg tablets) for each patient
,based on concentration values of the pre-dose PK samples .It is 
expected that all patients will achieve the planned target pre-dose trough level (Cmin) during 
this period. In order to keep the blind ,the IRTwill also instruct the site to adjust the dose for 
patients in the placebo arm based on a random scheme of dose changes .
After the completion of the titration period, the vast majority  ofpatients are expected to 
continue attheir current dose level during the entire [ADDRESS_760877], based on the planned pre-dose PK blood 
samples that will be collected every  4
 weeks during the maintenance period .In addition, pre-
dose PK blood samples should be collected two weeks after any everolimus dose 
adjustment , and so a patient having a titration at week 6 (end of titration period) would need 
to have a pre -dose PK sample collected at week 8 (2 weeks into the maintenance period) . This 
PK sample could then lead to a dose adjustment at the next planned visit at week 10, which if 
implemented would then necessitate a further pre-dose PK sample at week 12. Few patients 
are expected to need these extra titrations, but the possibility  exists in order to keep patients in 
their targeted trough range as assigned at randomization.

[COMPANY_001] Confidential Page 43
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 4-1 PK sampling and dose titration events durin g Core phase
Week Action Potential for titration
0 Start dosing
1 PK sample 1
2 PK result X
3 PK sample 2
4 PK result X
5 PK sample 3
6 PK result X
8 (only if titration occurred at week 6) Additional PK sample
10 Preplanned PK sample 4 X
12(only if titration occurred at week 10) Additional PK sample
14 Preplanned PK sample 5 X
16(only if titration occurred at week 1 4) Additional PK sample
18 Preplanned PK sample 6 X
4.1.3 Extension phase
The extension phase of this study  will allow further evaluation of the long-term safet y profile 
and efficacy  of everolimus in this patient population.
All patients who complete the Core phase will be offered continuation on the extension phase, 
during which all the patients will receive everolimus atWeek 18 [(V11) same visit as end of 
Core and start of Extension)] .Patients will enter into this phase upon completion of the core 
phase, and will continue until [ADDRESS_760878] patient completes the core phase.
(Patients enrolled earlier in the study may remain in the Extension phase for more than 48
weeks .)
The intention is to allow investigators to decide appropriate dose changes themselves, based 
on everolimus concentrations at trough (Cmin) obtained during the extension phase. However, 
in orde r to avoid compromising the blind ed nature of the study (including for the investigator, 
patient and sponsor) inthe earlier Core phase, all patients will first be transitioned towards a 
common targeted trough range of 6 to 10 ng/ml before any Cminvalue is shared with the 
investigator. Note that no individual patient unblinding will be performed at entry  into 
extension .
During the Extension phase, visits will be at Weeks 18 (V11 ), 19 (V12 ), 20 (V13), 22(V14), 
26(V15),and 30 (V16) , and then every 12 weeks thereafter, unless additional visits are 
clinically  indicated. Pre-dose blood samples will be collected at weeks 19 and 22 to allow 
possible titrations at Weeks 20 and 26.In addition, patients randomized to one of the two 
everolimus arms will betransitioned at week 18.Patients are expected to approach or be 
within the planned target trough range of 6 to 10 ng/ml after the week 20 titration . This will 
serve to preserve the blinding of the prior Core phase. At the Week 26 visit, investigators will 
be provided with the Cminresult from Week 22PK, and they will be permitted to make their 
own dose titration decisions. F urther titrations are possible based on the planned pre-dose PK 
samples collected every 12 weeks from Week 30, and any additional pre-dose PK blood 
sample collected two weeks after an y everolimus dose adjustment (see 
Table 4 -2).

[COMPANY_001] Confidential Page 44
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 4-2 PK sampling and dose titration events during Extension phase
Week Action Potential for titration
18 Switch to extension
19 Pre-planned PK sample E 1
20 PK result X
22 Pre-planned PK sample E2
26 Pre-p lanned PK sample E3 X
28(only if titration occurred at week 26) Additional PK sample
30 Pre-plan ned PK sample E4 X
32(only if titration occurred at week 30) Additional PK sample
42, 54, 66, etc. PK sample E5, E6, E7, etc. X
For patients who signed informed consent for Amendment 2 of the protocol after completing 
their week 18 visit, a modified transition schedule will be permitted in the Extension Phase.
This schedule will begin at week 26,30 or at any subsequent scheduled visit (every  12 weeks
thereafter ). At the first such visit, the everolimus dose will be transitioned based on the prior 
PK value using a targeted trough range of 6-10 ng/ml. The patient will return thefollowing 
week for an everolimus PK sample , and the following week, for disclosure of the PK value. 
The investigator may begin to make his/her own dose adjustment decisions or rely  on the IRT 
system to prescribe a dose that will maintain the everolimus trough within 3-15 ng/ml . (s ee
Section [IP_ADDRESS]).
At the start of the Extension Phase, during the transition to investigator control of everolimus 
dosing, and while the everolimus Cmin value is still not shared with the investigator, the 
investigato r should consider managing clinical deterioration in seizure control (as judged by 
[CONTACT_093]) by  [CONTACT_579235]. Starting at week 26, 
when everolimus Cmin values are made available to the investigator, the investig
ator may 
manage a patient’s clinical deterioration by [CONTACT_579236], adding and or subtracting 
AEDs and modify ing everolimus dosing in whatever order or combination the investigator 
chooses .
When the last patient completes the Core phase, the data will be analyzed.If the results are 
positive, patients will continue on study  treatment until the end of the Extension phase.
Patients deriving clinical benefit will also be offered continued treatment in a Post Extension 
phase. If the results are negative, the study  will be terminated.
When results of the Core phas e of the study  become available , if a more favorable risk -benefit 
ratio is identified for one of the two trough ranges, the protocol may be amended andpatients 
will be offered to be titrated to the preferred trough range .
The last Extension phase visit for a patient will be the last scheduled visit that occurs prior to 
or on September 2, 2016, at which point the patient will then enter the Post Extension phase.
After the Post Extension phase is completed, if the Core study  results arepositive and patients 
continue to receive benefit , everolimus will continue to be provided free of charge in a roll 
over protocol until the drug is approved and commerciall y available for use in TSC- associated 
refract ory partial onset seizures, or until the patient stops receiving everolimus for any  reason, 
whichever occurs first. Ifthis is prohibited by [CONTACT_427] (e.g.,in [LOCATION_006] and Norway )the 
patient will exit the study when the Post E xtension phase is completed (see Section 4.1.4).

[COMPANY_001] Confidential Page 45
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Additional Everolimus PK sampling
In addition to the time points described above in the Core, Extension and Post Extension 
sections, pre-dose blood samples for everolimus concentration determination should be 
collected two weeks after the following events:
Any everolimus dose adjustment
Starting or changing the dose of a CYP3A4/PgP inducer/ inhibitor
Anti-epi[INVESTIGATOR_579141]3A4 pathway  in the liver, and to some extent in the 
intestinal wall. Many  of the concomitantly  administered AEDs are also metabolized by [CONTACT_191700]3A4 pathway , which results in a potential for drug-drug interaction between the AEDs 
and everolimus. Therefore, levels of the AEDs listed below (considered to be CYP3A4 
substrates and /or inducers) will be measured to investigate the effect of everolimus on the 
AED level (i.e., if AED + everolimus leads to higher levels of AED compared to AED alone).
Inducers:
Carbamaze pi[INVESTIGATOR_050]
Oxcarbazepi[INVESTIGATOR_050]
Phenobarbital
Pheny toin
Primidone
Substrates:
Clobazam
Clonazepam
Diazepam
Felbamate
Topi[INVESTIGATOR_052]
Valproic acid
Zonisamide
Pre-dose blood samples of 6mL(5.2 mL for patients 6 and under) will be collected at Visits 1, 
2, 3, and 5for the measurement of antiepi[INVESTIGATOR_32551] (AED) concentration. Patients weighing 
12 to 20 kg will not be required to provide PK AED blood samples due to the high overall 
blood volume required at the early visits. Effects of everolimus on the exposure of anti-
epi[INVESTIGATOR_579142]
-epi[INVESTIGATOR_579143] 1
and 2(AEDs alone) and at Visits 3and 5(AEDs plus everolimus) .A list of commonly  
prescribed AEDs that are used in this population is provided in Section [IP_ADDRESS].
[IP_ADDRESS] Investigator -led dosing in patients past week [ADDRESS_760879] 
an opportunity  to ha ve their everolimus concentrations 
revealed after a transition process that can begin at any scheduled visit beginning from week 

[COMPANY_001] Confidential Page 46
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
26. At week 26, 30 or any other scheduled visit (every  12 weeks), the patient would first be 
transitioned using a targeted trough range of 6-10 ng/ml (Transition visit A). The IRT system 
would recommend dose instructions using the previous PK result (week 22, 26, etc). The 
patient would return at least 5 days later to provide an additional transition PK trough sample 
(Transiti on visit B), and then again at least one week later for a clinic visit (Transition visit C), 
when the investigator would be informed of the everolimus concentration. The investigator 
would then be permitted to modify  the patient’s dose of study  drug by  2mgdaily  (patients not 
on CYP3A4/PgP inducers) or 4mg daily (patients on CYP3A4/PgP inducers) to a minimum 
dose of 2 mg/day . A dose increase will not be permitted if the everolimus concentration 
exceeds 15 ng/ml. If the investigator chooses not to modify  dosing, the dose will be 
maintained by [CONTACT_579237] 3-15 ng/ml. Table 4 -3outlines the visits and 
actions to be taken. Additional assessments to be performed at unscheduled Transition visit C 
are outlined in Table 7 -1.
Table 4
-3 D ose transition of everolimus to 6-10 ng/ml beginning atWeek 26
Visit Week Action
14 22 Pre-planned PK sample
15 26 transition visit A Transition dose change by [CONTACT_579238] W 22
201 27 transition visit B Additional transition PK sample
202 28 transition visit C Cmin revealed, Investigator -led dosing may begin
16 30 transition visit A Transition dose change by [CONTACT_579238] W 26
201 31 transition visit B Additional transition PK sample
202 32 transition visit C Cmin revealed, Investigator -led dosing may begin
17+ 42, 54, 66, etc. transition visit A Transition dose change by [CONTACT_579238] W 30, 42, 54, etc
[ADDRESS_760880] Extens ion phase. Investigators will determine patient’s daily  dosing at their sole 
discretion based on 
guidance provided (see Section 6).The IRT system will respond to the 
investigator’s request and provide kit numbers to be dispensed to supply  the patient. In the 
Post Extension phase, the I RT s ystem will no longer provide daily  dosing recommendations.
During the Post Extension phase, visits will occur every  [ADDRESS_760881] Extension phase visit will occur 12 weeks after 
the patient’s last scheduled Extension phase visit.Additional pr
e-dose blood samples for 
everolimus concentration determination should be collected two weeks after the following 
events :
Any everolimus dose adjustment
Startin gor changing the dose of a CYP3A4/PgP inducer/inhibitor
Investigators will confirm the Cmin value from the last PK drawn and make a decision on 
dosing . The investigator will enter the chosen daily  dose into the IRT system and the IRT 
system will dispense the appropriate number of kits to supply  the patient until the next 
scheduled visit.

[COMPANY_001] Confidential Page 47
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
4.1.[ADDRESS_760882] patient reaches Visit 11 
(Week 18). At this point, the core data will be analyzed and, if the results are positive, all 
patients in the Extension phase will cont inue. If one trough level is found to be superior to the 
other, 
the protocol may  be amended and all patients will be offered to be titrated to that trough 
level. The Extension phase of the study  will end48 weeks after the last patient enters the 
Extension Phase. At thatpoint, long term safety  and efficacy  data will be analy zed. The last 
treatment in a patient’s Post Extension phase will be on or before September [ADDRESS_760883] patient completes their follow -up visit, the data will be cleaned and 
locked, and a final study  report written .
4.2 Early study  termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient willbe contact[INVESTIGATOR_530], requested to discontinue taking study  treatment, and be seen as 
soon as possible. The same assessments should be performed as described in Section 7.1.6 for 
a prematurely  withdrawn patient. The investigator may be informed of additional procedures 
to be followed in order to ensure that adequate consideration is given to the protection of the 
patient’s interests. The investigator will be responsible for informing IRBs and/or ECs of the 
early termination of the trial according to I CH-GCP and local regulations .
[ADDRESS_760884] to meet all of the following criteria:

[COMPANY_001] Confidential Page 48
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
1.Male or female between the ages of 2and 65 years(except in Europe where the minimum 
age will be [ADDRESS_760885] of the EMA) . (A minimum number of pediatric patients will be 
randomized in the following age groups: 1 to <6 years [ 40patients], 6 to <12 y ears[40 
patients], and 12 to <18 years [ 40 patients].)
2.Clinically  definite diagnosis of TSC see Table 5-1 (modified Gomez criteria, Gomez 
1999). Note: positive genetic test without definite diagnosis of TSC a s per the modified 
Gomez criteria is not allowed.
Table 5
-1 Diagnostic Criteria for Tuberous Sclerosis Complex
Major Features
Facial a ngiofibromas or forehead plaque
Nontraumatic ungual or periungual f ibroma
Hypome lanotic macules (three or more)
Shagreen patch (connective tissue nevus)
Multiple retinal nodular hamartomas
Cortical tubera
Subependymal nodule
Sube pendymal giant cell astrocytoma
Cardiac rhabdomyoma, single or multiple
Lymphangiomyomatosisb
Renal angiomyolipomab
Minor Features
Multiple, randomly di stributed pi[INVESTIGATOR_579144],d
Gingival fibromas
Non-renal hamartomac
Retinal achromic patc h
‘Confetti’ skin lesions
Multiple renal cystsc
Definite Tuberous Sclerosis Complex:
Either two Major Features or one Major Feature plus two Minor Features.
a.The co -occurrence of cerebral cortical dysplasia and cerebral white matter radial migration lines should be 
considered as one major feature of TSC.
b.In patients with both lymphangiomyomatosis and renal angiomyolipoma, another feature of TSC must be 
identified before a definite diagnosis is assigned.
c.Histological confirmatio n of these features is suggested.
d.Radiographic confirmation of these features is sufficient.

[COMPANY_001] Confidential Page 49
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
3.Diagnosis of partial -onset epi[INVESTIGATOR_579145] (Commission on Classification and Terminology  of the 
International League Against Epi[INVESTIGATOR_002] , 1989) and revised in 2009 ( Berg 2010). This 
classification is further modified for the purpose of capturing clinical details, and defines 
partial onset seizures in patients with TSC on the basis of the pathoph ysiology  of TSC as 
either :
any seizure that has been definitively  shown to be partial onset on ictal EEG, or
any probable seizure with motor signs (non- sensory ) that has NOT been documented 
to be a primary  generalized seizure on ictal EEG .
Seizure Classification:
I.Partial Onset Seizu res
A.Without impairment of consciousness or awareness
1. With observable motor or autonomic components. (Formerl y known as “simple 
partial seizures”) ‘‘Focal motor’’ and ‘‘autonomic’’ are terms that may  
adequatel y convey  this concept dependin g on the seizure m anifestations
2.Involving subjective sensory  or psy chic phenomena only .(This corresponds to the 
concept of an aura )
.
a.With ictal EEG confirmation
b.Without ictal EEG confirmation
B.With impairment of consciousness or awareness. (Formerly known as “complex 
partial seizures” , or partial onset seizures with Absence -like features )
1.Typi[INVESTIGATOR_579146]
2.Atypi[INVESTIGATOR_579147] e features
3. NOS (not otherwise specified)
C.Evolving to a bilateral, convulsive seizure (Formerly  known as “secondarily  
generalized seizure”)
1.Myoclonic f eatures
2.Clonic features
3.Tonic features
4.Tonic -clonic features (Older term: grand mal)
5.Atonic features
6.NOS
IIPrimary  Generalized seizures
A.Absence seizures
1.Typi[INVESTIGATOR_32539]
2.Atypi[INVESTIGATOR_32539]
B.Myoclonic seizures
C.Clonic seizures
D.Tonic seizures
E.Tonic-clonic seizures (Older term: grand mal)
F.Atonic seizures

[COMPANY_001] Confidential Page 50
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
G. NOS
4.Uncontrolled partial -onset sei zures; must meet the following:
a.At least 16 reported quantifiable (no cluster or innumerable seizures) partial -onset 
seizures (as defined in Inclusion Criteria 3) over the Baseline period (56 day s, 8 
weeks) with no continuous 21- day seizure -free period between Visit 1 (Screening 
Visit) and Visit 2 (Randomization visit), as per data captured in daily  seizure diaries .
b.Prior history  of failure to control partial
-onset seizures despi[INVESTIGATOR_579148]
c.Prior or concurrent use of vagal nerve stimulator (VNS) is allowed. If the patient is 
using VNS, device stimulator parameters must remain constant throughout the study .
d.Prior epi[INVESTIGATOR_579149] [ADDRESS_760886] 4 weeks at the start 
of the 8- week prospective Baseline phase, remain on the same regimen throughout the 
Baseline phase, and intend to continue the same regimen throughout the 18 -week double 
blind Core phase (rescue medications are permitted, as defined in the Rescue Medications 
Section 6.1.2). No more than oneof these can be a strong CYP3A4 inducer (e.g., 
Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_050], Phenobarbital, Pheny toin, Primidone)
6.If female of child bearing potential, documentation of negative pregnancy  test at time of 
informe d consent. Females of child -bearing potential, defined as all women 
physiologicall y capable of becoming pregnant, must use highl y effective contraception 
during the stud y and for 8 weeks after stoppi[INVESTIGATOR_056]. Highly effective contraception 
is defined a s either:
Total abstinence: When this is in line with the preferred and usual lifest yle of the 
subject. [Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception]
Sterilization: have had surgical bilateral oophorectomy  (with or without hysterectom y) 
or tubal ligation at least six weeks before taking study  treatment. In case of 
oophorectom y alone, only when the reproductive status of the woman has been 
confirmed b y follo w up hormone level assessment
Male partner sterilization , at least 6 months prior to screening visit, (with the 
appropriate post -vasectomy  documentation of the absence of sperm in the ejaculate). 
[For female subjects on the study , the vasectomized male par tner should be the sole 
partner for that subject].
Use of a combination of any  two of the following (a+b or a+c or b+c):
a.Use of oral, injected or implanted hormonal methods of contraception
b.Placement of an intrauterine device (IUD) or intrauterine s ystem ( IUS)
c.Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
In case of use of oral contraception women should have been stable on the oral agent before 
taking st udy treatment for at least 3 months.

[COMPANY_001] Confidential Page 51
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
7.Sexually  active males must use a condom during intercourse while taking study  drug, and 
for 8 weeks after stoppi[INVESTIGATOR_105762] y treatment. They  should not father a child during this 
period. A condom is required to be used also by [CONTACT_579239].
8.Hepatic, renal and blood laboratory  values within th
e following range at screening:
AST and ALT levels < 2.[ADDRESS_760887]
serum bilirubin <1.5 × ULN (this limit does not apply  to patients with an elevated 
indirect bilirubin, if they  have Gilbert’s S yndrome) ,
serum creatinine < 1.[ADDRESS_760888],
hemoglobin ≥ 9 g/dL,
platelets ≥ 80,000/mm3,
absolute neutrophil count ≥ 1,000/mm3
9. Written informed consent. Subjects or their legal guardians must have the ability  to 
comprehend the informed consent form and be willing to provide informed consent. For 
subjects who are too y oung or unable to comprehend the written consent, a legal guardian
who is able to describe and provide an understanding of the informed consent to the 
subject must sign the consent form on behalf of the subject. In all cases, the informed 
consent process will follow the local rules and regulations .
10.Patient or caregiver must be able to reliabl y record seizures and keep a daily  diary and 
recall adverse events.
5.[ADDRESS_760889] not meet anyof the following criteria:
1.Patients with seizures secondary  to metabolic, toxic, infectious or ps ychogenic disorder or 
drug abuse or current seizures related to an acute medical illness .
2.Presence of only  non-motor partial seizures (Criteria Not Applicable per Amendment 2)
3.Patients with TSC who have SEGA in need of immediate surgical intervention.
4.Patients under 2 years of age with untreated infantile spasms .
5.Within 52 weeks prior to study  entry , an epi[INVESTIGATOR_261407], defined as:
a.in adults and children 5 years and older 
--continuous or intermittent, convulsive 
seizures lasting more than 10 minutes and requiring additional medical intervention 
such as with rescue medication not commonly  used in the home (i.e., a convulsive 
seizure or series of convulsive seizures not within the patient’s t ypi[INVESTIGATOR_579150]).
b.in children less than 5 years of age -- continuous or intermittent, convulsive seizures 
lasting more than 10 minutes and requiring significant additional medical 
intervention such as hospi[INVESTIGATOR_059] (note: I t is recognized that some y oung patients 
may be sent for emergency  care despi[INVESTIGATOR_299575] a seizure within their 
typi[INVESTIGATOR_579151]. Onl y the more severe epi[INVESTIGATOR_579152], such as those leading to hospi[INVESTIGATOR_059], would 
qualify  as status epi[INVESTIGATOR_7397]).

[COMPANY_001] Confidential Page 52
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
6.Patients with history  of seizure clusters (where i ndividual seizures cannot be accuratel y 
counted according to the judgment of the investigator) occurring within 26 weeks prior to 
study  entry .
7.Patients who require rescue medication during the Baseline phase for more than 6 days.
8.Patients with n
on-TSC rela ted progressive encephalopathy .
9.Patients who weigh less than 12 kg .
10. Patients with coexisting malignancies within the 3 y ears prior to randomization, except for 
adequatel y treated carcinoma of the cervix or basal or squamous cell carcinomas of the 
skin.
11. Pat ients with a ny severe and/or uncontrolled medical conditions at randomization such as:
a.Symptomatic congestive heart failure of [LOCATION_001] Heart Association Class III or IV, 
history  of left ventricular ejection fraction (LVEF) < 50%, QTc interval >460ms, 
congenital QT s yndrome, unstable angina pectoris, myocardial infarction within [ADDRESS_760890] on room air should be considered to exclude restrictive pulmonary  
disease, pneumonitis or pulmonary  infiltrates.
c.Impairment of gastroin testinal function or gastrointestinal disease that may  
significantl y alter the absorption of everolimus (e.g., ulcerative disease, malabsorption 
syndrome or small bowel resection).
d.liver disease such as cirrhosis, decompensated liver disease, and chronic h epatitis (i.e. 
quantifiable HBV -DNA and/or positive HbsAg, quantifiable HCV- RNA),
e.Uncontrolled diabetes as defined b y fasting serum glucose > 1.5 × ULN.
f.Active skin, mucosa, ocular or GI disorders of Grade > 1.
g.Active (acute or chronic) or uncontrolled sev ere infections.
h.A known history  of HIV seropositivity  or other active viral infections .
12. Patients with an active, bleeding diathesis.
13.Patient with uncontrolled hy perlipi[INVESTIGATOR_035]: fasting serum cholesterol > 300 mg/dL 
OR >7.75 mmol/L  AND fasting trigl ycerides > 2.[ADDRESS_760891] not recovered from the side effects of an y major surgery  
(defined as requiring general anesthesia) ,or patients that may  requ ire major surgery  
during the course of the study .
15.Patients with a prior history  of organ transplant.
16. Patients receiving more than 3 antiepi[INVESTIGATOR_579153] y time in the baseline phase or at 
randomization or who change the dose of the AEDs during 4 weeks before screening or 
during the baseline period.
17. Patients being treated with felbamate, unless treatment has been continuous for ≥ 1year.
18.Patients currentl y receiving anticancer therapi[INVESTIGATOR_579154] 4 weeks of stud y entry (including chemotherapy , radiation therap y, antibody  based 
therap y, etc.).

[COMPANY_001] Confidential Page 53
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
19.Prior treatment with an y investigational drug within the preceding [ADDRESS_760892] received prior treatment with a systemic mTOR inhibitor (sirolimus, 
temsirolimus, everolimus) within [ADDRESS_760893] received 
prior treatment with a topi[INVESTIGATOR_579155] (sirolimus, temsirolimus, everolimus) 
within 4 weeks of stud y entry .
22.Patients with a known hypersensitivity  to everolimus or other rapam ycin-analogues 
(sirolimus, temsirolimus) or to its excipi[INVESTIGATOR_840].
23.Patients with a history  of non -compliance to medical regimens or who are considered 
potentially  unreliable or will not be able to complete the entire study.
24.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test.
25.Patients with a Score of 4 or 5 on the Suicidal Ideation item within 2 y ears of Screening, 
or an y “yes” on the Suicidal Behavior item of the Columbia -Suicide Severity  Rating Scale 
at Screening or Baseline who upon follow up with a healthcare professional are found to 
be severely depressed or suicidal .
26.Maintenance of a diet consisting of<40 g of carbohy drate per day  within 3 mon ths of 
screening .
6 Treatment
6.1 S
tudy  treatment
Patients will be randomized to one of the following three treatment arms:
Investigational therap y:
Everolimus tablets for oral suspension (dispersible tablets) with ti tration to trough range of
3-7 ng/mL
Everolimus 
tablets for oral suspension with tit ration to trough range of 9-15 ng/mL
Control therapy :
Placebo
6.1.1 Dosing Regimen
Table 6-1 Dose and Treatment Schedule
Study  drugs Pharmaceutical form and route of administration Freq uency Route of administration
Everolimus 2mg tablets for oral suspension daily (qd) Oral
Placebo Matching placebo tablets daily (qd) Oral

[COMPANY_001] Confidential Page 54
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Study  drug (everolimus or matching placebo) will be dispensed by [CONTACT_579240] 0, 2, 4, 6, 10, [ADDRESS_760894] the patient to take the study  drug 
exactly  as prescribed 
(promote compliance). The patient will take the first dose of study  drug 
(Day  1) at the center. All dosages prescribed and administered to the patient and all dose 
changes during the stud ymust be recorded on the Dosage Administration Record CRF.
Study  drug will be packaged in blister packs, and placed in boxes with color -coded labels of 
color [ADDRESS_760895] Extension phase, 
only everolimus will be dispensed. See Section 6.5.2 .
At the start of the Core phase, I RT will inform the investigator how many
 tablets from each of 
the Color 1 and Color 2 labeled boxes should be taken to administer the starting dose, as per 
Section [IP_ADDRESS]. Then at Weeks 1, [ADDRESS_760896] blood 
samples drawn and sent to a PK lab for determination of the trough level of everolimus, with 
results forwarded toIRT. In turn, IRT will inform the investigator of the dosing for the 
following 2 weeks, in terms of number of tablets to be taken from each of the Color 1and 
Color 2labeled boxes ,based on the observed everolimus trough level and the targeted trough 
range of the patient’s randomization arm. That is, the dose could be increased, maintained or 
decreased in order to reach and maintain the targeted trough range. For patients in the placebo 
arm, the starting dose will be increased, maintained or decreased acc ording to a randomization 
list, designed to resemble possible titrations on the everolimus arms. PK samples will also be 
taken at weeks 10 and 14 for all patients to monitor whether the targeted trough level is being 
maintained with I RT giving appropriate instructions to change the dose if necessary .
The potential for unmasking the blind is minimized because all patients in each treatment arm 
can receive either orboth Color 1 and Color 2 labeled boxes at each visit except 
Randomization , and because patients randomized to the Everolimus Low group (target trough 
3-7 ng/m L) will sometimes have placebo in the Color 1 labeled box and sometimes in the 
Color 2 labeled box
. At Randomization only one color labeled box will be dispensed because 
it would be possible to ascertain which box contained active drug due to the formula for the 
starting dose.
At the start of the Extension phase, patients will be assigned to new kit types 
(see Section 6.5.2). From Weeks 18-26 all patients will be transitioned towards a common
targeted trough range of 6 to 10 ng/ml to avoid compromising the blind in the earlier Core 
phase. Starting at Week 26, 
investigators will be provided with the Cmin results and will be 
permitted to make their own titration decisions.
Patients randomized to one of the two everolimus arms will be transitioned at Week 18based 
on the prior PK value .

[COMPANY_001] Confidential Page 55
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Placebo patients will start everolimus at Week 18, and be dosed according to the starting dose 
instructions in Section 
[IP_ADDRESS]. The targeted trough range will be 6to 10ng/mL .PK will be 
taken at Week 19with appropriate titration dosing instructions given at the Week 20 visit.
Patients are expected to approach or be within the planned target trough range of 6 to 10 
ng/ml after the Week 20 titration .
At the Week 26 visit, investigators will be provided with the Week 22 C minresult, and IRT 
will recommend a dose change using a wider targeted trough range of 3 to 15 ng/ml. 
Investigators will be able to override the IRT recommendation subject to the rules defined in 
Section 6.2.2, although dose increases will not be allowed if Cmin >=15 ng/ml . Investigator -
led titrations will be possible at all future visits in the extension phase, based on PK samples 
taken at Weeks 26, 30 and every
 12 weeks thereafter, until the Core phase results are ava ilable, 
and a preferred trough range can be recommended .
For patients who sign informed consent for Amendment 2 of the protocol after completing 
their Week 18 visit, a modified transition schedule will be permitted in the Extension Phase.
This s chedule may begin at week 26, 30 or at any subsequent scheduled visit (every  12 weeks
thereafter ).At the first such visit, the everolimus dose will be transitioned based on the prior 
PK value using a targeted trough 
range of 6-10 ng/ml (Transition visit A).The pati ent will 
return the following week for an everolimus PK sample (Transition visit B), and the following 
week, for disclosure of the PK value (Transition visit C). The investigator may begin to make 
his/her own dose adjustment decisions or rel y on the I RT s ystem to prescribe a dose .
For any patient participating in the Post Extension phase, the investigator will have complete 
control over the dosing, although dose increases should not be made if Cmin > 15 ng/ml. 
Investigators will confirm the Cmin value from the last PK drawn and make a decision on 
dosing. The investigator will enter into the IRT, the chosen total daily  dose in mg units and 
the IRT system will calculate how many  and which kits to dispense to supply  the patient until 
the next scheduled visit.
The results of the Core phase analy sis should be considered by [CONTACT_579241]/or Post Extension phase. Based on the 
analysis of the Core phase, it is recommended that the everolimus trough be maintained 
within 5 -15 ng/ml, subject to safet y and tolerability .
Dosing
Tablets for oral suspension are to be taken as a suspension only , and should not be swallowed 
whole, chewed, or crushed. The suspension can be prepared in an oral syringe or in a small 
drinking glass. Care should be taken to ensure the entire dose is administered. 
See Section 6.5.1.
Everolimus and/or the matching placebo should be administered after a light breakfast in the 
morning. If vomiting occurs, no attempt should be made to replace the vomited dose.
On the day s of PK sampling, patients should not take the dail y study  drug dose until AFTER 
blood work is drawn so that an accurate trough level of everolimus can be obtained. On days 
of scheduled visits, patients should bring their daily dose ofstudy drug into the clinic 
with them for administration after blood work is drawn .

[COMPANY_001] Confidential Page 56
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
During the titration periods, in absence of any other reason for holding study  drug, study  drug 
will be continued for up to 2 weeks while awaiting central PK lab results, which will be used 
to determine if a modification of the dosing regimen is indicated.
Patients should be requested to bring their unused study  drug, including the empt y blister 
packs, to the clinic at each visit. Compliance should be verified by [CONTACT_093] ’s staff by 
[CONTACT_579242]. The investigator (or his/her designee) 
will document dosage administration and all dose changes during the study  in the eCRF. The 
site must maintain an overall drug accountability  log for the study , as well as individual 
accountability  records for each patient. The dose, amount dispensed, amount received, and 
amount remaining unused must be recorded in the source document. Drug accountabilit y will 
be noted by [CONTACT_121191] . The patient 
will return all unused study  drug at each dispensing visit and at the end of the study .
[IP_ADDRESS] Starting Dose
Everolimus or matching placebo will be provided to the 
patient ,and the first dose will be 
taken at the site on the day of the Baseline visit (V2) after eligibility  is confirmed .Starting 
dose will be determined by [CONTACT_579243]’s age and concomita nt use of 
CYP3A4/PgP inducers is presented below in Table 6 -2.
Patients with TSC associated epi[INVESTIGATOR_579156]3A4 enzy me-inducing 
antiepi[INVESTIGATOR_006] (EIAEDs) which lead to an increase of everolimus apparent clearance. 
Some of these EIAEDs co
uld also be inducers of PgP .
Different starting doses, taking into account increased everolimus clearance in young patients 
and the use CYP3A4/PgP inducers (regardless of number) , will be used as follows:
Table 6
-2 Starting dose
Age Not receiving CYP3A4 /PgP inducer Receiving CYP3A4 /PgP inducer
Patients under the age of 10 6.0 mg/m2/day 9.0 mg/m2/day
Patients age 10 to 18 5.0 mg/m2/day 8.0 mg/m2/day
Patients age ≥18 3.0 mg/m2/day 5.0 mg/m2/day
The investigator will enter the patient’s age, height, weight, and CYP3A4/PgP inducer status 
into the IRT system, and the system will calculate the appropriate starting dose. Body surface 
area (BSA), in m2, will be calculated by [CONTACT_579244], where weight (W) 
is in kilograms and height (H) is in centimeters ( Dubois and Dubois 1916 ):
BSA = (W0.425X H0.725) X 0.[ADDRESS_760897] the investigator which kit number to 
assign to the patient, and how many  tablets should be taken from each color labeled box .
Commonly  prescribed EIAEDs that are used in this population include:
Pheny toin (Dy lantin®, Dilantin®Kapseals®, Dilantin®Infatabs®, Eptoin®, Epanutin®, 
Diphenin®, Dipheninum®, Pheny tek®)
Carbamazepi[INVESTIGATOR_050] (Tegretol®, Biston®, Calepsin®, Carbatrol®, Epi[INVESTIGATOR_29106]®, Equetro®, Finlepsin®, 
Sirtal®, Stazepi[INVESTIGATOR_050]®, Telesmin®, Teril®, Timonil®, Trimonil®, Epi[INVESTIGATOR_579157]®, and Degranol®)
Phenobarbital (Luminal®)

[COMPANY_001] Confidential Page 57
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Pentobarbital (Nembutal®)
Primidone (My soline®)
Oxcarbazepi[INVESTIGATOR_050] (Trileptal®)
6.1.[ADDRESS_760898] medical management. In such cases, rescue 
medications are permitted .
No new AEDs or changes to existing AED treatment (medication, dose, or frequency ) are 
permitted from 28 days prior to screening and throughout the Basel ine and Core phase of the 
study . In addition, the study  drug should not be increased beyond the protocol- defined limits 
to treat an y emerging/increasing epi[INVESTIGATOR_30989] y symptoms .
The choice of rescue medications (e.g., buccal midazolam, rectal diazepam and other 
benzodiazepi[INVESTIGATOR_1651]) to provide additional seizure control should follow the local institution’s 
practice. For the purpose of this study , rescue medications are only allowed for a period that 
does not exceed 6 cumulative days during the Baseline phase of the study; and does not 
exceed [ADDRESS_760899] during the Core Phase the study :
1.Loss of seizure control defined as an increase of 100% in the average weekly  number of 
partial -onset seizures for a minimum of 4 consecutive weeks as compared to the average
weekl y number of partial -onset seizures during the 8 weeks baseline period .
2. An epi[INVESTIGATOR_261407], defined as:
a.in adults and children 5 years and older -- continuous or intermittent, convulsive 
seizures lasting more than 10 minutes and requirin g additional medical intervention 
such as with rescue medication not commonly  used in the home (i.e., a convulsive 
seizure or series of convulsive seizures not within the patient’s t ypi[INVESTIGATOR_579150]).
b.in children less than 5 years of a ge --continuous or intermittent, convulsive seizures 
lasting more than 10 minutes and requiring significant additional medical intervention 
such as hospi[INVESTIGATOR_059] (note: I t is recognized that some y oung patients may be sent 
for emergency  care despi[INVESTIGATOR_299575] a seizure within their ty pi[INVESTIGATOR_579158]. Only  the more severe epi[INVESTIGATOR_579159], such as those leading to hospi[INVESTIGATOR_059], would qualify  as 
status epi[INVESTIGATOR_7397])

[COMPANY_001] Confidential Page 58
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
3.A single generalized tonic clonic seizure (non-febrile) , if none occurred during the 
baseline period , and if one has not occurred within the past y ear.
4. Use of rescue medications longer than the maximum duration described in Section 6.1.2.
5.
Treatment duration completed as per protocol: completion of the Core phase (if patients 
do not accept to start the extension phase), completion of the Extension phase or 
completion of the P ost Extension phase .
6. An interruption of one or more of the concomitant AEDs for more than 7 days
Other criteria for withdrawal from the stud y at an y time are:
Discovery  of failure of randomization or blinding
Discovery  of patient ineligibility
An interrupt ion of study  drug that lasts for more than 28 day s
Intolerable toxicity .
Pregnancy .
Withdrawal of consent.
In patients who have their dose interrupted for toxicity , if restarting study  drug upon 
resolution of the toxicity  requires dose reduction, and that reduction results in instruction 
to take [ADDRESS_760900] Extension phase.
6.2 Dose 
modif ication guidelines
6.2.1 Starting dose rationale
The starting doses shown in Table 6-2for patients in the different age groups were estimated 
based on data from Study  M2301. In this study , the geometric mean Cminvalues normalized to 
mg/m2dose were 0.97, 1.27, and 2.13 ng/mL per mg/m2dose for patients not taking 
CYP3A4/PgP inducer and of ages < 10 
years, 10to <18 y ears, and ≥ 18 y ears, respectivel y, 
suggesting a higher clearance of everolimus (normalized toBSA) in younger children. Based 
on these dose normalized Cminvalues , starting doses of 6.0, 5.0, and 3.0mg/m2/day for 
patients in the respective age groups are expected tolead to Cminsof 5.82, 
6.35, and 6.39 
ng/mL, respectivel y.
Table 6-3presents the predicted pre-dose concentration by [CONTACT_579245], for patients not taking CYP3A4/PgP inducers. 
The starting dose iscalculated based on BSA and then rounded to the nearest multiple of
2 
(everolimus is provided in 2-mg tablets )as described in Section 6.2.3.
The starting dose for patients receiving CYP3A4 /PgP inducers will be increased as per
Table 6-4.

[COMPANY_001] Confidential Page 59
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 6-3 Predicted pre -dose concentrations in patients of different age groups 
after the per protocol starting dose
For patients without concomitant use of CYP 3A4/PgP Enzyme Inducers (EI) :
Age groupBSA 
m2Starting 
dose 
(mg/m2)Starting dose 
in mg 
(calculated 
dose)Starting dose rounded to 
the nearest multiple of the 
2-mg tablet (actual dose) *Predicted Cminafter 
the rounded 
starting dose 
(ng/mL)
< 10 yr 0.4 6 2.40 2 mg (1 x 2 -mg tablet) 4.85
< 10 yr 0.5 6 3.00 4 mg ( 2x 2-mg tablet) 7.76
< 10 yr 0.6 6 3.60 4 mg (2 x 2 -mg tablets) 6.47
< 10 yr 0.7 6 4.20 4 mg (2 x 2 -mg tablets) 5.54
< 10 yr 0.8 6 4.80 4 mg (2 x 2 -mg tablets) 4.85
< 10 yr 0.9 6 5.40 6 mg (3 x 2 -mg tablets) 6.47
< 10 yr 1.0 6 6.00 6 mg (3 x 2 -mg tablets) 5.82
< 10 yr 1.1 6 6.60 6 mg (3 x 2 -mg tablets) 5.29
< 10 yr 1.2 6 7.20 8 mg (4 x 2 -mg tablets) 6.47
< 10 yr 1.3 6 7.80 8 mg (4 x 2 -mg tablets) 5.97
10 to <18 yr 0.9 5 4.50 4 mg (2 x 2 -mg tablets) 5.64
10 to <18 yr 1 5 5.00 6 mg ( 3x 2-mg tablets) 7.62
10 to <18 yr 1.1 5 5.50 6 mg (3 x 2 -mg tablets) 6.93
10 to <18 yr 1.2 5 6.00 6 mg (3 x 2 -mg tablets) 6.35
10 to <18 yr 1.3 5 6.50 6 mg (3 x 2 -mg tablets) 5.86
10 to <18 yr 1.4 5 7.00 8 mg ( 4x 2-mg tablets) 7.26
10 to <18 yr 1.5 5 7.50 8 mg (4 x 2 -mg tablets) 6.77
10 to <18 yr 1.6 5 8.00 8 mg (4 x 2 -mg tablets) 6.35
10 to <18 yr 1.7 5 8.50 8 mg (4 x 2 -mg tablets) 5.98
10 to <18 yr 1.8 5 9.00 10 mg (5 x 2 -mg tablets) 7.06
10 to <18 yr 1.9 5 9.50 10 mg (5 x 2 -mg tablets) 6.68
10 to <18 yr 2.0 5 10.00 10 mg (5 x 2 -mg tablets) 6.35
≥18 yr 1.5 3 4.50 4 mg (2 x 2 -mg tablets) 5.68
≥18 yr 1.6 3 4.80 4 mg (2 x 2-mg tablets) 5.33
≥18 yr 1.7 3 5.10 6 mg (3 x 2 -mg tablets) 7.52
≥18 yr 1.8 3 5.40 6 mg (3 x 2 -mg tablets) 7.10
≥18 yr 1.9 3 5.70 6 mg (3 x 2 -mg tablets) 6.73
≥18 yr 2.0 3 6.00 6 mg (3 x 2 -mg tablets) 6.39
*This is the dose of active drug. During the study patients may hav e placebo tablets added and sub tracted to 
maintain the blind.
6.2.2 Dose Titration
Table 6-2describes the starting dose and the dose levels that may be evaluated during this
trial.
Dose will be titrated viaInteractive Response Technology (IRT) in a blinded fashion until 
each patient reaches their assigned target trough range. The IRT will indicate from which of 
the 2 labeled boxes (color 1 or color 2) the tablet/s should be titrated or down titrated (to attain 
trough level or adverse events management).

[COMPANY_001] Confidential Page 60
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
The titration will be performed as follows:
Any age, NOCYP3A4/PgP inducers :one tablet (2 mg) total increments, regardless of 
BSA
Any age, WITH CYP3A4/PgP inducers : two tablets (4 mg) total increment, regardless of 
BSA .(In cases where a patient is taking 4 mg/day  and requires a dose reduction, the 
reduction would be b y one tablet ( 2 mg) .)
For example, a 4 year old patient not taking CYP3A4 /PgP inducers with a BSA of 0.65:
calculated as 0.65 × 6.0 = 3.9mg, rounded up to 4mg (2 tablets). If this patient’s first Cminis 
below 3ng/mL, his dose would be adjusted up from 4 mg (2 tablets) by [CONTACT_579246] 2 
mg(1 tablet) , for a total daily dose of 6 mg (3 tablets ).
Patients on placebo will have random increases and decreases in number of tablets taken to 
simulate titration and to maintain the blind. Patients in the low trough group will also have 
random increases and decreases in placebo tablets to simulate titration for the high trough 
group.
During the extension phase, placebo dose changes will be possible at the start of dose 
transition .Starting at the visit at which everolimus concentrations may be disclosed, placebo 
tablets will no longer be dispensed .
In the Extension phase, from Week 26 onwards when investigator -led dose titration is 
possible, dose changes should continue to be in units of 1 tablet (2 mg) for patients not taking 
CYP3A4/PgP inducers, and 2 tablets (4 mg) for patients taking CYP3A4/PgP inducers. The 
investigator will be allowed full discretion to increase the dose, as long as Cmindoes not 
exceed 15 ng/ml and to decrease the dose to a minimum of 1 tablet (2mg) per day .A dose and 
frequency  of less than 2 mg/day  requires study  treatment discontinu ation (see Section [IP_ADDRESS]).
In the Post Extension phase, the investigator will have indepe ndent control over the dosing to 
increase or decrease the dose. Dose increases should not be attempted if Cminis ≥15 ng/ml .
6.2.[ADDRESS_760901] multiple of 2 mg in order to 
use whole 2- mgtablets. For example:
Table 6-4 Examples for how to dose a patient
Patient 
ageBSA 
m2CYP3A4/PgP 
inducers?Starting 
dose 
(mg/m2) CalculationStarting 
dose in 
mg RoundStarting dose rounded 
to nearest multiple 2 -
mg tablet*
2 0.5 No 6 0.5 x 6 3.0 Up 4 mg (2 x 2 -mg tablet)
9 1.2 Yes 9 1.2 x 9 10.8 Down 10 mg (5 x 2 -mg tablets)
22 1.8 No 3 1.8 x 3 5.4 Up 6 mg (3 x 2 -mg tablets)
*This will be the active dose. Additional placebo tablets may be added or subtracted to maintain the blind.
If the starting dose in mg is an odd integer (i.e., 1, 3, 5, etc.), then the dose should be rounded 
up to the nearest multiple of 2 mg tablets (e.g., a starting dose of 3 mg would be rounded up to 
4 mg, corresponding to two 2 mg tablets).

[COMPANY_001] Confidential Page 61
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Titration
Titrati on will be done by [CONTACT_579247] 2 mg (patients not taking CYP3A4/PgP
inducers ) and 4 mg (patients taking CYP3A4 /PgP inducers ), so rounding will not be necessary .
In the examples above in Table 6-4, patients illustrated in rows 1 and 3 (2 and 22 y ears of age) 
will be titrated by 1 tablet, whereas the patient in row 2 (9 years old) will be titrated by [ADDRESS_760902] in 
titration .However, in the absence of adverse events requi ring a site visit (as assessed by [CONTACT_579248]), and if there are circumstances that 
make it difficult for the patient to go to the site, the PK samples can be taken at a local facility 
and sent to the central laboratory  for analysis, provided the study  PK kit is used and proper 
labeling, handling, and shipment procedures are followed. This will be done on an exception 
basis only .
6.2.[ADDRESS_760903] be communicated to the IRT.The IRT will give instructions as to the new number of 
tablets to be taken from each blister pack in order to implement the dose adjustment through 
the end of the Extension phase .
The following guidelines need to be applied:
All changes in dose must be recorded on the Dosage Administration Record eCRF.
The study  drug at the day of treatment can be administered at full dose, at reduced dose or 
held according to the below dose adjustment Table 6 -5, Table 6 - 6, Table 6 - 7, Table 6 -8, 
Table 6-9 and Table 6 -10andaccording to the actu al instructions from I RT as to the new 
number of tablets to be taken from each blister pack (Core and E xtension phase sonly).
During the Post Extension phase, IRT will dispense kit packs based on the dose 
determined b y the investigator.
If the stud y drug cannot be administered on the scheduled day , the administration of the 
study  drug will be skipped until the next day .
If the interruption of study drug lasts for more than [ADDRESS_760904] be withdrawn 
from the study .

[COMPANY_001] Confidential Page 62
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 6-5 Everolimus dose modification guidelines for non -hematologic 
toxicities
Toxicity Action
Pneumonitis Please refer to Section [IP_ADDRESS]
Reactivation of HBV or HCV flare Please refer to Section [IP_ADDRESS]
AST or ALT elevation
Grade 1 (> ULN -3.[ADDRESS_760905])
Grade 2 (> 3.[ADDRESS_760906])Maintain current dose level
AST or ALT elevation
Grade 3 ( > 5.[ADDRESS_760907])*Interrupt study drug administration until resolution to ≤ grade 1 (or ≤ 
grade 2 if baseline values were within the range of grade 2). If 
resolution occurs ≤ 7 days, study drug should be re- started at the dose 
level prior to interruption.
If resolution takes > 7 days, or if event recurs within 28 days, hold study 
drug until recovery to ≤ grade 1 or baseline grade / value and 
reintroduce study drug 2 tablets less for patients taking CYP3A4 /PgP
inducers, or 1 tablet less for patients NOT tak ing CYP3A4 /PgP inducers
AST or ALT elevation
Grade 4 (> [ADDRESS_760908])*
Recurrence of grade 4 after dose 
reduction or toxicity requiring study 
drug interruption for > 28 daysInterrupt study drug administration until resolution to ≤ grade 1 (or ≤ 
grade 2 if baseline values were within the range of grade 2). If 
resolution occurs ≤ 7 days, study drug should be re- started at 2 tablets 
less for patients taking CYP3A4 /PgP inducers, or 1 tablet less for 
patients NOT taking CYP3A4 /PgP inducers . If resolution tak es > 7 
days, discontinue study drug.
Discontinue study drug.
Intolerable grade 2 mucositis (see 
Section [IP_ADDRESS] ), or grade 3 AE, except 
hyperglycemia or hypertriglyceridemia 
or hypercholesterolemia (see Section 
[IP_ADDRESS] )Interrupt study drug administration until resolution to ≤ grade 1 or 
baseline grade / value.
If resolution occurs within ≤ 7 days, study drug should be re -started at 
the dose level prior to interruption.
If resolution takes > 7 days, or if event recurs within 28 days, hold study 
drug until recovery to ≤ grade 1 or baseline grade / value and 
reintroduce study drug 2 tablets less for patients taking CYP3A4 /PgP
inducers, or 1 tablet le ss for patients NOT taking CYP3A4 /PgP
inducers , if available.
Patients will be withdrawn from the study if they fail to recover to 
grade 1 or baseline grade / value within 28 days.
Any other grade 4 Hold study drug until recovery to grade 1 or baselin e value
Reintroduce study drug at one 2 tablets less for patients taking 
CYP3A4 /PgP inducers, or 1 tablet less for patients NOT taking 
CYP3A4 /PgP inducers , if available.
Grade 3 or 4 clinical liver failure 
(asterixis or encephalopathy/coma)Discontinue study drug
Recurrence of intolerable grade 2 
mucositis or grade 3 event after dose 
reductionReduce dose by 2 tablets less for patients taking CYP3A4 /PgP
inducers, or 1 tablet less for patients NOT taking CYP3A4 /PgP
inducers . The lowest possible dose leve l of study drug is [ADDRESS_760909] be discontinued.
Recurrence of grade 4 after dose 
reductionDiscontinue study drug
Any non -hematologic toxicity requiring 
study drug interruption for > 28 daysDiscontinue study drug
* Should HCV flare be confirmed, the guidelines for flare must take precedence

[COMPANY_001] Confidential Page 63
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 6-6 Dosing guidelines for study  drug -related hematologic toxicities
Toxicity Action
Grade 2 thrombocytopenia No action
Grade 3 thrombocytopenia Interrupt study drug until resolution to grade 1
If resolution occurs ≤ 7 days, reintroduce study drug at the dose level 
prior to interruption.
If resolution occurs > 7 days, or event occurs within 2 8 days, 
reintroduce study drug reduced 2 tablets less for patients taking 
CYP3A4 /PgP inducers, or 1 tablet less for patients NOT taking 
CYP3A4 /PgP inducers , if available.
Grade 4 thrombocytopenia Interrupt study drug until recovery to grade 1. Then reintroduce study 
drug at 2 tablets less for patients taking CYP3A4 /PgP inducers, or 1 
tablet less for patients NOT taking CYP3A4 /PgP inducers, if available.
Grade 3 neutropenia or anemia Interrupt study drug until resolution to grade ≤1 or baseline value
If AE resolution occurs ≤ 7 days, reintroduce study drug at the same 
dose level.
If AE resolution occurs > 7 days, or event occurs within 28 days, 
reintroduce study drug 2 tablets less for patients taking CYP3A4 /PgP
inducers, or 1 tablet les s for patients NOT taking CYP3A4 /PgP
inducers , if available.
Grade 4 neutropenia or anemia Interrupt study drug until recovery to grade 1 or baseline value. 
Reintroduce study drug at 2 tablets less for patients taking 
CYP3A4 /PgP inducers, or 1 tablet le ss for patients NOT taking 
CYP3A4 /PgP inducers , if available.
Febrile neutropenia Interrupt study drug until resolution to grade 1 (or baseline value) and 
no fever. Reintroduce study drug 2 tablets less for patients taking 
CYP3A4 /PgP inducers, or 1 tabl et less for patients NOT taking 
CYP3A4 /PgP inducers , if available.
Recurrence of grade 3 toxicity after 
dose reductionReduce dose 2 tablets less for patients taking CYP3A4 /PgP inducers, 
or 1 tablet less for patients NOT taking CYP3A4 /PgP inducers . The 
lowest possible dose level of study drug is [ADDRESS_760910] be discontinued.
Recurrence of grade 4 toxicity 
(including febrile neutropenia) after 
dose reductionDiscontinue study drug
Any hematologic toxicity requiring 
study drug interruption for > [ADDRESS_760911] frequently  observed with everolimus are rash, stomatitis /oral mucositis, 
non-infectious pneumonitis, fatigue, headache, anorexia, nausea, vomiting, diarrhea, and 
infections. Overall, the most frequently  observed laboratory  abnormalities include neutropenia, 
thrombocy topenia, hypercholester olemia, and/or hypertrigly ceridemia. The majority  of these 
AEs have 
been of mild to moderate severit y (NCI  CTC grade 1-2). Recommendations for 
dose adjustments, should any of these treatment -
related adverse events occur, are given in
Table 6-5, Table 6 -6,Table 6 - 7, Table 6 -9and Table 6 -10.
[IP_ADDRESS] Management of infections
Everolimus has immunosuppressive properties and may predispose patients to bacterial, 
fungal, viral or protozoal infections, including infections with opportunistic pathogens. 
Loca lized and systemic infections, including pneumonia, other bacterial infections, invasive 

[COMPANY_001] Confidential Page 64
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
fungal infections, such as aspergillosis or candidiasis and viral infections including 
reactivation of hepatitis B virus, have been described in patients taking e verol imus. Some of 
these infections have been severe (e.g. leading tosepsis, respi[INVESTIGATOR_579160]) and 
occasionall y have had a fatal outcome.
Physicians and patients should be aware of the increased risk of infection with everolimus. 
Treat pre-existing infections prior to starting treatment with everolimus. While taking 
everolimus, be vigilant for symptoms and signs of infection; if a diagnosis of infection is 
made, institute appropriate treatment promptly  and consider interruption or discontinuation of 
everolimus.
If a diagnosis of invasive systemic fungal infection is made, discontinue everolimus and treat 
with appropriate antifungal therap y.
[IP_ADDRESS] Management of skin toxicity
For patients with grade [ADDRESS_760912] be reported as an AE. Patients with grade 2 or higher toxicity  may be treated with 
the following suggested supportive measures at the discretion of the investigator: oral 
minocy cline, topi[INVESTIGATOR_321779], topi[INVESTIGATOR_579161], topi[INVESTIGATOR_029], 
diphenhy dramine, oral prednisolone (short course), topi[INVESTIGATOR_11930], or pi[INVESTIGATOR_031].
[IP_ADDRESS] Management of stomatitis / oral mucositis / mouth ulcers
Patients with a clinical history  of stomatitis/mucositis/mouth ulcers and those with 
gastrointestinal morbidity  associated with mouth/dental infections, irritation of esophageal 
mucosa e.g. gastroesophageal reflux disease (GERD) and pre-existing stomatitis/mucositis 
must be monitored even more closely . Patients should be instructed to report the first onset of 
buccal mucosa irritation/reddening to their stud y physician immediatel y.
Stomatitis/oral mucositis/mouth ulcers due to study  drug should be treated using local 
supportive care. Please note that investigators in e arlier trials have described the oral toxicities 
associated with everolimus as mouth ulcers, rather than mucositis or stomatitis. If your 
examination reveals mouth ulcers rather than a more general inflammation of the mouth, 
please classify  the adverse event as such. Please follow the paradigm below for treatment of 
stomatitis/oral mucositis/mouth ulcers:
1.For mild toxicity  (grade 1), use conservative measures such as non- alcoholic mouth wash 
or salt water (0.9%) mouth wash several times a day  until resoluti on.
2.For more severe toxicity  (grade [ADDRESS_760913] pain but are able to maintain 
adequate oral alimentation, or grade 3 in which case patients cannot maintain adequate 
oral alimentation), the suggested treatments are topi[INVESTIGATOR_032] (i.e., 
local anesthetics such as, benzocaine, but yl aminobenzoate, tetracaine hy drochloride, 
menthol, or phenol) with or without topi[INVESTIGATOR_11930], such as triamcinolone oral 
paste 0.1% (Kenalog in Orabase®).
3.Agents containing alcohol, hy drogen peroxide, iodine, and thy me derivatives may  tend to 
worsen mouth ulcers. It is preferable to avoid these agents.
Antifungal agents should be avoided unless a fungal infection is diagnosed. In particular, 
systemic imidazole antifungal agents (ketocona zole, fluconazole, itraconazole, etc.) should be 

[COMPANY_001] Confidential Page 65
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
avoided in all patients due to their strong inhibition of everolimus metabolism, therefore 
leading to higher everolimus exposures. Therefore, topi[INVESTIGATOR_579162].
[IP_ADDRESS] Management of diarrhea
Appearance of grade 1-[ADDRESS_760914] onset (for example 4 mg orally 
followed b y 2 mg orall y every  2 hours until reso
lution of diarrhea).
[IP_ADDRESS] Management of amenorrhea
Investigators should be aware of the identified risk of secondary  amenorrhea in post-
adolescent females. No changes in study  drug treatment or treatment with concomitant 
medications was implemented in prior cases.Nearl y all previous cases of amenorrhea for 
patients on study  resolved without treatment action. Amenorrhea did not result in any 
treatment discontinuations. If an amenorrhea event of at least [ADDRESS_760915] or other appropriate medical personnel is recommended.
[IP_ADDRESS] Management of hy perlipi[INVESTIGATOR_579163]-treatment status and dietary 
habits of the patient. Grade 2 or higher hypercholeste rolemia (>300 mg/dL or 7.75 mmol/L) 
or grade 2 hypertrigl yceridemia or higher (>2.5x upper normal limit) should be treated with a 
3-hydroxy - 3 -methy l-glutary l (HMG) -CoA reductase inhibitor (e.g. atorvastatin, pravastatin, 
fluvastatin) or appropriate trigl yceride -lowering medication, in addition to diet.
Note: Concomitant therapy  with fibrates and an HMG -CoA reductase inhibitor is associated 
with an increased risk of a rare but serious skeletal muscle toxicity  manifested by 
[CONTACT_579249], markedly  elevated creatine phosphokinase (CPK) levels and myoglobinuria, 
acute renal failure and sometimes death. The risk versus benefit of using this therap y should 
be determined for individual patients based on their risk of cardiovascular complications of 
hyperlipi[INVESTIGATOR_035].
Hypergl ycemia has been reported in clinical trials. Monitoring of fasting serum glucose is 
recommended prior to the start of study  drug and periodicall y thereafter. Optimal glycemic 
control should be achieved before starting a patient on study  drug.
[IP_ADDRESS] Management of non -infectious pneumonitis
Non-infectious pneumonitis is a class effect of rapamy cin derivatives. Cases of non -infectious 
pneumonitis (including interstitial lung disease) have also been described in patients taking 
everolimus. Some of these have been severe and on rare occasions, a fatal outcome was 
observed .
Individuals participating in this trial will be routinely questioned as to the presence of new or 
changed pulmonary  symptoms consistent with lung toxicity . Chest X -ray or CT/MRI  scan can
be performed if clinically  indicated. If non-infectious pneumonitis develops, the guidelines in 
Table 6-7should be followed. Consultation with a pulmonologist is recommended for any 
case of pneumoniti s that develops during the study.

[COMPANY_001] Confidential Page 66
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
A diagnosis of non -infectious pneumonitis should be considered in patients presenting 
with non- specific respi[INVESTIGATOR_579164] s ymptoms such as hy poxia, pleural effusion, cough 
or dy spnea, and in whom infectious, neoplastic and other non-medicinal causes have been 
excluded by  [CONTACT_129575]. Patients should be advised to report 
promptly  any new or worsening respi[INVESTIGATOR_23908].
Patients who develop radiological changes suggestive of non -infectious pneum onitis and 
have few or no s ymptoms may  continue everolimus therap y without dose alteration.
Table 6-[ADDRESS_760916] scans with lung windows. No specific 
therapy is requiredAdminister 100% of study 
treatment dose.
Grade 2 CT scan with lung windows. 
Consider pulmonary function testing 
includes: spi[INVESTIGATOR_038], D LCO, and 
room air O 2saturation at rest. 
Consider a bronchoscopy with 
biopsy and/or BAL. Monitoring at 
each visit until return to ≤ grade 1. 
Return to initial monitoring 
frequency if no recurrence.Symptomatic only. 
Consider 
corticos teroids 
and/or other 
supportive therapy 
if symptoms are 
troublesome.Reduce study treatment dose by 2 
tablets less for patients taking 
CYP3A4 /PgP inducers, or 1 tablet 
less for patients NOT taking 
CYP3A4 /PgP inducers until 
recovery to < Grade 1. Study 
treatment may also be interrupted 
if symptoms are troublesome. 
Patients will discontinue study 
treatment if they fail to recover to ≤
Grade [ADDRESS_760917] scan with lung windows and 
pulmonary function testing includes: 
spi[INVESTIGATOR_038], D LCO, and room air O [ADDRESS_760918]. Monitoring at 
each visit until return to ≤ grade 1. 
Return to initial monitoring 
frequency if no recurrence. 
Bronchoscopy with biopsy and/or 
BAL is recommended.Consider 
corticosteroids if 
infective origin is 
ruled out. Taper as
medically 
indicated.Hold treatment until recovery to ≤
Grade 1. May restart study 
treatment within 4 weeks at a 
reduced dose ( 2 tablets less for 
patients taking CYP3A4 /PgP
inducers, or 1 tablet less for 
patients NOT taking CYP3A4 /PgP
inducers ) if evidenc e of clinical 
benefit.
If toxicity recurs at grade 3, 
consider discontinuation of study 
drug.
Grade 4 CT scan with lung windows and 
required pulmonary function testing, 
if possible, includes: spi[INVESTIGATOR_038], 
DLCO, and room air O 2saturation at 
rest. Monitorin g at each visit until 
return to ≤ grade 1. Return to initial 
monitoring frequency if no 
recurrence. Bronchoscopy with 
biopsy and/or BAL is recommended 
if possible.Consider 
corticosteroids if 
infective origin is 
ruled out. Taper as 
medically 
indicated.Discontinue treatment.

[COMPANY_001] Confidential Page 67
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Management of hepatitis reactivation / flare
Monitoring and prophy lactic treatment for hepatitis B reactivation
Table 6-8provides details of monitoring and prophy lactic therap y according to the screening 
results of viral load and serologic markers testing.
Table [ADDRESS_760919] Result Result Result Result Result
HBV-DNA + + or - - - -
HbsAg + or - + - - -
HbsAb + or - + or - +
and no prior HBV 
vaccination+ or - -
or + with prior HBV 
vaccination
HbcAb + or - + or - + or - + -
Recommendation Excluded from the study No prophylaxis
Monitor HBV-DNA every 4 weeks 
(from Visit 2 and onwards)No specific action
Antiviral proph ylaxis therapy  should continue for at least [ADDRESS_760920] dose of study  drug. 
For HBV reactivation definition and management guidelines, see Table 6 -9.
Table 6
-9 Guidelines for the management of hepatitis B reactivation
HBV reactivation (with or without clinical signs and sy mptoms)*
For patients with baseline 
results: 
Positive HBV-DNA
OR
positive HBsAg
--------------------------------------
reactivation is defined as:
[Increase of 1 log in HBV-DNA 
relative to baseline HBV -DNA 
value OR new appearance of 
measurable HBV-DNA]Excluded from study
For patients with baseline 
results:
Negative HBV-DNA and HBsAg
AND
[Positive HBsAb (with no prior 
history of vaccination against 
HBV), OR positive HBcAb]
-------------------------------------
Reactivation is defined as:
New appearance of 
measurable HBV-DNATreat : Start first antiviral medic ation
AND
Interrupt study drug administration until resolution:
≤ undetectable (negative) HBV -DNA levels
If resolution occurs within ≤ 28 days, study drug should be re -started at 2 
tablets less for patients taking CYP3A4 /PgP inducers, or 1 tablet less for 
patients NOT taking CYP3A4 /PgP inducers , if available. If the patient is 
already receiving the lowest dose of study drug according to the protocol, the 
patient should restart at the same dose after resolution. Antiviral therapy 
should continue at least [ADDRESS_760921] dose of study drug.
If resolution occurs > [ADDRESS_760922] dose of study drug.
* All reactivations of HBV are to be recorde d as grade 3 (CTCAE Versi on 4.0 3 -Investigations/Other: Viral 
Reactivation), unless considered life threatening by [CONTACT_093], in which case they should be recorded as 
grade 4. Date of viral reactivation is the date on which the rise or reappearance of HBV -DNA was recorded.

[COMPANY_001] Confidential Page 68
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Monitoring for hepatitis C flare
The following categor yof patients should be monitored every  8 to 12 weeks for HCV flare:
Patients known to have a history  of HCV infection, despi[INVESTIGATOR_040] a negative viral load test at 
screening (including those that were treated and are considered ‘cured’)
For definitions of HCV flare and actions to be taken in the event of a flare, please refer to 
Table 6
-10.
Table 6-10 Guidelines for the management of hepatitis C flare
Baseline results HCV flare definition* HCV flare management
Detectable HCV -RNA > 2 log 10IU/mL increase in HCV-RNA
AND
ALT elevation > [ADDRESS_760923] hepatitis C 
infection with no detectable HCV-
RNANew appearance of detectable HCV -RNA
AND
ALT elevation > [ADDRESS_760924] or 3 x baseline level, 
whichever is higher.Discontinue study drug
* All flares of HCV are to be recorde d as grade 3 (CTCAE Version 4.0 3 -Investigations -Other: Viral Flare), 
unless considered life threatening by [CONTACT_093]; in which case they should be recorded as grade 4. Date of 
viral flare is the date on which both the cli nical criteria described above were met. (e.g., for a patient whose HCV -
RNA increased by 2 logs on 01 JAN 2011 and whose ALT reached > [ADDRESS_760925] on 22 JAN 2011, the date of viral 
flare is 22 JAN 2011).
6.[ADDRESS_760926] be instructed notto take any medications (over -the-counter or other products) 
during the protocol treatment period without prior consultation with the investigator. The 
investigator should instruct the patient to notify the study  site about any new medications 
he/she takes after the start of study  drug. All medications (other than study  drug) and 
significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) taken from 
thescreening visit through the 30-day safety follow up visit must be reported on the
Concomitant Medication/Significant Non Drug Therapi[INVESTIGATOR_14932]
.
6.3.1 Permitted concomitant therapy  requiring caution and/or action
[IP_ADDRESS] CYP3A 4 and P -glycoprotein inhibitors/inducers/substrates
Everolimus is metabolized by [CONTACT_097]3A4 in the liver and to some extent in the intestinal wall.
Everolimus is also a substrate of PgP .
For this study  patient population, many  patients will be taking concomitant CYP3A4/PgP
enzy me inducing drug .Therefore, their PK trough levels will be monitored closely .
Therefore:
Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, 
ritonavir) or P -glycoprotein (PgP) inhibitor should be avoided.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Co-administration with moderate CYP3A4 inhibitors (e.g., ery thromy cin, fluconazole) or 
PgP inhibitors should be used with caution. If a patient requires co -administration of 
moderate CYP3A4 inhibitors or PgP inhibitors, reduce the dose of study  drug to half the 
currentl y used dose. If the inhibitor is discontinued, consider a washout period of at least 
2-3 day s (average for the most commonly  used moderate inhibitors), before the study  drug 
dose is returned to the dose used prior to initiation of the moderate CYP3A4 and/or PgP 
inhibitor.
Seville orange s, star fruit, grapefr uit and their juices affect CYP3A4 and PgP activit y. 
Concomitant use should be avoided.
Forpatient s who require co-administration of strong CYP3A4 /PgP inducers (i.e., 
pheny toin, carbamazepi[INVESTIGATOR_050], rifampin, rifabutin, phenobarbital, St. John’s wort), the starting 
dose will be increased per Section [IP_ADDRESS], and titration will be done by  4mg increments .
This dose adjustment of study  drug is intended to achieve similar AUC to the range 
observed without i nducers. However, there are no clinical data with this dose adjustment 
in patients receiving CYP3A4 /PgP inducers. If the inducer is discontinued , consider a 
washout period of at least 3 -5 day s (reasonable time for significant enz yme de-induction), 
before the study  drug dose isreturned to the dose used prior to initiation of the 
CYP3A4/PgP inducer.
Anytime there is a change in inducers or inhibitors of CYP3A4 and/or PgP , trough PK 
levels will be checked and study  drug dose will be adjusted accordingly .
Please refer to Table 6-11listing relevant inducers and inhibitors of CYP3A 4and to Table 6-
12for a list of relevant substrates, inducers, and inhib itors of PgP. These table sare not all 
inclusive and are only  provided as guidance to the investigator.
Everolimus may affect the response to vaccinations making the response to the vaccination 
less effective. Live vaccines
, or contact [CONTACT_579250], should 
be avoided while a patient is treated with study  drug. Everolimus should not be administered 
within 2 weeks of receiving a live vaccine, //cdc.gov/mmwr/pdf/rr/rr6002.pdf .

[COMPANY_001] Confidential Page 70
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 6-11 Clinically  relevant drug interactions: inducers, and inhibitors of 
isoenzy me CYP3A [ADDRESS_760927]. John’s wort, rifabutin, phenobarbital, mitotane, enzalutamide, 
bosentan, efavirenz, etravirine, modafinil, nafcillin, genistein, ritonavir, thioridazine, tipranavir, semagacestat, 
talviraline, lopi[INVESTIGATOR_054], lersivirine, amprenavir, aprepi[INVESTIGATOR_053], armodafinil bexarotene, clobazam, danshen, 
dexamethasone, echinacea, garlic, g ingko (ginkgo biloba), glycyrrhizin, methylprednisolone, nevirapi[INVESTIGATOR_050], 
oxcarbazepi[INVESTIGATOR_050], pi[INVESTIGATOR_051], prednisone, pleconaril, primidone, raltegravir, rufinamide, sorafenib, telaprevir, 
terbinafine, topi[INVESTIGATOR_052], troglitazone, vinblastine, eslicarbazepi[INVESTIGATOR_050], ginsen g, vemurafenib, boceprevir, 
sulfinpyrazone, ticagleror, vicriviroc/ritonavir, ritonavir, ticlopi[INVESTIGATOR_5325], brivacetam, Stribild (combo of elvitegravir, 
cobicistat, emtricitabine, and tenofovir), quercetin.
Inhibitors
Strong inhibitors:
boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopi[INVESTIGATOR_054]/ritonavir, 
mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, sequinavir/ritonavir, telaprevir, 
telithromycin, voriconazole, indinavir/rito navir, tipranoavir/ritonavir, cobicistat, troleandomycin, danoprevir/ritonavir, 
eltegravir/ritonavir
Moderate inhibitors:
amprenavir, aprepi[INVESTIGATOR_053], atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, 
fosamprenavir, grapefru it juice, nilotinib imatinib, tofisopam, cyclosporin, ciprofloxacin, verapamil, dronedarone, 
crizotinib, casopi[INVESTIGATOR_053], amprenavir, atazanavir/ritonavir, duranavir, netupi[INVESTIGATOR_053], schisandra sphenanthera, cimetidine, 
lomitapi[INVESTIGATOR_579165] 6-12 Clinically  relevant drug interactions: substrates, inducers, inhibitors 
of PgP and PgP/CYP3A4 dual inhibitors
Substrates
digoxin, quinidine, paclitaxel, cyclosporine, sirolimus, tacrolimus, fentanyl, pphenytoin
Inducers
avasimibe , carbamazepi[INVESTIGATOR_050], efavirenz, genistein , phenytoin, quercetin, rifampin, St. John’s wort extract
PgP Inhibitors and PgP/CYP3A Dual Inhibitors
alogliptin, amiodarone, azithromycin, canaglifozin, captopril, carvedilol, clarithromycin, conivaptan, cremophor 
RH40, curcumin, diltiazem, dronedarone, elacridar, erythromycin, felodipi[INVESTIGATOR_050], fluvoxamine, ginko, indinavir, 
indinavir/ritonavir, itraconazole, ketoconazole, lapatinib, lopi[INVESTIGATOR_054]/ritonavir, mibefradil, milk thisle, mirabegron, 
nelfinavir, nifedipi[INVESTIGATOR_050], nitredipi[INVESTIGATOR_050], paroxetine, propafenone, quercetin, quinidine, ranolazine, rifampin, ritonavir, 
sequinavir/ritonavir, schisandra chinesis extract, simepravir, St. John’s wort extract, talinolol, telaprevir, 
telmisar tan, ticagrelor, tipranavir/ritonavir, tolvaptan, valspodar, vandetanib, verapamil voclosporin
Reference: Internal Clinical Pharmacology Drug -drug interaction (DDI) memo, updated 2015 , which summarizes 
DDI data from three sources including the FDA’s “Guidance for Industry, Drug Interaction Studies”, the University 
of Washington’s Drug Interaction Database, and Indiana University School of Medicine's Drug Interaction Table.
6.3.2 Prohibited concomitant therapy
No new AEDs or changes to existing AED treatme nt (medication, dose, or frequency ) are 
permitted from 28 days prior to screening and throughout the Baseline and Core phase of the 
study . In addition, the study  drug should not be increased beyond the protocol- defined limits 
to treat an y emerging/increasi ng epi[INVESTIGATOR_30989] y symptoms .
Patients may not take any  other mTOR inhibitor swhile on study .

[COMPANY_001] Confidential Page 71
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
6.4 Patient numbering, treatment assignment or randomization
6.4.1 Patient numbering
Each patient is identified in the study  by a Patient Number ( Patient No.), that is assigned whe n 
the patient is first enrolled for screening and is retained as the primary  identifier for the patient 
throughout his/her entire participation in the study . The Patient No. consists of the Center 
Number (Center No.) (as assigned by [CONTACT_579251]) with a sequential 
patient number suffixed to it, so that each subject is numbered uniquely  across the entire 
database. Upon signing the informed consent form, the patient is assigned to the next 
sequential Patient No. available to the investigator .
The investigator or designated staff will contact [CONTACT_64081]. Once assigned, the Patient No. must 
not be reused for any  other patient and the Patient No. for that individual must not be changed, 
even if the patient is re-screened. If the patient fails to be randomized or start treatment for 
any reason, the reason will be entered into the Screening Log eCRF .IRT must be notified 
within 2 day sof the Bas eline visit, that the patient was not randomized.
6.4.2 Treatment assignment or randomization
Patients will be assigned to one of the three treatment arms (Section 6.1) in order to obtain 
115 
patients in the placeb o arm, 115 patients in the everolimus 3-7 ng/ml trough arm and 125 
patients in the everolimus 9-15 ng/ml trough arm, which corresponds to a ratio of 
approximately  
1 : 1 : 1.09. See Section 10.[ADDRESS_760928] anation ofwhy 10 additional patients will 
be randomized in the everolimus 9 -15 ng/ml arm.
Randomization will be stratified by [CONTACT_579221]: (i) 1 to <6 
years; (ii) 6 to <12 y ears; (iii) 12 to <18 y ears; and (iv) ≥ [ADDRESS_760929] will be produced by [CONTACT_579252] (IRT)provider 
using a validated system that automates the random assignment of patient numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers. A separate medication randomization 
list will be produced by [CONTACT_64083] a validated system that automates the random assignment of medication numbers to 
medication packs containing each of the stud y treatments.
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized via 
IRT to one of the treatment arms. The investigator or his/her delegate will call or log on to the 
IRTand will enter the patient’s age, height, weight, and CYP3A4/PgP inducer status. The IRT 
system will then calculate the appropriate starting dose. The IRT will assign a randomization 
number to the patient, which will be used to link the patient to a treatment arm and will 
specify  a unique medication number fo r the first package of study treatment to be dispensed to 
the patient. The randomization number will not be communicated to the caller.

[COMPANY_001] Confidential Page 72
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
6.4.3 Treatment blinding
This is a double -blind study . Patients, investigators, site personnel and the [COMPANY_001] trial team 
will make every  effort to remain blinded to the identity  of the treatment from the time of 
randomization until database lock for the Core phase , using the following methods: (1) 
randomization data are kept strictly  confidential until the time of treatment unblinding. This 
information will not be accessible to anyone involved in the conduct of the study  with the 
exception of the DMC who will perform periodic safet y reviews. The DMC independent 
statistician and programmers, producing outputs for the DMC, will re main semi
-blinded to the 
treatment groups. (2) the identity  of the treatments will be concealed by [CONTACT_579253], labeling, schedule of administration and 
appearance. The following [COMPANY_001] personnel, all non-members of the study  team, will be 
unblinded: PK DMPK/BA (BA monitor) , 
Drug Suppl y Manager ,IRT Trials Account 
Manager, Independent Randomization Expert and Independent PK Expert .In addition, the 
following CRO vendors will be unblinded: for IRT  and for PK bioanaly sis(  
.
Unblinding will only occur in the case of patient emergencies (Section 8.3), during safet y 
review in the DMC if required (Section 
8.6), for regulatory  reporting purposes (if requested) 
and at the conclusion of the study .
6.[ADDRESS_760930] the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages 
prescribed to the patient and all dose changes during the study 
must be recorded o n the Dosage Administration Record eCRF .
Everolimus Dispersible Tablets are to be taken as a suspension only and should not be 
swallowed whole, chewed, or crushed. The suspension can be prepared in an oral s yringe or in 
a small drinking glass. Care should be taken to ensure the entire dose is administered .Enteric 
feeding tubes may  be used.
Administer the suspension immediately  after preparation. Discard the suspension if not 
administered within 60 minutes of preparation. Prepare the suspension in water onl y.
1.Using an oral syringe : The required number of tablets for oral suspension (maximum of 
five 2- mg tablets) should be placed into a [ADDRESS_760931] with the
dispersible tablet(s) .
2.A sufficient volume of water (approximately  5 mL) should be drawn up from a glass to 
cover the dispersible tablet(s). In addition, approximately  4 mL of air should be drawn up 
into the oral sy ringe. The filled oral sy ringe should be placed in a glass (tip up) and the 
contents left to disintegrate for 3 minutes, until the Everolimus Dispersible Tablets are in 
suspension.

[COMPANY_001] Confidential Page 73
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
3.Prior to administration, the oral s yringe should be inverted gentl y five times. While 
holding the oral s yringe in a n upright position (tip up), excess air should be removed 
carefully . The full contents of the oral s yringe should be immediately dispensed into the 
mouth of the patient, slowly  and gently .
4. The same volume of water and air should then be drawn up into the o ral syringe, and the 
contents should be swirled to suspend any  remaining particles. The full contents of the 
syringe should be dispensed into the mouth of the patient, slowly  and gently .
If more than five tablets are to be dispersed, steps [ADDRESS_760932] dispersion.
Using a small drinking glass or cup :
1.
The required number of tablets for oral suspension (maximum of five 2 -mg tablets) sh ould 
be placed into a small drinking glass (maximum size 100 mL  or 3.38 oz. ) containing 
approximately  25 mL (.85 oz.) of water. Do not break or crush tablets.
2. The tablets should be left to disintegrate for [ADDRESS_760933] with the drug.
6.5.2 Study drug packaging and labeling
The study  medication packaging has a 2 -part label. A unique medication number is printed on 
each part of this label which corresponds to one of the treatment arms. Responsible site 
personnel will identify  the study  treatment package(s) to dispense to the patient by [CONTACT_579254](s). Site personnel will add the patient number on 
the labe ls. Immediately before dispensing the package to the patient, site personnel will 
detach the outer part of the label from the packaging and affix it to the source document (Drug 
Accountability  Log) for that patient’s unique patient number.
Medication label s will be in the local language and comply  with the legal requirements of 
each country . They  will include storage conditions for the drug and the medication number 
but no information about the patient.
Study  drug will be packaged in blister packs, andplaced in boxes with color -coded labels 
color 1 or color 2 in order to maintain the blind. At each visit a patient will receive one or 
multiple boxes of medication of one or both color labels and the contents of each labeled box
will be as follows:

[COMPANY_001] Confidential Page 74
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 6-13 Core Phase Treatment
Patients randomized to: Core Phase Treatment
Everolimus High (target 
trough 9 -15 ng/ml)Color 1 Labeled box = everolimus 2mg tablets & Color 2 Labeled box= everolimus 
2mg tablets
Everolimus Low (target 
trough 3 -7 ng/ml)Color 1 Labeled box = everolimus 2mg tablets & Color 2 Labeled box = matching 
placebo tablets ,or
Color 1 Labeled box =matching placebo tablets & Color 2 Labeled box = 
everolimus 2mg t ablets
Placebo Color 1 Labeled box = placebo 2mg tablets & Color 2 Labeled box = matching 
placebo tablets
The potential for unmasking the blind is minimized because all patients in each treatment arm
receive either one or both Color 1 and Color 2 labeled boxes at each visit, and because 
patients randomized to the Everolimus Low group (target trough 3-7 ng/ml) will sometimes 
have placebo in the Color 1 labeled 
boxes and sometimes in the Color 2 labeled box .
At the start of the Extension phase, patie nts who were receiving placebo will receive
everolimus. At Week 26 and thereafter , investigators will be permitted to make their own dose 
titrations and only  everolimus tablets will be dispensed .
For patients alread y having completed week 18 of the study  at the time of signing the 
informed consent for protocol amendment 2, investigators will also be permitted to make their 
own dose changes, but only after a 2 week titration process that can begin at any upcoming 
scheduled visit on or after week 26. 
Such pat ients may continue to receive everolimus and 
placebo tablets, although only everolimus tablets will be dispensed once the Cmin value has 
been shared with the investigator.
Table 6
-14 Extension Phase Treatment
Patients originally  
randomized to: Dispensing Visit Extension Phase Treatment
Any treatment arm Before the first visit when 
Cmin is provided to the 
investigatorColor 1 Labeled box = everolimus 2mg tablets & Color 2 
Labeled box = matching placebo tablets
or
Color 1 Labeled box = matching placebo tablets & Color 2 
Labeled box = everolimus 2mg tablets
or
Color 1 Labeled box = everolimus 2mg tablets & Color 2 
Labeled box = everolimus 2mg tablets
On or after the first visit 
when Cmin is provided to 
the investigatorColor 1 Labeled box = everolimus 2mg tablets
or
Color 2 Labeled box = everolimus 2mg tablets
The dosing in the extension phase is designed to minimize the potential for unmasking the 
blind in the earlier Core phase. This is achieved by [CONTACT_579255] a common 
trough range of 6 to 10 ng/ml before any Cminvalue is provided to the investigator, and by 
[CONTACT_579256] .

[COMPANY_001] Confidential Page 75
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 6-[ADDRESS_760934] Extension Phase Treatment
Patients originally  
randomized to:Dispensing Visit Extension Phase Treatment
Any treatment arm Any dispensing visit everolimus 2mg tablets with Open Label design
As soon as the site is approved for the Post Extension Phase and the patient has signed the 
Informed Consent Form for the Post Extension Phase and related actions are completed in the 
IRT, the sy stem will assign onl y Open Label boxes to patients based on the selected dose. The 
system is managing the number of kits neede d by [CONTACT_102].
6.5.[ADDRESS_760935] access. Upon receipt, the study  treatment should be stored 
according to the instructions specified on the drug labels and in the [ Investigator’s Brochure ].
6.5.4 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit 
and information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Log.Information will be collected on the DAR eCRF as to how many  tablets 
each patient is taking from the Color [ADDRESS_760936] 
be captured in the source document at each patient visit. Study  site personnel will also affix 
the medication labels to the appropriate source document each time drug is dispensed to a 
patient.
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by [CONTACT_579257] . Patients will be asked to return 
all unused study  treatment and packaging 
on a regular basis, at the end of the study  or at the 
time of study  treatment discontinuation.
At study  close-out, and as appropriate during the course of the study , the investigator will 
return all used and unused study  treatment, packaging, drug labels, and a copy  of the 
completed drug accountability  logto the field monitor or to the [COMPANY_001] address provided in 
the investigator folder at each site.

[COMPANY_001] Confidential Page 76
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Handling of other study  treatment
Not applicable.
6.5.[ADDRESS_760937] all of the assessments and indicate with an “X”, the visits when 
they are performed. All data obtained from these assessments must be supported in the 
patient’s source documentation. No eCRF will be used as a source document. The category  in 
table indicates which data are entered into the database (D) or remain in source documents 
only (S).
T
ests, procedures and visits should occur on schedule whenever possible. However, test, 
procedures and visit that occur within the prescribed allowance windows indicated in Table 7 -
1andTable 7-2 will not constitute protocol deviations.

[COMPANY_001] Confidential Page 77
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7-1 Visit evaluation scheduleCategory
Protocol 
Section
Screening
BaselineCore PhaseEoT 
Core
(11)Extension Phase 
(visits every  12 weeks 
after #16)Transition
Visits8End of 
treatment 
Extensio
n (EoT)Follow 
up/Study  
Completio
n
Visit Number 1 2 3 4 5 6 7 8 9 10 777 12 13 14 15 16+ 201 202 778 779
Study  Week-8 0 1 2 3 4 5 6 10 14 18 19 20 2226
8308+
within 7 days of 
stoppi[INVESTIGATOR_126149]
30 days after EOT-2 to +4 wks*
56 to 70 days 
after V1*± 2 day s± 7 
days
± 2 days5
± 2 
days ± 7 day s
Obtain Informed 
ConsentD 11.3 X
IRT Registration S [IP_ADDRESS].1 X
Demography D [IP_ADDRESS] X
Inclusion/exclusion 
criteriaD [IP_ADDRESS] X X4
Screen failure log 
as neededD [IP_ADDRESS] X X
Relevant medical 
history/current 
medical conditionsD [IP_ADDRESS] X
Diagnosis of TSC D [IP_ADDRESS] X
Prior anti -TSC 
therapyD [IP_ADDRESS] X
Seizure history D [IP_ADDRESS] X
Previous AED 
therapyD [IP_ADDRESS] X

[COMPANY_001] Confidential Page 78
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304Category
Protocol 
Section
Screening
BaselineCore PhaseEoT 
Core
(11)Extension Phase 
(visits every  12 weeks 
after #16)Transition
Visits8End of 
treatment 
Extensio
n (EoT)Follow 
up/Study  
Completio
n
Visit Number 1 2 3 4 5 6 7 8 9 10 777 12 13 14 15 16+ 201 202 778 779
Study  Week-8 0 1 2 3 4 5 6 10 14 18 19 20 2226
8308+
within 7 days of 
stoppi[INVESTIGATOR_126149]
30 days after EOT-2 to +4 wks*
56 to 70 days 
after V1*± 2 day s± 7 
days
± 2 days5
± 2 
days ± 7 day s
Current AED 
therapyD [IP_ADDRESS] X
Concomitant 
medicationsD [IP_ADDRESS] X X X X X X X X X X X X X X X
Rescue 
medicationsD [IP_ADDRESS] X X X X X X X X X X X X X X
IRT Randomization S [IP_ADDRESS] X
Physical 
examinationS [IP_ADDRESS] X X X X X X X X X X X X X X
Neurological exam S [IP_ADDRESS] X X X X X X X X X X X X X X
Contact [CONTACT_55396][INVESTIGATOR_579166] 7.1.1 X
Distribute Seizure 
DiaryS [IP_ADDRESS] X X X X X X X X X X X X
Seizure data from 
diaryD [IP_ADDRESS] X X X X X X X X X X X X
Height7D [IP_ADDRESS] X X X X X X X X X X X X X X
Parental height D [IP_ADDRESS] X
Weight D [IP_ADDRESS] X X X X X X X X X X X X X X

[COMPANY_001] Confidential Page 79
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304Category
Protocol 
Section
Screening
BaselineCore PhaseEoT 
Core
(11)Extension Phase 
(visits every  12 weeks 
after #16)Transition
Visits8End of 
treatment 
Extensio
n (EoT)Follow 
up/Study  
Completio
n
Visit Number 1 2 3 4 5 6 7 8 9 10 777 12 13 14 15 16+ 201 202 778 779
Study  Week-8 0 1 2 3 4 5 6 10 14 18 19 20 2226
8308+
within 7 days of 
stoppi[INVESTIGATOR_126149]
30 days after EOT-2 to +4 wks*
56 to 70 days 
after V1*± 2 day s± 7 
days
± 2 days5
± 2 
days ± 7 day s
Vital signs D [IP_ADDRESS] X X X X X X X X X X X X X X
Tanner Staging6D [IP_ADDRESS] X X X X2X2
Developmental 
milestones6D [IP_ADDRESS] X X X X2X2
EOT (Core and 
Extension)D 7.1.6 X X
Pregnancy History, 
Menstrual History D [IP_ADDRESS] X
Distribute 
Menstrual DiaryS [IP_ADDRESS] X X X X X X X X X X X X
Menstrual 
MonitoringD [IP_ADDRESS] X X X X X X X X X X X
Laboratory  
assessments7.2.3.11
Hematology D [IP_ADDRESS].
1X X X X X X X X X X X X X X
Chemistry D [IP_ADDRESS].
2X X X X X X X X X X X X X X
Endocrine tests D [IP_ADDRESS].
3X X X X X

[COMPANY_001] Confidential Page 80
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304Category
Protocol 
Section
Screening
BaselineCore PhaseEoT 
Core
(11)Extension Phase 
(visits every  12 weeks 
after #16)Transition
Visits8End of 
treatment 
Extensio
n (EoT)Follow 
up/Study  
Completio
n
Visit Number 1 2 3 4 5 6 7 8 9 10 777 12 13 14 15 16+ 201 202 778 779
Study  Week-8 0 1 2 3 4 5 6 10 14 18 19 20 2226
8308+
within 7 days of 
stoppi[INVESTIGATOR_126149]
30 days after EOT-2 to +4 wks*
56 to 70 days 
after V1*± 2 day s± 7 
days
± 2 days5
± 2 
days ± 7 day s
Lipid Panel D [IP_ADDRESS].
4X X X X X X X X X X X X X X
Hepatitis testing D [IP_ADDRESS] , 
7.2.3.13X X X X X X X X X X X
Urinalysis D [IP_ADDRESS].
5X X X X X X X X X X X X X
Urine Pregnancy 
testD [IP_ADDRESS].
6X X X X X X X X X X
Serum Pregnancy 
testD [IP_ADDRESS].
6X X X
Anti-Mullerian 
HormoneD [IP_ADDRESS].
7X X X9X9
ECG D [IP_ADDRESS].
1X
MRI1D [IP_ADDRESS] X X
EEG1D [IP_ADDRESS] X X
Safety
Adverse events D 8.1 X X X X X X X X X X X X X X X
Patient reported 
Outcomes7.2.5

[COMPANY_001] Confidential Page 81
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304Category
Protocol 
Section
Screening
BaselineCore PhaseEoT 
Core
(11)Extension Phase 
(visits every  12 weeks 
after #16)Transition
Visits8End of 
treatment 
Extensio
n (EoT)Follow 
up/Study  
Completio
n
Visit Number 1 2 3 4 5 6 7 8 9 10 777 12 13 14 15 16+ 201 202 778 779
Study  Week-8 0 1 2 3 4 5 6 10 14 18 19 20 2226
8308+
within 7 days of 
stoppi[INVESTIGATOR_126149]
30 days after EOT-2 to +4 wks*
56 to 70 days 
after V1*± 2 day s± 7 
days
± 2 days5
± 2 
days ± 7 day s
Seizure diaries S [IP_ADDRESS] X X X X X X X X X X X X X X X X X X X
WNV2D [IP_ADDRESS] X X X2X
Vineland2D [IP_ADDRESS] X X X2X
QOL D 7.2.5 X X X
eC-SSRS D [IP_ADDRESS] X X X X X X X X X X X X X X
Study Drug 
administration via 
IRT recorded on 
Everolimus/Placeb
o DARD [IP_ADDRESS] X X X X X X X X X X X X X
AED administration 
recorded on AED 
DARD [IP_ADDRESS] X` X X X X X X X X X X X X
Everolimus PK 
sampling D 7.2.4 X X X X X X X X X X X X
AED PK sampling D 7.2.4 X X X X

[COMPANY_001] Confidential Page 82
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304Category
Protocol 
Section
Screening
BaselineCore PhaseEoT 
Core
(11)Extension Phase 
(visits every  12 weeks 
after #16)Transition
Visits8End of 
treatment 
Extensio
n (EoT)Follow 
up/Study  
Completio
n
Visit Number 1 2 3 4 5 6 7 8 9 10 777 12 13 14 15 16+ 201 202 778 779
Study  Week-8 0 1 2 3 4 5 6 10 14 18 19 20 2226
8308+
within 7 days of 
stoppi[INVESTIGATOR_126149]
30 days after EOT-2 to +4 wks*
56 to 70 days 
after V1*± 2 day s± 7 
days
± 2 days5
± 2 
days ± [ADDRESS_760938] extension 
phaseS 4.1.4 ,
7.1.5X

[COMPANY_001] Confidential Page 83
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304Category
Protocol 
Section
Screening
BaselineCore PhaseEoT 
Core
(11)Extension Phase 
(visits every  12 weeks 
after #16)Transition
Visits8End of 
treatment 
Extensio
n (EoT)Follow 
up/Study  
Completio
n
Visit Number 1 2 3 4 5 6 7 8 9 10 777 12 13 14 15 16+ 201 202 778 779
Study  Week-8 0 1 2 3 4 5 6 10 14 18 19 20 2226
8308+
within 7 days of 
stoppi[INVESTIGATOR_126149]
30 days after EOT-2 to +4 wks*
56 to 70 days 
after V1*± 2 day s± 7 
days
± 2 days5
± 2 
days ± 7 day s
Study completion 
CRFD 7.1.7 X
* All procedures for screening visit must be performed within -2 weeks to + [ADDRESS_760939] be performed within -2 days of 
Baseline visit ( V2) and occur prior to first dose.
[ADDRESS_760940] sites during the study. Please refer to protocol Appendix A for more information
2WNV, Vineland, Tanner Staging, Develo pmental milestones, will be completed every 6 months after End of Core, i.e., Week 42, W eek 66 etc. Although there is an “X” in 
the Visit 16+ column, these assessments will not be done at Visit [ADDRESS_760941] passed since EOT Core Vis it 11 (777).
3
4Eligibility related to lab criteria will be based on central lab results from the Screening visit.
5+/- 7 days for permanent discontinuation. 
6Tanner staging is not required after 2 consecutive assessment scores of Stage 5 on both assessments. Tanner Staging will occu r at Baseline only for patients who enter 
the study with Stage 5 f or both assessments. Developmental milestones will be completed at the same time and frequency as Tanner Staging.
7Height is to be performed for adults at full development only at screening visit. Patients who are still growing will measure height at all visits.
8 Please refer to Section 4.1.3 for details and actions to be performed when transitioning patients to 6 to10 ng/ml starting at visits 26, 30+ in the Extension Phase
9AMH will be tested in females ≥10 years of age at Baseline, EOT core, Week 54 and every 48 weeks thereafter.

[COMPANY_001] Confidential Page 84
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7-2 Visit Evaluation Schedule: Post Extension PhaseCategoryProtocol 
Section Post Extension Phase Visits
(every  12 weeks)End of treatment
Post Extension (EoT) Follow up/Study  Completion
Visit Number401, 402, 403+
±7 day s780
±7 day s 779
Obtain Informed 
Consent 1S 11.3 X
Physical examination S [IP_ADDRESS] X X
Tanner Staging2D [IP_ADDRESS] X
Development 
Milestones2D [IP_ADDRESS] X
Neurological exam S [IP_ADDRESS] X X
Height D [IP_ADDRESS] X X
Weight D [IP_ADDRESS] X X
Vital signs D [IP_ADDRESS] X X
EOT (Post Extension) D 7.1.6 X
Laboratory  
assessments7.2.3.11
Hematology D [IP_ADDRESS].1 X X
Chemistry D [IP_ADDRESS].2 X X
Endocrine tests D [IP_ADDRESS].3 X X
Lipid Panel D [IP_ADDRESS].4 X X
Hepatitis testing
(if indicated)D [IP_ADDRESS] , 
7.2.3.13X X X
Urinalysis D [IP_ADDRESS].5 X X

[COMPANY_001] Confidential Page 85
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304CategoryProtocol 
Section Post Extension Phase Visits
(every  12 weeks)End of treatment
Post Extension (EoT) Follow up/Study  Completion
Visit Number401, 402, 403+
±7 day s780
±[ADDRESS_760942] D [IP_ADDRESS].6 X X
Serum Pregnancy 
test3D [IP_ADDRESS].6 X* X
Anti-Mullerian 
HormoneD [IP_ADDRESS].7 X X
ECG D [IP_ADDRESS].1 If clinically indicated
Safety
Adverse events D 8.1 X X X
eC-SSRS / 
Assessment of Mood 
and behaviorD [IP_ADDRESS] X X
Assessment of 
changes in seizure 
presentationD 7.2.[ADDRESS_760943] [IP_ADDRESS] X
AED administration 
recorded on AED 
DARD [IP_ADDRESS] X X
Everolimus PK 
sampling 4D 7.2.4 X
Concomitant 
medicationsD [IP_ADDRESS] X X X

[COMPANY_001] Confidential Page 86
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304CategoryProtocol 
Section Post Extension Phase Visits
(every  12 weeks)End of treatment
Post Extension (EoT) Follow up/Study  Completion
Visit Number401, 402, 403+
±7 day s780
±7 day s 779
Rescue medications D [IP_ADDRESS] X X X
Study completion 
CRFD 7.1.[ADDRESS_760944]
4Additional PK required as per Section 4.1.4

[COMPANY_001] Confidential Page 87
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
7.1.[ADDRESS_760945] be signed prior to any  screening procedure. The informed consent 
will provide information on study  requirements and study  procedures.
During the Screening visit (V1 /Week -8), the patient demographics and medical history , 
including TSC diagnos is, prior anti-TSC therapy , seizure history  and prior AED use will be 
assessed. A physical and neurological examination will be performed, as well as assessments 
for height, weight, vital signs , and risk of suicide using the eC-SSRS .Laboratory tests for 
hematology ,chemistry , hepatitis, lipi[INVESTIGATOR_805] , urinaly sis, and pregnancy  will be assessed. Also, PK 
sampling for the specified AEDs will be collected. An ECG will also be performed at 
screening. For applicable patients, all available pre-baseline height and weig ht data should be 
collected in order to adequatel y represent the patient’s rate of growth prior to starting the 
study .
In addition, inclusion and exclusion criteria will be evaluated. The patient should also be 
registered into the IRT s ystem as described i n the IRT Manual.
The Epi[INVESTIGATOR_579167], investigators will be asked to complete a detailed description of each patient’s 
seizures along with the seizure classification on a form that will be faxed tothe Epi[INVESTIGATOR_353243] .
A reviewer at the Consortium will review the form and provide feedback about the patient’s 
seizure classification to the Investigator.
Rescreening
Reassessment of any screening criteria is permitted for previously  screen failed patients.
Patients who did not meet the required seizures counts during the baseline phase would need 
to wait at least [ADDRESS_760946] two weeks prior to randomization.
Screening for hepatitis B
Prior to randomization, the following three categories of patients should be tested for hepatitis 
B viral load and serologic markers, that is, HBV -DNA, HBsAg, HBs Ab, and HBc Ab:
All patients who currently live in (or have lived in) Asia, Africa, Central and South 
America, Eastern Europe, Spain, Portugal and Greece.
[nc.cdc.gov/travel/ yellowbook/2010/chapter -2/hepatitis -b.aspx#849]
Patients with any  of the following risk factors:
known or suspected past hepatitis B infection,
blood transfusion(s) prior to 1990,
current or prior IV drug users,
current or prior dial ysis,

[COMPANY_001] Confidential Page 88
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
household contact [CONTACT_084] B infected patient(s),
current or prior high -risk sexual activity ,
body  pi[INVESTIGATOR_025],
mother known to have hepatitis B,
history  suggestive of hepatitis B infection, e.g., dark urine, jaundice, rig ht upper 
quadrant pain.
Additional patients at the discretion of the investigator
Patients with serological markers indicative of prior hepatitis B will be excluded from the 
study .
The management guidelines, inSection [IP_ADDRESS], are provided according to the results of the 
baseline assessment of viral load and serological markers for hepatitis B.
Screening for hepatitis C
Patients with any of the following risk factors for hepatitis C should be tested using 
quantitative RNA
-PCR:
known or suspected past hepatitis C infection (including patients with past interferon 
‘curative’ treatment),
blood transfusions prior to 1990,
current or prior IV drug users,
current or prior dial ysis,
household contact [CONTACT_579258] C infected patient(s),
current or prior high -risk sexual activity ,
body  pi[INVESTIGATOR_025].
At the discretion of the investigator, additional patients may  also be tested for hepatitis C.
The management guidelines, in Section [IP_ADDRESS], are provided according to the results of the 
baseline assessment of hepatitis C viral load.
For other screening assessments refer to 
Table 7 -1.
[IP_ADDRESS] Eligib ility screening
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The eligibility  check will be embedded in the IRT 
system. Please refer and comply  with detailed guidelines in the I RT manual.
[IP_ADDRESS] Information to be collected on screening failures
Patients who sign an informed consent but fail to be randomized for any reason will be 
considered a screen failure. The reason for not being randomized will be entered on the 
Screening Failure Log. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for Screen Failure patients. No other data 
will be entered into the clinical database for patients who are screen failures, u nless the patient 
experienced a Serious Adverse Event during the Baseline Phase (see Section 8 for SAE 

[COMPANY_001] Confidential Page 89
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
reporting details). Any data other than these that are entered by [CONTACT_579259], but they  will not be included for analy sis.If the patient fails to be randomized, 
the IRT must be notified within 2 day s of the screen fail that the patient was not randomized.
[IP_ADDRESS] Patient demographics and other baseline characteristics
Data wi ll be collected on patient characteristics, including demographic information (age, sex, 
ethnicity , race, weight) and other background or relevant medical history  (seizure type and 
frequency , date of epi[INVESTIGATOR_579168], and treatment history ).Information will also be 
collected regarding child -bearing potential, TSC diagnosis, TSC genetic testing, and any  other 
assessments that are done for the purpose of eligibility  for inclusion into the study  (physical 
and neurological examination, 
vital signs, hematolog y and blood chemistry , urinal ysis, 
pregnancy  test, ECG , and suicide risk assessed by [CONTACT_35959]-SSRS ).The prior and current AED 
and concomitant medication use , including VNS and ketogenic diet, will also be collected and 
recorded. For further details on eligi bility  assessments, please see Table 7 -1.
7.1.2 Baseline phase
The baseline phase consists of a screen ing visit (V1) at week -8 through the baseline visit (V2) 
at week 0.For more information on the screening visit, please see Section 
7.1.1. During this 
phase, patients should keep track of any seizures in the seizure diaries and any change in 
AEDs taken during this time.
Baselin e visit
During the baseline visit, inclusion and exclusion criteria will be re-assessed ,
(central lab 
results from the Screening visit), along with other assessments outlined in Table 7-1.
performed pri
or to first dose The use of seizure rescue medication from time of screening to 
baseline will also be collected. If a patient requires rescue medication for 7 or more
cumulative days during the Baseline phase , they  will not be able to continue to the Core phase 
of the study .A physical and neurological exam will be performed, as well as assessments for 
height, weight, vital signs, tanner staging, and laboratory  tests (hematology , chemistry , lipi[INVESTIGATOR_805], 
hepatitis, endocrine function, urinaly sis, and pregnancy ).  
 
 
The patient’s seizure history 
and AED use from screening to baseline will be assessed from the seizure diaries .In addition, 
assessments for developmental milestones, suicidality , qualit y of life and neurops ychological 
assessments will beperformed. Also, pregnancy  history , menstrual history , and mother’s 
reproductive history , andassessment of 
parental height will be conducted.
Adverse events and concomitant medications will also be assessed at this visit. For patients 
participating in the MRI substudy , an MRI and EEG will also be conducted at the Baseline 
visit. For more information on the MRI and EEG substudy , please see Appendix A .
All patients who continue to meet eligibility  criteria at the baseline visit (V2), including 
demonstrating the minimum seizure frequency  during the 8-week baseline phase (seeSection 
5.2), will be randomized in a 1:1:1 .09ratio to one of the three treatment arms as described in 
Section 
6.1. The patient should be randomized via the IRT system as described in the IRT 

[COMPANY_001] Confidential Page 90
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
manual. At that time, study  medication pack details and admini stration guidelines will be 
provided. Also, the first dose of study  drug should be administered.
7.1.3 Core phase
The Core phase begins at the baseline visit (Visit 2) and continues up to and includes Visit 11 
(week 18), at which time the patient would be offered inclusion into the extension phase.
At W eeks 2 (V4), 4 (V6), 6 (V8), 10 (V9), 14 (V10), and 18 (V11); assessments will include 
seizure diaries, use of AED medications, and suicidality  risk.Other assessments include use 
of rescue medications, physical and neurological exams, and height, weight, vital signs, and 
laboratory  tests (hematology , chemistry , lipi[INVESTIGATOR_805], hepatitis, and urinal ysis) .If applicable, 
pregnancy  testing and/or hepatit is testing will be assessed approximately  every month.
Endocrine testing will be done every  12 weeks.
At each visit during the Core phase , study  drug titration (if applicable) and dosing will also 
occur. Adverse events, concomitant medications, and drug accountabilit y will also be assessed 
at each visit.
Pharmacokinetic testing will be performed at various visits throughout the core phase for 
dosing and titration purposes. For more information on PK testing, see Section 7.2.4. Only  at 
the Week 14(V10) visit during the Core Phase, development milestones and Tanner staging 
will be assessed
.
The end of treatment (EOT) in the Core Phase is at Week 18 (Visit 11). In addition to the 
assessments above , at this visit , neuropsy chological and qualit y of life assessments will be 
performe d.
For more information about assessments, please see Table 7 -1.
7.1.4 Extension phase
All patients who complete the Core phase will be offered continuation on the Extension phase, 
during which all the patien
ts will receive everolimus at Week 18 [(V11) same visit as end of 
Core and start of extension)]. Patients will enter into this phase upon completion of the core 
phase, and will continue in the Extension phase until [ADDRESS_760947] patient completes 
the core phase. (Patients enrolled earlier in the study  may remain in the Extension phase for 
more than 1.5 years.)
During the Extension phase, visits will be at Weeks 18 (V11), 19 (V12), 20 (V13), 22 (V14), 
26 (V15), and 30 (V16), and then every  [ADDRESS_760948] two additional visits will be added for the purpose of 
transitioning towards a trough concentration range of 6
-10 ng/ml.
Assessments during the extension phase should be performed pre-dose andinclude seizure 
diaries, use of AED medications, and suicidality  risk will also be assessed and recorded. Other 
assessments include use of rescue medications, physical and neurological exams, and height, 
weight, vital signs, and laboratory  m easurements (including pregnancy  tests).
Pharmacokinetic testing for everolimus will be performed at all visits throughout the 
extension phase , except at Week 20 .

[COMPANY_001] Confidential Page 91
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
In the Extension phase, development milestones and Tanner staging will be done as outlined 
in Table 7-1. Menstrual monitoring will be assessed every  month (if applicable) .
At each visit during the Extension phase, study  drug titration (if applicable) and dosing will 
also occur. Adverse events, concomitant medications, and drug accountability  will also be 
assessed at each visit.
At the end of the Extension phase, an end of treatment visit will occur as described in Section 
7.1.[ADDRESS_760949] control over patient dosing and should follow the guidance outlined in 
Section 6 . Modified safety  assessm entswill be performed as described in Table 7 -2.
7.1.6 End of treatment visit and premature withdrawal
Premature withdrawal
Patients may voluntarily  withdraw from the study  or be dropped from the study at the 
discretion of the investigator at any time. For more detailed information, please see Section 
[IP_ADDRESS]
End of treatment (EOT)
There are three time points at which an EOT eCRF canbe completed for each patient. One 
will be at Visit 11/Week 18, marking the end of the Core phase of the study. Asecond will be 
when the patient completes the study  treatment in the Extension Phase and the third will be 
when the patient completes the Post Extension phase . At the time patients discontinue study 
treatment ,a visit should be scheduled as soon as possible, at which time all of the assessments 
listed for the End of Treatment (EOT )visit will be performed (Core ,  Extension or Post 
Extension as applicable) . An End of Treatment eCRF page should be completed, giving the 
date and reason for stoppi[INVESTIGATOR_271436] y treatment.
During the EOT visits
, assessments will include collection of concomitant and rescue 
medications, physical and neurological exam, height, weight, vital signs, and laboratory  tests 
assessments, including a pregnancy  test, the use of AED medications, and therisk of 
suicidality .For the Core and Extension phase EOT visits, seizure diary review ,  quality  of life 
and neurops ychological assessments will also be performed , and m enstrual monitoring will be 
reviewed as applicable.
At a minimum, all patients who discontinue study  treatment, including those who refuse to 
return for a final visit, will be contact[CONTACT_317609] [ADDRESS_760950] dose of study  treatment.

[COMPANY_001] Confidential Page 92
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Patients who discontinue study  treatment should be considered withdrawn from the study  after 
the final visit assessments are performed or when it is clear that the patient will not return for 
these assessments.
If a study withdrawal occurs, or if the patient fails to return for visits, the investigator must 
determine the primary  reason for a patient’s premature withdrawal from the study  and record 
this information on the End of Treatment eCRF .
The Investigator must contact [CONTACT_37284]’s discontinuation.
End of treatment/Premature withdrawal visit is not considered as the end of the study .
[IP_ADDRESS] Criteria for premature patient withdrawal
Patients may voluntaril y withdraw from the study or be dropped from it atthe discretion of 
the investigator at any time. Patients should be withdrawn from the study  if any of the 
following occur:
Pregnancy
Discovery  of failure of randomization or blinding
Discovery  of patient ineligibility
An interruption of study  drug that lasts for more than 28 day s.
Intolerable toxicity
Withdrawal of Consent
In patients who have their dose interrupted for toxicity , if restarting study  drug upon 
resolution of the toxicity  requires dose reduction, and that reduction results in instruction 
totake [ADDRESS_760951] Extension phases.
In addition to the general withdrawal criteria, the following study  specific criteria will also 
require stud y treatment discontinuation during the Core Phase :
Loss of seizure control defined as an increase of 100% in the average weekly  number of 
partial -onset seizures for a minimum of 4 consecutive weeks as compared to the average 
weekl y number of partial -onset seizures during the 8 weeks baseline period .
An epi[INVESTIGATOR_261407], defined as: in adults and children older than 5 y ears --
continuous or intermittent, convulsive seizures lasting more than 10 minutes and requiring 
additional medical intervention such as with rescue medication not commonly  used in the 
home (i.e., a convulsive seizure or series of convulsive seizures not within the patient’s 
typi[INVESTIGATOR_579151]) .
A single generalized tonic clonic seizure (non-febrile) , if none occurred during the 
baseline period, and if one has not occurred within the past y ear.
Use of rescue medications longer than the maximum duration described in Section 6.1.2.
An interruption of one or more of the concomitant AEDs for more than 7 day s
.

[COMPANY_001] Confidential Page 93
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Treatment duration completed as per protocol: completion of the Core phase (if patients 
do not accept to start the extension phase), completion of the E xtension phase (if patients 
do not accept to start the post extension phase) or completion of the Post Extension phase .
At the start of the Extension Phase, during the transition to investigator control of everolimus 
dosing, and while the everolimus Cmin value is still not shared with the investigator, the 
investigator should consider managing clinical deterioration in seizure control (as judged by 
[CONTACT_093]) , if it should occur, by [CONTACT_579235].
Starting at week 26, when everolimus Cmin values are made available to the investigator, the 
investigator may manage a patient’s clinical deterioration by [CONTACT_579236], adding 
and or subtracting AEDs and modify ing everolimus dosing in whatever order or combination 
the investigator chooses.
Patients who are withdrawn prematurely  will have an End of Treatment visit as close as 
possible to the day that study  drug is stopped. There will then be a follow -up visit 30 days 
after stud y drug is stopped.
7.1.7 Follow up /Study  compl etion
All patients will be followed for adverse events and serious adverse events for at least [ADDRESS_760952] dose of study  treatment. At the end of this period, the investigator should 
follow up with the patient about any adverse event observe d/concomitant medication taken 
during this period either in person (for patients who have continuing adverse events) or via a 
phone visit (for patients who do not have continuing adverse events .Also, patients who are 
being followed for possible hepatitis flare ups will have an office visit where they will be 
tested for hepatitis for the final time in the study .Female patients of child bearing potential 
will perform a urine pregnancy  test at home and report the results at this follow up.
Patients whose treatment is interrupted or permanently  discontinued due to an adverse event 
or abnormal laboratory  value must be followed until resolution or stabilization of the event, 
whichever comes first. In case the patient has any abnormal laboratory  values at end of 
treatment that are considered clinicall y significant by [CONTACT_093], the patient needs to 
come to the site for repeat blood analysis until resolution or stabilization including at least a 
site visit with respective anal yses [ADDRESS_760953] to 
follow -
up, the investigator should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, 
etc.

[COMPANY_001] Confidential Page 94
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
7.2 Assessment ty pes
7.2.1 Eligibility  assessments
[IP_ADDRESS] Patient History
A detailed patient history  will be taken, to include seizure history , TSC history  and any TSC-
related problems, major illness, surgeries, concomitant conditions. This information, including 
dates of diagnosis and whether or not the condition is still present will be recorded on the 
Relevant Medical History  eCRF.
[IP_ADDRESS] Diagnosis of TSC
Each patient must have a documented diagnosis of TSC per the modified Gomez criteria. See
Section 5.2, Inclusion criterion #2.This diagnosis will be recorded on the TSCDiagnosis 
eCRF.
[IP_ADDRESS] Prior anti -TSC therapy
A history  should be taken from each patient to document any  previous anti -TSC therapy  taken.
This information will be recorded on the Prior TSC therapy  eCRF. Patients may  not have been 
on prior anti -TSC therapy  within 24 months of randomization, unless they  were treated with a 
topi[INVESTIGATOR_579155] , in which case the washout time is 4 weeks.
[IP_ADDRESS] Prior A ED therapy
Each patient will be questioned to get 
a history  of prior anti-epi[INVESTIGATOR_579169] 4B is met, and the failed therapi[INVESTIGATOR_523765]. These prior therapi[INVESTIGATOR_579170].
[IP_ADDRESS] Inclusion/Exclusion criteria
Once all screening procedures have been completed, and the laboratory  results are back from 
the central lab, the patient’s results should be compared with the list of Inclusion/Exclusion 
Criteria in Section 5.2 and Section 5.3. If all criteria aremet at the Baseline visit (using lab 
results from screening visit)
, the patient may be randomized to receive study  drug. The 
eligibility  questionnaire must be completed per the I RT manual in order to initiate therapy .
[IP_ADDRESS] IRT randomization
When screening procedures are complete, and eligibility  is confirmed, the patient will be 
entered into the IRT sy stem to be randomized and have their first drug package assigned. This 
will be done per the IRT manual.

[COMPANY_001] Confidential Page 95
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
7.2.2 Efficacy  assessments
[IP_ADDRESS] Seizure diaries and counts
The investigator will review patient -specific seizure types and descriptions with the patient or 
caregiver at the screening visit, in order to ensure that all events are appropriatel y recorded 
throughout the study (the investigator may believe that some stereotypi[INVESTIGATOR_579171], but for patient safety , and to limit patient confusion, the investigator may 
instruct the patient to record and count such events as well) .Events will be counted daily  by 
[CONTACT_144911] ,following the Screening Visit , and entered into the diary  by [CONTACT_568], with 
seizures lasting more than [ADDRESS_760954] of 
“probable seizures” in consultation with the Epi[INVESTIGATOR_579172] (see Section 7.1.1 ) 
after the Screening Visit. Only  events characterized as “probable seizures” by [CONTACT_579260] , which will 
then be entered into t he eCRF.
[IP_ADDRESS] Study drug administration
At each study  visit, the site will log into the IRT system to get the next drug assignment for 
each patient. The assigned number package will be dispensed to the patient. The tear off 
portion of the label will be affixed to the patient -specific drug accountability log. The 
specifics of the drug administration will be recorded on DAR eCRF.
[IP_ADDRESS] AED therapy and administration
Patients must be taking one to three concomitant AEDs during the baseline and core phases of 
the study .These medications will be recorded on the AED DAR eCRF. The specific drugs 
and doses of these medications may not change 28 days prior to the screening visit and
through the core phase of the study .
The name , dose, and frequency  of concomitant AED therapy  will be asked about at every  visit.
Any changes will be recorded on the AED DAR eCRF.
[IP_ADDRESS] Rescue medications
Rescue medications are permitted as per Section 6.1.2. Any use of rescue medications will be 
recorded on the Rescue Medications eCRF.
7.2.[ADDRESS_760955] Extension phase, as part of safet y monitoring, assessments of changes 
in seizure presentation (i .e. frequency , intensit y and/or development of new seizure t ypes) will 
be collected.

[COMPANY_001] Confidential Page 96
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Neurobehavioral, neurode velopmental, and neurocognitive 
assessments
Wechsler Non- Verbal Scale of A bility
All patients aged >4 and <[ADDRESS_760956] Battery  at 
Baseline, at completion of the Core phase (EoT Core/ Visit 11/Week 18), and then every  6 
months (24 weeks)   through theEnd of Treatment Visit of the Extension phase .If the last 
assessment before the EOT Visit of the Extension phasewas less than 3 months prior to the 
EOT visit, the assessment does not need to be repeated.
For children >
4 and <8 years of age, the following 3 subtests will be administered at the 
aforementioned visits in the following order :Matrices, Coding, and Recognition.
For children and young adults >8 and <22 years of age, the following 3 subtests will be 
administered at the aforementioned visits in the following order : Matrices, Coding, and 
Spatial Span.
The instructions for this scale will be provided in English, German, Spanish, French, Chinese 
and Dutch.
Vineland II A daptive Behavior Scale
The Vineland is a scale that measures changes in certain behaviors. There are two forms 
which can be used to complete this scale. One is the Survey Interview Form, which a 
physician completes while interviewing /observing the patient. This form will be used when 
the investigator assesses that the patient is able to provide the information for the scale. The 
preference is for the Survey  Interview Form to be used. The second form is the 
Parent/Caregiver Form which is completed by [CONTACT_579261]. This form will be 
used when the physician assesses that the patient cannot provide the information for the scale.
The Parent/Caregiver Form should only  be considered for pa rents/caregivers who are likely  to 
complete the form accurately . Whichever form is used for the first assessment will be used 
throughout the stud y.
The appropriate Vineland Scale (Survey Interview or Parent/Caregiver) will be complete dat 
Baseline (Visit 2),completion of the Core phase (EOT Core/Visit 11/Week 18), and then 
every  6 months (24 weeks) through theEnd of Treatment Visit of the Extension phase . If the 
last assessment before the EOT Extension were to be less than 3 months pri
or to the EOT visit, 
the assessment need not be repeated. The Vineland aids in diagnosing and classify ing 
intellectual and developmental disabilities and other disorders, such as Autism, Asperger 
Syndrome, and developmental delay s. The Vineland will be provided in the following 
languages: Dutch, Dutch (BELG), English (Australian), English ([LOCATION_006]), English (US), English 
(CA), French, French (BELG), French (CA), German, German (BELG), Italian, Japanese, 
Polish, Spanish, Spanish (COL), and Spanish (US). These arethe only countries in which the 
Vineland Scale will be used. Other countries will skip the Vineland, and only complete the 
other scales. Scoring b y the site is not required for Vineland scales .

[COMPANY_001] Confidential Page 97
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Physical examination
Physical examination must include a total body  examination including: general appearance, 
skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph 
nodes, extremities, and basic neurological exam. If indicated based on medical history  and/or 
symptoms, rectal, e xternal genitalia, breast, and pelvic exams will be performed.
Significant findings that were present prior to the signing of informed consent must be 
included in the Relevant Medical History /Current Medical Conditions page on the patient’s 
eCRF. Significa nt new findings that begin or worsen after informed consent must be recorded 
on the Adverse Event page of the eCRF.
[IP_ADDRESS] Neurological examination
Neurological examination must include level of consciousness, mental status, speech, vision,
cranial nerves III, IV , and VI, motor, sensory  and gait/limb ataxia assessments.
Significant findings that were present prior to the signing of informed consent must be 
included in the Relevant Medical History /Current Medical Conditions page on the patient’s 
eCRF. Significant n ew findings that begin or worsen after informed consent must be recorded 
on the Adverse Event page of the eCRF.
[IP_ADDRESS] Tanner staging
Tanner staging will be performed as described in Table 7-1and Table 7-2and will consist of 
the parameters below for both males and females.
[IP_ADDRESS].1 Males
Genitalia stages:
Stage 1: Pre-adolescent. Testes, scrotum, and penis are of about the same size and proportion 
as in ea rly childhood.
Stage 2: The scrotum and testes have enlarged and there is a change in the texture of the 
scrotal skin. There is also some reddening of the scrotal skin.
Stage 3: Growth of the penis has occurred, at first mainly  in length but with some increase in 
breadth. There has been further growth of testes and scrotum.
Stage 4: Penis further enlarged in length and breadth with development of glans. Testes and 
scrotum further enlarged. There is also further darkening of the scrotal skin.
Stage 5: Genita lia adult in size and shape. No further enlargement takes place after Stage 5 is 
reached.
Pubic Hair Stages:
Stage 1: Pre -adolescent , no pubic hair .
Stage 2: Sparse growth of long, slightl y pi[INVESTIGATOR_49194], down y hair, straight or only slightl y 
curled, appearing chiefl y at the base of the penis .

[COMPANY_001] Confidential Page 98
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Stage 3: Considerably  darker, coarser, and more curled. The hair spreads sparsel y over the 
junction of the pubes.
Stage 4: Hair is now adult in type, but the area covered by [CONTACT_579262] y smaller than 
in most a dults. There is no spread to the medial surface of the thighs.
Stage 5: Adult in quantity and pattern and present along the inner borders of the thighs.
[IP_ADDRESS].[ADDRESS_760957] stages:
Stage 1: Pre -adolescent; elevation of papi[INVESTIGATOR_579173] y.
Stage 2: Breast bud stage; elevation of breast and papi[INVESTIGATOR_361491] a small mound, enlargement of 
areola diameter.
Stage 3: Further enlargement of breast and areola, with no separation of their contours.
Stage 4: Projection of areola and papi[INVESTIGATOR_361492] a secondary  mound above the level of the 
breast.
Stage 5: Mature stage; projection of papi[INVESTIGATOR_141877], due to recession of the areola to the general 
contour of the breast.
Pubic Hair Stages:
Stage 1: Pre-adolescent; the vellus over the pubes is not further developed than that over the 
anterior abdominal wall, i.e. no pubic hair.
Stage 2:Sparse growth of long, slightl y pi[INVESTIGATOR_49194], down y hair, straight or only slightl y 
curled, appearing chiefl y along the labia .
Stage 3: Considerably  darker, coarser, and more curled. The hair spreads sparsel y over the 
junction of the pubes.
Stage 4: Hair is now adult in type, but the area covered by [CONTACT_579262] y smaller than 
in most adults. There is no spread to the medial surface of the thighs.
Stage 5: Adult in quantity  and type, distributed as an inverse triangle of the classically 
feminine pattern. Spread to the medial surface of the thighs, 
but not up the linea alba or 
elsewhere above the base of the inverse triangle.
[IP_ADDRESS] Developmental milestones
Developmental milestones will be assessed at the visits listed in Table 7-1and Table 7-2and 
will include questions related to the expected secondary  sexual characteristics such as body 
hair, breast develo pment and voice change. Females will also be assessed on date of thelarch e, 
which is the first stage of secondary  (postnatal) breast development .
Males will be assessed on 
date of adrenarche , which includes changes in sweat composition, pubic hair growth, and 
increasing skin oiliness or acne .

[COMPANY_001] Confidential Page 99
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Pregnancy  Histor y, Menstrual History  and Monitoring
In order to provide additional follow -up on cases of amenorrhea, increased hormonal 
evaluation will be performed and supplemental medical history  will be collected .
Additional menstrual history  (previous cases of amenorrhea or menstrual disorders, biological 
mother’s age at menopause) and pregnancy  history  (pregnancies, full-term gestations, 
abortions, live births, living children) will be collected at baseline. Patients will be distributed 
menstrual diaries starting at the screening visit.
Menstrual monitoring will be collected 
monthly  at baseline and then every  4 weeks through Week 30. After Week 30, menstrual 
status will be collected monthly  until the End of Treatmen t Extension via patient menstrual 
diary  for source documentation ,data from the patient menstrual diary  will be collected during 
patient’s visit at clinical site for eCRF entry .Pregnancy  testing will be performed as described 
in Table 7-1and Table 7-2. It is recommended that study  coordinators contact [CONTACT_579263] 3 months to remind patients to document menstrual status in patient diary.
[IP_ADDRESS] Vital signs
Vital signs include blood pressure, temperature, pulse and respi[INVESTIGATOR_579174]. The 
results will be recorded on source documents, repeated at each visit and entered in eCRF 
starting at the screening visit and until the 30-day Safety Follow -upas described in 
Table 7
-1and Table 7 -2.
[IP_ADDRESS] Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured as described in 
Table [ADDRESS_760958] 
Extension Phase End of Treatment Visit. Pre-baseline height and weight will also be collected 
with a goal of collecting a minimum of three data points each 6 months apart for patients who 
enter the study  with a Tanner Stage of less than 5.Parental height will also be captured at 
baseline for purposes of comparing children’s height.
[IP_ADDRESS] Concomitant medications
Each patient will be queried at each visit regarding the use of any medication other than study 
drug. These drugs will be listed on the Concomitant Medications eCRF. The start date, stop 
date, and reason for each drug should be recorded. If the reason for a concomitant medication 
constitutes an 
adverse event after signing informed consent , this AE should be added to the 
AE eCRF.
[IP_ADDRESS] Columbia Suicide Severity Rating Scale (C- SSRS)
The Columbia -Suicide Severit y Rating Scale (C-SSRS) is a questionnaire that prospectively 
assesses Suicidal Ideation and Suicidal Behavior using a semi -structured interview to probe 
patient responses. The electronic version of this scale (eC-SSRS) will be administered via the 
IVR s ystem and will be completed at every  visit as outlined in Table 7- 1and Table 7-2.

[COMPANY_001] Confidential Page 100
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Patients [ADDRESS_760959] it completed by [CONTACT_579264]/Caregiver.
If at any assessment after Screening and/or Baseline the score is 4 or above on the Suicidal 
Ideation item or any “yes” on the Suicidal Behavior item, the patient must be referred to a 
health care professional for further assessment and/o r treatment. The decision on whether the 
study  treatment should be discontinued is to be taken by [CONTACT_352000].
Per health authorit y recommendations, it is important to closel y monitor the mental well-
being of patients taking medications actively  targeting their central nervous system. In the 
event that a patient ≥13 years of agedoes not complete the scale via the IVR system, the 
investigator will proactively  assess the patient for the presence of suicidality and mood 
disturbance as part of the monitoring of adverse events. The investigator should ask the 
patient whether he or she has thought about hurting himself/herself and whether the patients 
wished they  were dead, using words appropriate to the understanding of the individual patient. 
For all patients, t he investigator will also ask the caregiver whether the patient has done 
anything to seriousl y injure himself/herself (but excluding behaviors previously  associated 
with frustration, like hand biting, head banging etc.), or has expressed or exhibited significant 
changes in mood or behavior . These questions will be asked at every  visit during the study as 
described in Table [ADDRESS_760960] suicidal ideation or behavior is currently  mandated in 
studies of CNS active drugs.
The eC-SSRS system is available in various languages including but not limited to Chinese, 
Danish, Dutch, Dutch (BELG), English (Australian), English ([LOCATION_006]), English (US), English 
(CA), French, French (BEL G), French (CA), German, German (BELG), Greek, Hungarian, 
Italian, Japanese, Korean, Norwegian, Polish, Russian, Spanish, Spanish (MEX), Spanish 
(US), Swedish, Turkish and Thai.

[COMPANY_001] Confidential Page 101
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Laboratory  evaluations
Table 7-[ADDRESS_760961] Name
[CONTACT_157131], Hemoglobin, Platelets, Red blood cells, W hite blood cells, WBCMorphology with
Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils) , ANC
Chemistry Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Bicarbonate, Calcium, Chloride, 
Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Total Cholesterol (fasting) , LDL, 
HDL, Glucose (fasting), LDH (lactate dehydrogenase), Magnesium, Phosph ate, Potassium, 
Total Protein, Sodium, Triglycerides, Blood Urea Nitrogen (BUN), Uric Acid , Creatinine 
Clearance (calculated)
Urinalysis Macroscopic Panel (Dipstick) (Bilirubin, Blood, Glucose, Ketones, Leukocytes esterase, 
Nitrite, Protein, pH, Urobilinogen)
Hepatitis markers HBV-DNA, HbsAg, HbsAb, HbcAb, HCV RNA -PCR
Endocrine tests FSH, L H, estradiol, β-HCG and testosterone , Anti -Mullerian Hormone
A central laboratory  will be used for analy sis of all specimens collected. Details on the 
collections, shipment of samples and reporting of results by [CONTACT_64093] [Laboratory  Manual ].If a central lab result comes back that 
requires stat re-testing for safety , a local lab may be used. However, the central lab must be 
used for all stud y visits.
[IP_ADDRESS].[ADDRESS_760962] 
include: hemoglobin, hematocrit, platelets, red blood cell (RBC) count, total white blood cell 
(WBC) count and differential including lymphocy tes, monocy tes, neutrophils, eosinophils, 
basophils. Absolute Neutrophil Count (ANC) will be calculated b y the laboratory.
[IP_ADDRESS].2 Clinical chemistry
The following tests will be performed as indicated in Table 7-1and Table 7-2: sodium, 
potassium, chloride, bicarbonate, creatinine, LDH, albumin, total protein, SGOT (AST), 
SGPT (AL T), total bilirubin, indirect bilirubin, direct bilirubin, alkaline phosphatase, uric acid, 
BUN, calcium, magnesium, phosphate, and fasting glucose. Creatinine clearance will also be 
calculated.
[IP_ADDRESS].[ADDRESS_760963] s will be performed at baseline , Visit 10, every  12 weeks, and EOT visits (Core ,
Extension and Post -Extension
). Tests will include L H, FSH, estradiol, and testosterone. Please 
refer to Table 7-1 and Table 7 -2for more information.
[IP_ADDRESS].4 Lipid profile
A lipid profile (total cholesterol, triglycerides, LDL, HDL) will be determined at screenin g 
and repeated at the same time points inTable 7-1and Table 7-2. A final assessment will be 
performed at EOT Visit s
. The patient must be in a fasting state at the time of blood sampling 
for the lipid profile evaluation.

[COMPANY_001] Confidential Page 102
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS].[ADDRESS_760964] can be omitted.
[IP_ADDRESS].[ADDRESS_760965] 
should be withdrawn from the study .For further guidance see Section 8.4.
Women of child -bearing potential, defined as all women physiologically  capable of becoming 
pregnant, unless they are using highl y effective methods of contraception during dosing and 
for 8 weeks after stoppi[INVESTIGATOR_79558]. Highl y effective contraception methods include :
Total abstinence: When this is in line with the preferred and usual lifest yle of the subject. 
[Periodic abstinenc e (e.g., calendar, ovulation, symptothermal, post
-ovulation methods) 
and withdrawal are not acceptable methods of contraception]
Female Sterilization: Have had surgical bilateral oophorectom y (with or without 
hysterectom y), total hy sterectomy or tubal liga tion at least six weeks before taking study  
treatment. In case of oophorectom y alone, onl y when the reproductive status of the woman 
has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). The vasectomized male partner 
should be the sole partner for that subject.
Use of oral, injected or implanted hormonal methods of contraception
or placement of an intrauterine device (IUD) or intrauterine s ystem (IUS) , or other forms 
of hormonal contraception tha t have comparable efficacy  (failure rate <1%), for example 
hormone vaginal ring or transdermal hormonal contraception
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_760966] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age 
appropriate, history  of vasomotor symptoms) or have had surgical bilate ral oophorectomy 
(with or without hy sterectomy ), total hy sterectomy , or tubal ligation at least six weeks ago. In 
the case of oophorectomy  alone, only when the reproductive status of the woman has been 
confirmed by [CONTACT_579265].
Sexually  active males unless they use a condom during intercourse while taking drug
treatment   for 8 weeks after stoppi[INVESTIGATOR_63950] a child in this period.

[COMPANY_001] Confidential Page 103
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
A condom is required to be used also by  [CONTACT_579266] 
a male partner in order to prevent delivery  of the drug via sem en.
[IP_ADDRESS].[ADDRESS_760967]
Female patients ≥[ADDRESS_760968] AMH.
[IP_ADDRESS] HBV testing
Prior to randomization, the categories of patients listed inSection 7.1.1 should be tested for 
hepatitis B serologic markers and viral load (local results are acceptable for screening onl y):
HBV -DNA, HBsAg, HBc Ab, and HBs Ab.
During the treatment period, HBV DNA monitoring should be done depending on results 
from se rologic markers and viral load as listed in Table 6
-8.
The final monitoring visit for HBV will be at the 30 -day safety  follow -up.
[IP_ADDRESS] HCV testing
Patients with hepatitis C risk factors and at the discretion of the investigator should be tested 
for HCV RNA prior to randomization (local results are acceptable for screening only). For a 
list of hepatitis C risk factors, refer to Section 7.1.1.
Follow -
up testing willbe performed, as per the visit schedule, only if the patient has a history  
of Hepatitis C. The final monitoring visit for HCV will be at the 30 -day safety  follow -up.
[IP_ADDRESS] Radiological examinations
Magnetic Resonance Imaging (MRI) with diffuse tensor imaging (D TI)will be performed at 
select sites during the study .These scans will be per formed at baseline, or within 7 day s prior 
to the baseline visit and again at the end of the Core phase (V11) or within 7 day s prior to the 
end of Core phase. Please refer to protocol Appendix A for more information .
[IP_ADDRESS] Electroencephalogram (EEG) assessments
High frequency  oscillation EEGs will be performed at select edsites during the study .These 
tests will beperformed at baseline, or within 7 days prior to baseline visit, and again at the 
end of Core phase (V11) or within 7 days prior to the end of Core phase. Please refer to 
protocol Appendix A for more i nformation.

[COMPANY_001] Confidential Page 104
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Cardiac assessments
[IP_ADDRESS].1 Electrocardiogram (ECG)
A standard [ADDRESS_760969] be made by a qualified physician. Each ECG tracing should 
be labeled with the study  number, patient initials (where regulations permit), patient number, 
date, and kept in the source documents at the study  site. Clinically  significant abnormalities 
present when the patient signed informed consent should be reported on the Medical History  
eCRF. Clinically  significant findings must be discussed with the [COMPANY_001] Medical Monitor 
prior to enrolling the patient in the study . New or worsened clinically  significant findings 
occurring after informed consent must be recorded on the Adverse Events eCRF.
7.2.4 Pharmacokinetics
During the 6 week titration period, three pre-dose PK blood samples will be taken for 
potential dose adjustments as described in Table 4-1. A local lab (at the treating center) will 
collect the blood samples and send them to a central laboratory  for determination of 
everolimus concentrations. The site will receive recommendations from the central Interactive 
Response Technology  (IRT) on dose adjustmen t (to maintain, increase or decrease the number 
of the 2-mg tablets) for each patient, based on concentration values of the pre-dose PK 
samples. A sample of blood collected immediately prior to dosing on the study day and at 
22-26 hours after the patient’s last daily dose of study drug following 5 days of consistent 
(daily dose and timing of dose) dosing is a valid trough PK blood sample. Any sample 
collected outside of these parameters is not considered a true trough and therefore 
should not be used as a basis for adjusting the patient's dose. It is expected that 
all the 
patients will achieve the desired target pre-dose trough level (Cmin) during this period. In 
order to keep the blind, the IRT will also instruct the site to adjust the dose for patients inthe 
placebo arm .
After the completion of the titration period, patients will continue their current dose level 
during a 12 weeks maintenance period. Pre-dose PK blood samples will be collected every  4 
weeks during the maintenance period.
In order to minimize total blood samples taken from pediatric patients, the amount of blood 
required for everolimus PK samples will be 0.5 mL for patients from 1 to < 2 years of age, 
and 1 mL  for patients 2 to≤ 6 years of age. For patients > [ADDRESS_760970] Extension 
phase sections, pre-dose blood samples for everolimus concentration determination should be 
collected two weeks after the following events:
Any everolimus dose adjustment
Starting or changing the dose of a CYP3A4/PgP inducer/inhibitor

[COMPANY_001] Confidential Page 105
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Anti-epi[INVESTIGATOR_579141]3A4 pathway  in the liver, and to some extent in the 
intestinal wall. Many  of the concomitantly  administered AEDs are also metabolized by [CONTACT_191700]3A4 pathway , which results in a potential for drug-drug interaction between the AEDs 
and everolimus. Therefore, levels of the AEDs listed in Section 4.1.3 (considered to be 
CYP3A4 substrates and /or inducers) will be measured to investigate the effect of everolimus 
on the AED level (i.e., if AED + everolimus leads to higher levels of AED compare d to AED 
alone) .
Pre-dose plasma samples will be collected at Visits 1, 2, 
3, and 5 for the measurement of 
antiepi[INVESTIGATOR_32551] (AED) concentration. Effects of everolimus on the exposure of anti-
epi[INVESTIGATOR_579142]- epi[INVESTIGATOR_353033] c drug concentrations at Visits 1 
and 2 (AEDs alone) and at Visits 3 and 5 (AEDs plus everolimus). A list of commonly  
prescribed AEDs that are used in this population is provided in Section 6.1.1.F or a li st of 
inducers and inhibitors, please refer to Section 4.1.3 and Table 6 -11andTable 6 -12.
Table 7
-4 Everolimus /Placebo PK Sample Log Table for Study core phase, Visits 
0-11(777)
Study  visitStudy  
Week TimePK Collection 
NumberbPK Sample 
NumbercSample Volumed
(mL)
Visit 3 Week 1 Pre-dose 401/501 401 2 mL (blood)
Visit 5 Week 3 Pre-dose 402/502 402 2 mL (blood)
Visit 7 Week 5 Pre-dose 403/503 403 2 mL (blood)
Visit 9 Week 10 Pre-dose 404/504 404 2 mL (blood)
Visit 10 Week 14 Pre-dose 405/505 405 2 mL (blood)
Visit 11 (777) Week 18 Pre-dose 406/506 406 2 mL (blood)
AdditionalaPre-dose [ZIP_CODE]/[ZIP_CODE] 
[ZIP_CODE]/[ZIP_CODE] 
[ZIP_CODE]/[ZIP_CODE] . . .3001, 3002, 
3003, . . .2 mL (blood)
aadditional visit at two weeks after any everolimus dose adjustment or start/change in dose of the CYP3A4 /PgP
inhibitor/inducer
bThe first PK collection number refers to the first dose of everolimus received after collection of the PK sample, 
while the second PK col lection number is the last dose the subject received prior to the collection of the PK 
sample
cThe PK sample number uniquely identifies the PK sample for a particular visit and should be written on the tube 
label of samples sent to the central PK lab. 
dSample volume is dependent on patient’s age. 0.5 mL for 1 to <2, 1 mL for 2 to ≤ 6, and 2 mL for > 6
During the Extension phase, Everolimus PK samples will be drawn at Weeks 19 (V12), 22 
(V14), 26 (V15), and 30 (V16), and then every  [ADDRESS_760971] Extension phase .

[COMPANY_001] Confidential Page 106
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7-5 Everolimus PK Sample Log Table for Study extension phase, starting 
at Visit 12
Study  visit Study  Week TimePK Collection 
NumberbPK Sample 
NumbercSample Volumed
(mL)
Visit 12 Week 19 Pre-dose 601/701 601 2 mL (blood)
Visit 14 Week 22 Pre-dose 602/702 602 2 mL (blood)
Visit 15 Week 26 Pre-dose 603/703 603 2 mL (blood)
Visit 16 Week 30 Pre-dose 604/704 604 2 mL (blood)
Every 12 weeks 
afterPre-dose 605/705, 606/706, 
607/707….605,606, 
607….2 mL (blood)
End of 
Treatment 
Extension (V778)Pre-dose 699/799 699 2 mL (blood)
Visit 201 Transition B: 
Week 27, 31, 
43, 55, 67, etcPre-dose 801/901 801 2 mL (blood)
AdditionalaPre-dose [ZIP_CODE]/[ZIP_CODE],
[ZIP_CODE]/[ZIP_CODE],
[ZIP_CODE]/[ZIP_CODE],…4001, 4002, 
4003, . . .2 mL (blood)
aadditional visit at two weeks after any everolimus dose adjustment or start/change in dose of the CYP3A4/PgP 
inhibitor/inducer
bThe first PK collection number refers to the first dose of everolimus received after collection of the PK sample, 
while the second PK collection number is the last dose the subject received prior to the collection of the PK 
sample
c The PK sample number uniquely identifies the PK sample for a particular visit and should be written on the tube 
label of samples sent to the central PK lab. 
dSample volume is dependent on patient’s age. 0.5 mL for 1 to <2, 1 mL for 2 to ≤ 6, and 2 mL for > [ADDRESS_760972] -
Extension 
Phas eeTimePK Collection 
NumberbPK Sample 
NumbercSample Volumed
(mL)
Visit 401 Weekn+12 Pre-dose 1101/1201 1101 2 mL (blood)
Visit 402 Week n+24 Pre-dose 1102/1202 1102 2 mL (blood)
Visit 403 Week n+36 Pre-dose 1103/1203 1103 2 mL (blood)
Visit 404 Week n+48 Pre-dose 1104/1204 1104 2 mL (blood)
Visit 405 Week n+60 Pre-dose 1105/1205 1105 2 mL (blood)
AdditionalaPre-dose [ZIP_CODE]/[ZIP_CODE],
[ZIP_CODE]/[ZIP_CODE],
[ZIP_CODE]/[ZIP_CODE],…[ZIP_CODE], 11 002, 
[ZIP_CODE], . . .2 mL (blood)
aAdditional visit at two weeks after any everolimus dose adjustment or start/change in dose of the CYP3A4/PgP 
inhibitor/inducer
bThe first PK collection number refers to the first dose of everolimus received after collection of the PK sample, 
while the second PK collection number is the last dose the subject received prior to the collection of the PK 
sample
c The PK sample number uniquely identi fies the PK sample for a particular visit and should be written on the tube 
label of samples sent to the central PK lab. 
dSample volume is dependent on patient’s age. 0.5 mL for 1 to <2, 1 mL for 2 to ≤ 6, and 2 mL for > 6
e n = the week at which the patient’s last scheduled Extension phase visit occurred

[COMPANY_001] Confidential Page 107
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7-7 PK Sample Log Table for Carbamazepi[INVESTIGATOR_579175] 1 Week -8 Pre-dose 1/201 1 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 2/202 2 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 3/203 3 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 4/204 4 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760973] es taken. Patients ≤ [ADDRESS_760974] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_760975] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-8 PK Sample Log Table for Oxcarbazepi[INVESTIGATOR_579175] 1 Week -8 Pre-dose 11/211 11 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 12/212 12 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 13/213 13 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 14/214 14 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760976] AED PK 
samples taken. Patients ≤ [ADDRESS_760977] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma .Patients > [ADDRESS_760978] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-9 PK Sample Log Table for Clonazepam
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
NumberSample 
Volumeb
Visit 1 Week -8 Pre-dose 21/221 21 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 22/222 22 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 23/223 23 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 24/224 24 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760979] AED PK 
samples taken. Patients ≤ [ADDRESS_760980] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_760981] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-10 PK Sample Log Table for Diazepam
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
NumberSample 
Volumeb
Visit 1 Week -8 Pre-dose 31/231 31 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 32/232 32 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 33/233 33 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 34/234 34 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760982] AED PK 
samples taken. Patients ≤ [ADDRESS_760983] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_760984] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.

[COMPANY_001] Confidential Page 108
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7-11 PK Sample Log Table for Clobazam
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
NumberSample 
Volumeb
Visit 1 Week -8 Pre-dose 41/241 41 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 42/242 42 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 43/243 43 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 44/244 44 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760985] es taken. Patients ≤ [ADDRESS_760986] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_760987] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-12 PK Sample Log Table for Felbamate
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
Number Sample Volumeb
Visit 1 Week -8 Pre-dose 51/251 51 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 52/252 52 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 53/253 53 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 54/254 54 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760988] AED PK 
samples taken. Patients ≤ [ADDRESS_760989] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_760990] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-13 PK Sample Log Table for Phenobarbital
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
Number Sample Volumeb
Visit 1 Week -8 Pre-dose 61/261 61 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 62/262 62 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 63/263 63 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 64/264 64 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760991] AED PK 
samples taken. Patients ≤ [ADDRESS_760992] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_760993] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.

[COMPANY_001] Confidential Page 109
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7-14 PK Sample Log Table for Pheny toin
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
Number Sample Volumeb 
Visit 1 Week -8 Pre-dose 71/271 71 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 72/272 72 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 73/273 73 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 74/274 74 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760994] es taken. Patients ≤ [ADDRESS_760995] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_760996] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-15 PK Sample Log Table for Primidone
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
Number Sample Volumeb
Visit 1 Week -8 Pre-dose 81/281 81 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 82/282 82 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 83/283 83 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 84/284 84 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_760997] AED PK 
samples taken. Patients ≤ [ADDRESS_760998] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma .Patients > [ADDRESS_760999] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-16 PK Sample Log Table for Topi[INVESTIGATOR_579176] 1 Week -8 Pre-dose 91/291 91 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 92/292 92 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 93/293 93 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 94/294 94 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_761000] AED PK 
samples taken. Patients ≤ [ADDRESS_761001] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_761002] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.

[COMPANY_001] Confidential Page 110
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Table 7-17 PK Sample Log Table for Valproic acid
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
NumberSample 
Volumeb
Visit 1 Week -8 Pre-dose 101/301 101 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 102/302 102 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 103/303 103 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 104/304 104 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_761003] es taken. Patients ≤ [ADDRESS_761004] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma. Patients > [ADDRESS_761005] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
Table 7-18 PK Sample Log Table for Zonisamide
Study  visit Study  Week TimePK Collection 
NumberaPK Sample 
NumberSample 
Volumeb
Visit 1 Week -8 Pre-dose 111/311 111 ~1mL (plasma)
Visit 2 Week 0 Pre-dose 112/312 112 ~1mL (plasma )
Visit 3 Week 1 Pre-dose 113/313 113 ~1mL (plasma )
Visit 5 Week 3 Pre-dose 114/314 114 ~1mL (plasma )
aThe first PK collection number is for current dose, while the second PK collection number is for last dose the 
subject received prior to the collection of the PK sample
bSample collection is dependent on patient’s weight. Patients weighing ≥ 12 kg to ≤ [ADDRESS_761006] AED PK 
samples taken. Patients ≤ [ADDRESS_761007] 5.2 mL blood taken to yield 2.6 mL plasma for three .87 mL aliquots of 
plasma .Patients > [ADDRESS_761008] 6 mL blood taken to yield 3 mL plasma for 3 1 mL aliquots of plasma.
[IP_ADDRESS] Analytical method
Everolimus concentrations in whole blood will be determined by a LC-MS/MS method 
following solid phase extraction. The method has a lower limit of quantification (LLOQ) of 
0.300 ng/mL.
Plasma concentrations of Clobazam, N -desmethy lClobazam ; Clonazepam andDiazepam will 
be measured using a validated liquid chromatography -tandem mass spectrometry  (LC-MS/MS)
assay  with a lower limit of quantificati on (LLOQ) 1, 1, 1 and 2 ng/mL , respectivel y .Plasma 
concentrations of Felbamate, Pheny toin 
will be measured using a validated liquid 
chromatograph y-tandem mass spectrometry  (LC-MS/MS) assay  with a lower limit of 
quan tification (LLOQ) 50 and 100 ng/mL , respectively .
Plasma concentrations of P rimidone andZonisamide will be measured using a validated liquid 
chromatograph y-tandem mass spectrometry  (LC-MS/MS) assay  with a lower limit of 
quantification (LLOQ) 10 and 20 ng/m L, respectively .
Concentrations below the LLOQ will be reported as 0 ng/mL or 0 μM or 0 μg/mL and missing 
samples will be labeled accordingl y.
Additional details regarding the analytical Method for quantification of everolimus (and other 
analytes, as applicable) shall be de scribe d in the Bioanaly tical Report issued at the final of the 
Clinical Study  Report .

[COMPANY_001] Confidential Page 111
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Other assessments
[IP_ADDRESS].[ADDRESS_761009] be registered into the IRT system 
to obtain the patie nt number, and enter the patient to the study .Instructions should be 
followed as per the IRT manual .
[IP_ADDRESS].2 TSC genetic testing
In addition to the safet y and efficacy  assessments described above, blood will be taken at the 
Baseline visit to measure TSC genetic markers (TSC1 / TSC2) if they have not been tested 
prior to entering the trial.If these tests have been analyzed and reported prior to study  start, 
the date of testing, results of those tests , and the lab that performed the test will be collected.
7.2.5 Patient reported outcomes
The following scales will be completed used to assess all health-related quality  of life
(HRQoL) issues. One instrument will be used per subject determined by [CONTACT_24362]’s 
chronological age at Baseline. These questionnaires should be completed only by [CONTACT_579267][INVESTIGATOR_579177]/caregiver for children <10 years old. The same questionnaires 
completed at Baseline will continue to be completed throughout the study .This will be 
collected at Baseline, Week 18 (End of Core) and End of Treatment for the Extension phase , 
see Table 7 -1.
Quality  of Life in Childhood Epi[INVESTIGATOR_122146] (QOLCE) for children ≤10 years old 
with epi[INVESTIGATOR_002]
Quality  of Life in Epi[INVESTIGATOR_579178] 
–48 (QOLIE -AD-48) for 
Adolescents 11- 17 years old with epi[INVESTIGATOR_002]
Quality  of Life in Epi[INVESTIGATOR_122198]  -31- Problems (QOLIE-31- P) for adults >18 years 
old with epi[INVESTIGATOR_579179] (QOLIE -AD-48 and QOLIE -31-P) by [CONTACT_579268], but the subject is either a) unable to sign the instrument, or 
b) capable of 
indicating the correct response but phy sicall y incapable of marking the score sheet, the subject 
may be assisted by a parent or caregiver in completing the instrument. No other assistance is 
permissible in order to maintain the validity  of the results.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained .

[COMPANY_001] Confidential Page 112
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Abnormal laboratory  values or test results occurring after informed consent constitute adve rse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Excep t for screening failures, adverse events that begin or worsen after informed consent 
should be recorded in the Adverse Events CRF. Conditions that were already  present at the 
time of informed consent should be recorded in the Relevant Medical History /Curre nt 
Medical Conditions page of the patient’s CRF. Adverse event monitoring should be continued 
for at least [ADDRESS_761010] dose of study  treatment. Adverse events (including lab 
abnormalities that constitute AEs) should be described using a diagnosis whenever possible, 
rather than indivi dual underly ing signs and symptoms. When a clear diagnosis cannot be 
identified, each sign or symptom should be reported as a separate Adverse Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) ve rsion 4.03.
If CTCAE grading does not exist for an 
adverse event, the severit y of mild, moderate, severe, 
and life -threatening, corresponding to Grades 1 -4, will be used. CTCAE Grade 5 (death) will 
not be used in this study; rather, information about deaths will be collected though the EOT
eCRF.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments .
As far as possible, each adverse event should be evaluate d to determine:
The severit y grade (CTCAE Grade 1 -4)
Its duration (Start and end dates or ongoing at end of study )
Its relationship to the study  treatment ( suspected or not suspected)
Action taken with respect to study  or investigational treatment (no action taken, study  
drug dosage adjusted/ temporarily  interrupted or permanentl y discontinued).
Whether medication or therap y was given (concomitant medication/non -drug therap y
given )
Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.

[COMPANY_001] Confidential Page 113
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
8.1.[ADDRESS_761011] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatment), should be recorded on the Adverse Events CRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found. When an abnormal laboratory  or test result corresponds to a 
sign/sy mptom of an already  reported adverse ev ent, it is not necessary  to separately  record the 
lab/test result as an additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meets 
the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required by [CONTACT_64103], by [CONTACT_108], be an 
adverse event and must be reported as such.
8.1.[ADDRESS_761012]
In clinical trials, everolimus has been associated with infections (including exacerbation, 
aggravation or reactivation of pre -existing infections) , and serious cases of hepatitis B 
reactivation, including fatal outcome. Infections and reactivation of infections is an expected 
event during periods of immunosuppression.
In clinical trials and post-marketing spontaneous reports, everolimus has been associated with 
renal failure events (including fatal ones) and proteinuria. Renal function will be monitored 
throughout the stud y.
Also in clinical trials, everolimus has been associated with noninfectious pneumonitis, 
stomatitis, hypergl ycemia, hypophosphat emia, and dyslipi[INVESTIGATOR_035]. These events will be 
monitored throughout the study  as described in Section 6.2.5 .
Additional events associated with everolimus in clinical trials include hemorrhages, 
thrombotic and embolic events, cytopenias, cardiac failure, amenorrhea , male infertility , and 
hypersensitivity  reactions. Potential risks also include intestinal obstruction/ileus, pancreatitis, 
and cholelithiasis.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect

[COMPANY_001] Confidential Page 114
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospi[INVESTIGATOR_110353],
Note that hospi[INVESTIGATOR_14944]:
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_579180] y of the definitions of a SAE given above 
is not a serious a dverse event
8.2.[ADDRESS_761013] be reported as follow -up to the original 
epi[INVESTIGATOR_5319] 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously  reported one should be reported separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form ; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Repor t 
Form in English, except for countries applied with local [COMPANY_001] operation procedure in local 
languages , and send the completed, signed form by [CONTACT_87109] 24 hours to the oncology 
[COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_623]  (DS&E) department as managed by [CONTACT_579269] .
The telephone and telefax number of the contact [CONTACT_230785][INVESTIGATOR_623]  (DS&E), specific to the site, are listed in the investigator folder 
provided to each site. The original copy of the SAE Report Form and the fax confirmation 
sheet must be kept with the investigator folder at the study  site.
Follow -up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow -up to the previously  
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 

[COMPANY_001] Confidential Page 115
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
continues, if and how it was treated, whether the blind was broken or not, and whether the 
patient continued or withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the [COMPANY_001] study  treatment, an oncology 
[COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_623]  (DS&E) department associate may urgently  require 
further information from the investigator for Healt h Authority  reporting. [COMPANY_001] may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs) will be colle cted and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.
8.[ADDRESS_761014] often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  patient who presents with an emergency 
condition. Emergency  code breaks are performed using the IRT. When the investigator 
contacts the IRT to unblind a patient, he/she must provide the requested patient identify ing 
information and confirm the necessity  to unblind the patient. The investigator will then 
receive details of the drug treatment for the specified patient and a fax confirming this 
information. The system will automatically  inform the [COMPANY_001] monitor for the site and the 
Study  Leadthat the code has been broken.
It is the investigator’s responsibility  to ensure that there is a procedure in place to allow access 
to the IRTin case of emergency .The investigator will inform the patient how to contact 
[CONTACT_5657]/her backup in cases of emergency  when he/she is unavailable. The protocol number, study
treatment name [CONTACT_90228], patient number, and instructions for contact[CONTACT_579270] (or any entity to which it has delegated responsibility  for emergency code breaks) will 
be provided to the patient in case emergency  unblinding is required at a time when the 
investigator and backup are unavailable. However, if a mechanism is alread y in place to 
ensure that the investigator and/or back -up can alway s be reached in case of emergency  then 
the procedure above is not required.
8.[ADDRESS_761015] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_5373][INVESTIGATOR_18540] (DS&E). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study  treatment any pregnancy  outcome. Any SAE 
experienced during p regnancy  must be reported on the SAE Report Form.

[COMPANY_001] Confidential Page 116
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Pregnancy  outcomes must be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [Investigator 
Brochure ]. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.6 Data Monitoring Committee
A Data Monitoring Committee (DMC) will be constituted prior to the randomization of the 
first patient. The DMC is an external independent group including at least two phy sicians with 
expertise in epi[INVESTIGATOR_420340]/or TSC and one statistician . The DMC will perform the first safet y 
review using a data cutoff [ADDRESS_761016] received treatment for 4 weeks (whichever occurs first) , and every  6 months 
thereafter until the Core Database Lock, unless otherwise requested by [CONTACT_579271]. The DMC will also receive reports on a regular basis on all SAEs reported for this trial. 
No interim analy sis is planned. Recruitment will not be interrupted unless otherwise requested 
by [CONTACT_356107].
Details on the membership, responsibilities and working procedures of the DMC will be 
described in the DMC Charter.
8.7 Steering Committee
The Steering Committee (SC) will be established comprising investigators participating in the 
trial (i.e., not members of the DMC) and [COMPANY_001] representatives from the Clinical Trial 
Team.
The SC will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as circumstances require. The SC will review 
protocol amendments as appropriate. Together with the clinical trial team, the SC will also 
develop recommendations for publications of study  results including authorship rules. The 
details of the role of the SC will be defined in the SC Charter.
[ADDRESS_761017] of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y

[COMPANY_001] Confidential Page 117
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g.has the 
subject experienced an y new or worsened AEs ) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigato r must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
thedata required by [CONTACT_5374] (eCRF). The eCRFs 
have been built using fully  validated secure web-enabled software that conforms to [ADDRESS_761018] the information required by  [CONTACT_579272] -

[COMPANY_001] Confidential Page 118
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
part, non-carbon -required paper. Field monitors will review the Vineland Scales for completeness 
and accuracy and instruct site personnel to make any required corrections or additions. The 
harvested Vineland Scales will be forwarded to [COMPANY_001] (or designated CRO). The carbon copi[INVESTIGATOR_579181].
The Principal Investigator [INVESTIGATOR_579182] s and on
Vineland Scales is complete, accurate, and that entry  and updates are performed in a timel y 
manner.
An IRT system will be used for drug dispensing and titration purposes for this study .There 
will be regular reports of enrollment at site activity. In order to maintain the blind, there will 
data transfers of operational details onl y from IRT until analysis of the Core data. After the 
Core data have been analyzed, regular full data transfers will be established.
Safety labs will be collected centrall y and data transferred to the study  database, at regular 
intervals. The C-SSRS will be administered via IVRS, and there will be regular transfers of 
these data. PK analysis will also be done at a central lab.In order tomaintain the blind, the 
PK results will only  be transferred at the time of analy sis of the Core data. DTI MRI and EEG 
performed will be transmitted by [CONTACT_579273]. Refer to Appendix A for further d etails.
9.4 Database management and quality  control
For Vineland Scales used in this study , data will be entered into a fully  validated study 
database b y [COMPANY_001] Data Management personnel (or designated CRO). Following entry  from 
the Vineland Scales, the data are systematically  checked by [CONTACT_579274] (or designated CRO) using programmed checks and data review tools/reports. 
Electronic data queries stating the nature of the problem and requesting clarification will be 
created for discrepa ncies and missing values and sent to the investigational site via the EDC 
system on the corresponding eCRF. Designated investigator site staff are required to respond 
promptly  to queries. [COMPANY_001] Data Management personnel (or designated CRO) will make 
anynecessary  changes to the data.
For theeCRFs used in this study , [COMPANY_001] personnel (or designated CRO) will review the 
data entered by [CONTACT_5375] . Electronic data queries 
stating the nature of the problem and requesting clarification will be created for discrepancies 
and missing values and sent to the investigational site via the EDC system. Designated 
investigator site staff are required to respond promptly  to queries and to make any necessary 
changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using 
the WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical 
classification system. Medical history /current medical conditions and adverse events will be 
coded using the Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed centrall y and the results will be sent electronically to 
[COMPANY_001] (or a designated CRO).
Randomization codes and data about allstudy  treatments dispensed to the patient and all IRT 
assigned dosage changes will be tracked using an IRT. The system will be supplied by a 

[COMPANY_001] Confidential Page 119
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
vendor(s), who will also manage the database. The data will be sent electronically to [COMPANY_001] 
personnel (or desig nated CRO).
At the conclusion of the study , the occurrence of any emergency  code breaks will be 
determined after return of all code break reports and unused drug supplies to [COMPANY_001] 
personnel (or designated CRO). The occurrence of any  protocol violations will be determined. 
After these actions have been completed and the data has been verified to be complete and 
accurate, the database will be declared locked and the treatment codes will be unblinded and 
made available for data analy sis. Authorization is required prior to making any database 
changes to locked data, by [CONTACT_348454].
For EDC studies, after database lock, the investigator will rec eive a CD-ROM or paper copi[INVESTIGATOR_5322].
[ADDRESS_761019] discontinued early. At that time, all data from the 
Core phase will be available as well aspart of the Extension phase data. The analy ses for the 
reports will thus cover both periods:
The main focus will be on descriptive and inferential comparisons of both everolimus 
arms versus placebo on efficacy  and safet y in the Core phase.
Descriptive efficacy  and safet y analyses on Extension phase data will also be conducted in 
order to explore the longer term effects of everolimus.
The second data cut-off will be at the end of the extension phase, which is planned [ADDRESS_761020] Extension phase, 
which is planned on October 30, 2017.
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all patients to whom study  treatment has been 
assigned b y randomization. According to the intent to treat principle, patients will be analy zed 
according to the treatment and stratum they have been assigned to during the randomization 
procedure. 
This will be the primary  anal ysis set for all Core phase effi cacy anal yses.
10.1.[ADDRESS_761021] -baseline safety  assessment in the Core Phase (where the 
statement that a patient had no adverse event (on the Adverse Events CRF) constitutes a 
safet y assessment) . Patients will be analy zed according to the study  treatment (regimen) they 
actuall y received. This will be the primary anal ysis set for all Core phase safety anal yses.

[COMPANY_001] Confidential Page 120
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
A precise definition of “actuall y received” ,will be added in the Report and Analy sis Plan 
(RAP).
10.1.3 Per-Protocol Set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with requirements of the CSP.
Protocol deviations leading to exclusion from the PPS are:
Absence of diagnosis of TSC or partial- onset epi[INVESTIGATOR_002] .
Baseline phase with less than [ADDRESS_761022] 21 day s seizure -free.
Previously  failed less than two sequential regimens of single or combined AEDs.
Use of more than 3 concomitant AEDs in the baseline phase or the core phase AEDs .
Non-use of concomitant AEDs in the baseline phase or the core phase.
Use of a different 1 to 3 concomitant AEDs in the Core phase to that in the Baseline phase.
Rescue medication during the Core phase modified bey ond the accepted limits defining 
rescue medication .
Study  treatment received different from treatment assigned by  [CONTACT_17628].
Missing seizure information on > 50% of day s in the Core phase.
10.1.[ADDRESS_761023] oneefficacy /safet y 
measure. Patients will be analyzed as a single everolimus group as well as separatel y 
according to their randomized treatment arm in the Core phase (i.e., everolimus trough ranges 
of 9-15 ng/ml and 3-7 ng/ml, or forpatients originally  randomized to placebo who enter the 
extension phase , everolimus trough range of 3-15 ng/ml) . This analysis set will be used for 
long-term efficacy  and safety  anal yses.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline characte ristics will be summarized descriptively  by [CONTACT_243652]. Categorical data will be presented by [CONTACT_22977]. For 
continuous data the mean, standard deviation (SD), median, 25thand 75thpercentiles, 
minimum and maximum will b
e presented.
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014] )
10.3.1 Study medication
Duration of study  treatment exposure, cumulative dose (mg/m2) and dose intensit y 
(mg/m2/day) will be summarized by [CONTACT_1570]. The number of patients with dose 
changes/interruptions will be presented by [CONTACT_1570], along with reasons for the dose 
change. These analyses will be conducted over the Core phase on the Safety  set,and over the 
extension phase on the Long -Term Evaluation set.

[COMPANY_001] Confidential Page 121
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
10.3.2 Concomitant medication
Concomitant medications and significant non-drug therapi[INVESTIGATOR_579183] (ATC) 
class, preferred term and treatment arm by [CONTACT_314718]. These 
summaries will include medications starting on or after the start of study  treatment or 
medications starting prior to the start of study  treatment and continuing after the start of study 
treatment. These summaries will be presented separ ately for anti-epi[INVESTIGATOR_579184] .
Any prior concomitant medications or significant non-drug therapi[INVESTIGATOR_157812]. The Safety  Set and the Long-Term Eva luation Set 
will be used for all above -
mentioned concomitant medication tables and listings.
10.4 Primary  objective
The primary  objective is to compare the reduction in frequency  of partial -onset seizures on 
each of two trough ranges of everolimus (3-7 ng/mL  and 9-15 ng/mL) versus placebo in 
patients with TSC who have refractory  partial -onset seizures and are already  receiving one to 
three AEDs .
10.4.1 Variable
The regulatory  requirements for demonstrating efficacy  of an anti-epi[INVESTIGATOR_579185]: whereas the EMA prefers response rate to be the primary  variable, 
the FDA prefers percentage reduction in seizure frequency . 
It is understood that each Agency
will use their preferred variable as the primary  variable, with the other (non-primary ) variable 
being used in a supportive analysis. As each Agency will only use their preferred primary 
variable to make a decision on the primary  objective, the full alpha level can be used for each 
Agency ’s primary  variable, without correction for multiplicity .
[IP_ADDRESS] EMA  primary variable: response rate
The EMA primary  variable is response rate in the maintenance period of the Core phase, 
determined using counts of partial -onset seizures (as defined in Inclusion Criterion 4a) from 
patient seizure diaries (see Section [IP_ADDRESS]) and the following definitions :
Average weekly  seizure frequency  in the Baseline phase (SF B) = 7 × numbe r of partial -
onset seizures recorded over the 8 week prospective Baseline phase ÷ number of days with 
evaluable seizures in the prospective Baseline phase.
Average weekly  seizure frequency  in the maintenance period of the Core phase (SF M):
If patient does 
not discontinue during the 6 week titration phase, SF M= 7 × number of 
partial -onset seizures recorded during the maintenance period of the Core phase ÷ 
number of day s with evaluable seizures in the maintenance period of the Core phase.
Otherwise, SF M= 7 × number of partial -onset seizures recorded during the titration 
period of the Core phase ÷ number of day s with evaluable seizures in the titration 
period of the Core phase.

[COMPANY_001] Confidential Page 122
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
That is, patients who discontinue prior to the maintenance period have seizure fre quency  
determined using their data from the titration period, thereby [CONTACT_579275] a value for SF M.
Percentage reduction from baseline in average weekly  seizure frequency  during the 
maintenance period of the Core phase (% Red) = 100 × (SF B-SFM) ÷ SF B.
A responder is a patient with ≥ 50% reduction from baseline in average weekl y partial -onset 
seizure frequency  during the maintenance period of the Core phase, that is, when % Red ≥ 50.
[IP_ADDRESS] FDA primary variable: percentage reduction in seizure frequency
The FDA primary  variable is percentage reduction from baseline in average weekly  frequenc y 
of partial -onset seizures during the maintenance period of the Core phase, and is defined by 
[CONTACT_491514] % Red in Section [IP_ADDRESS] above.
10.4.2 Statistical hy pothesis, model, and method of analy sis
[IP_ADDRESS] EMA  primary variable: response rate
Response rate in the maintenance period of the Core phase will be compared between each 
everolimus arm versus the placebo arm, according to a Bonferroni -Holm procedure , assurin g 
an overall experiment- wise alpha level of 2.5% one-sided. Cochran- Mantel -Haenszel (CMH)
chi-square tests will be used (implemented via SAS procedure FREQ with CMH optio n in the 
TABLES statement), stratified by [CONTACT_579276] (the randomization 
stratification factor, consisting of 4 subgroups: 1 to < 6, 6 to < 12, 12 to < 18, ≥18 years). The 
p-value will be obtained from the “General association” CMH statis tic.
The statistical hy potheses are
H01: RR EVE1 ≤ RR PLBversus H 11: RR EVE1 > RR PLB, and
H02: RR EVE2 ≤ RR PLBversus H 12: RR EVE2 > RR PLB
where RR EVE1 is the probability  of response on the everolimus 3-7 ng/mL trough arm, RR EVE2
is the probabilit y of response on the everolimus 9-15 ng/mL trough arm, and RR PLBis the 
probability  of response on the placebo arm.
Response rates will be provided with exact 95% confidence intervals (Clopper and Pearson, 
1934).
In addition, the odds ratio will be used as a measure of association between treatment and 
response. It will be derived for each everolimus arm versus placebo from a logistic regression 
model (implemented using SAS procedure LOGISTIC, with treatment specified as an 
explanatory  variable in the CLASS statement), stratified by [CONTACT_579276]. 
The two odds ratio s
will be presented with two- sided 95% Wald confidence limits.
[IP_ADDRESS] FDA primary variable: percentage reduction in seizure frequency
Percentage reduction in seizure frequency in the maintenance period of the Core phase will be 
compared between each everolimus arm versus the placebo arm, according to a Bonferroni -
Holm procedure, assuring an overall experiment- wise alpha level of 2.5% one-sided. Rank 
ANCOVA will be used (impleme nted via SAS procedures RANK, REG and FREQ), with 

[COMPANY_001] Confidential Page 123
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
baseline average weekly seizure frequency  as covariate, and stratified by [CONTACT_579277].
The statistical hypotheses are:
H01: μEVE1 ≤ μPLBversus H 11: μEVE1 > μ PLB, and
H02: μEVE2 ≤ μPLBversus H 12: μEVE2 > μ PLB
where μ EVE1 is the population mean of the reduction in seizure frequency  for the everolimus 3 -
7 ng/mL trough arm, and where μEVE2 and μPLBare the equivalent quantities for the 
everolimus 9 -15 ng/mL  trough armand the placebo arm.
The median percentage reduction from baseline will be presented for each everolimus arm 
versus the placebo arm, along with 95% confidence intervals computed using the bootstrap 
percentile method.
10.4.3 Handling of missing values/censoring/discontinuations
Patients with no data in their seizure diary  during the Core phase will be assumed to be non-
responders for the EMA primary  analysis, and to have a percentage reduction from baseline in 
seizure frequency  of 0% for the FDA primary  analy sis.In addition, in case of one or more 
individual days with missing seizure information within a period, those days are excluded 
from the period duration when computing the standardized seizure frequency  over the period 
(e.g. in case [ADDRESS_761024] 
been reported over a period of 28 days, but one of those 28 days 
had missing seizure evaluation, the seizure frequency  will be computed as 3 seizures over 27 
days and not 3 seizures over 28 day s).
10.4.4 Supportive and s ensitivity analy ses
For the EMA primary  variable on response rate, a supportive analysis will be the FDA 
primary  anal ysis on percentage reduction in seizure frequency , and vice versa .
The primary  analysis of both the EMA and FDA primary  variables will be repeated in the Per 
Protocol Set .
In addition, sensitivity  analy ses will be conducted in the FAS to assess robustness of the 
primary  analysis to (i) patient discontinuation before the end of the Core phase, and (ii) the 
calculation of seizure frequency  across the entire Core phase (i.e., titration period as well as 
maintenan ce period ).
For (i), the sensitivity  analysis will assume no change from baseline in seizure frequency  for
patients discontinuing in the Core phase, whereas the primary  analysis uses the actual seizure 
frequency  calculated up to the day of discontinuation. Response rate and percentage change 
from baseline in seizure frequency  will be recalculated for this sensitivity  analysis and 
analyzed per the primary  anal ysis.
For (ii), thesensitivity  analy sis will usethe average weekl y seizure frequency  over the entire 
Core phase, that is, over the 6-week titration period plus the 12-week maintenance period .
This compares with the primary  analysis where titration period data is not used to calculate 
average weekl y seizure frequency  if the patient continues into the maintenance period. The 
variable used in the sensitivity
 anal ysis, labeled SF TMis defined as follows:

[COMPANY_001] Confidential Page 124
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Average weekly  seizure frequency  in the entire Core phase (SF TM) = 7 × number of 
seizures recorded over the entire Core phase (titration plus maintenance) ÷ number of day s 
with evaluable seizures in the entire Core phase (titration plus maintenance).
Response rate and percentage reduction in seizure frequency  will be re-calculated using SFTM
instead of SF M, and anal yzed as per the primary  analy sis.
Table 10-1 Supportive and s ensitivity analy ses for primary  objective
Variable Population Time PeriodVariable for seizure 
frequencyRule for 
discontinuations
EMA % reduction in 
seizure frequencyFAS Maintenance SFM None
Response rate PPS Maintenance SFM None
Response rate FAS Maintenance SFM SFM= SF B
Response rate FAS Titration + 
maintenanceSFTM None
FDA Response rate FAS Maintenance SFM None
% reduction in 
seizure frequencyPPS Maintenance SFM None
% reduction in 
seizure frequencyFAS Maintenance SFM SFM= SF B
% reduction in 
seizure frequencyFAS Titration + 
maintenanceSFTM None
FAS = Full Analysis Set, PPS = Per Protocol Set, SF M= average weekly seizure frequency in the maintenance 
period of the Core phase, SF TM= average weekly seizure frequency in the entire Core phase (titration + 
maintenance), SF B= average weekly seizure frequency in the Baseline phase.
10.5 Secondary  objectives
Secondary  objectives are described below, separated into sections for efficacy , safet y, 
pharmacokinetics and patient- reported outcomes .
10.5.1 Efficacy objectives
Seizure freedom
The ability  to completely  suppress partial -onset seizures will be assessed by [CONTACT_579278] -free during the maintenance period of the Core phase. 
A patient will be considered seizure -free if the percentage reduction from baseline in average 
weekl y frequency  of partial -onset seizures 
during the maintenance period of the Core phase is 
100%, that is, if % Red = 100 using the definitions given in Section [IP_ADDRESS] . Patients with no 
data in their seizure diary during the Core phase will be assumed n ot to be seizure -free.
The seizure -free rates for each treatment arm will be presented along with exact 95% 
confidence intervals (Clopper and Pearson, 1934). The odds ratio for each everolimus arm 
versus placebo, plus the Wald 95% confidence interval, will be derived from a logistic 
regression model stratified by  [CONTACT_579276] .
A sensitivity  analysis will be performed where patients who discontinue during the Core 
phase are assumed n ot to be seizure -
free even if % Red = 100.

[COMPANY_001] Confidential Page 125
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Proportion of patients with at least 25% reduction in seizure frequency
This objective is assessed by [CONTACT_579279] a 25% reduction from baseline in average weekl y frequency  of partial -onset 
seizures during the maintenance period of the Core phase, defined by % R ed ≥ 25 using the 
definitions given in Section [IP_ADDRESS]. Patients with no data in their seizure diary  during the 
Core phase will be assumed to have less than a 25% reduction .
The proportion of patients with at least a 25% reduction will be presented in each treatment 
arm along with exact 95% confidence intervals (Clopper and Pearson, 1934). The odds ratio 
for each everolimus arm versus placebo
, plus the Wald 95% confidence interval, will be 
derived from a logistic regression model stratified by  [CONTACT_579276].
Distribution of re duction from baseline in seizure frequency
The reduction from baseline in average weekl y frequency  of partial -onset seizures in the 
maintenance period of the core phase will be categorized into six levels using the variable % 
Red defined in Section [IP_ADDRESS] . The six levels will be: (≤ -25% (exacerbation); > -25% to < 
25% 
(no change); ≥ 25% to < 50%; ≥ 50% to < 75%; ≥ 75% to < 100%; 100% (seizure -
freedom)). Patients with no seizure diary  data in the Core phase will be assigned as missing.
The proportions of patients in each category
 will be presented for each treatment arm .
Seizure -free day s
The frequency  of partial -onset seizure -free days per 28 day s during the maintenance period of 
the Core phase will be obtained for each patient, calculated as 28× number of partial -onset 
seizure -free days in the maintenance period of the Core phase ÷ number of non-days with 
evaluable 
seizures in the maintenance period of the Core phase. A similar quantity  will be 
calculated for the Baseline phase. Patients with no seizure data in the Core phase will be 
assumed to have the same number of seizure- free day s as during the Baseline phase.
The change from baseline in frequ ency  ofpartial -onset seizure -free days per 28 dayswill be 
summarized by [CONTACT_2939] (mean, standard deviation, range). Mean differences between 
each everolimus arm and the placebo arm in change from baseline in frequency  of seizure -free 
days will prese nted, along with 95% confidence intervals .
Treatment duration
Treatment duration is defined as the time from randomization until the date of permanent 
study  treatment discontinuation (for any reason) during the entire Core phase (i.e., including 
the titrat ion period and the maintenance period). Patients who complete the Core phase 
without discontinuing will have treatment duration censored on the last day of the Core phase.
The treatment duration distributions in each arm will be presented descriptively  in the FAS 
using Kaplan -Meier curves, from which summary statistics will be determined, including the 
median treatment duration and the proportions of patients on treatment at 6 and 12 weeks. 
These statistics will be given as point estimates with 95% confidence intervals. The hazard 
ratio (and two sided 95% confidence interval) for each everolimus arm versus placebo will be 
obtained from a Cox proportional hazards model stratified by [CONTACT_579276].

[COMPANY_001] Confidential Page 126
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Long -term efficacy  evaluation over the extensi on phase
Descriptive statistics on percent reduction from baseline in partial onset seizure -frequency, 
responder rate and seizure -free days will be computed by [CONTACT_579280] -Term Evaluation S et.
10.5.2 Safety  objectives
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_63964] y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_1570]. The assessment of safet y will be based mainl y on the frequency  of adverse 
events and on the number of laboratory  values that fall outside of pre -determined normal 
ranges. Other safet y data (e.g., electrocardiogram, vital signs) will be considered as 
appropriate. All safety data will be listed.
For the analy sis of safet y data from the Core phase of the study , the overall observation period 
will be divided into three mutually  exclusive segments:
1.pre-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication in Core phase
2. on- treatment period: from day  of first dose of study  medication in the Core phase until [ADDRESS_761025]-treatment period: starting the day  after the end of the on -treatment period.
[IP_ADDRESS] Adverse events (AEs)
Summary  tables for AEs will only include AEs that started or worsened during the on-
treatment 
period, the treatment -emergent AEs. However, all safet y data (including those 
from the pre and post-treatment periods) will be listed and those collected during the pre-
treatment and post -treatment period are to be flagged.
The incidence of treatment- emergent advers e events (new or worsening from baseline) will be 
summarized by [CONTACT_30826], severit y (based on CTCAE grades), 
type of adverse event, relation to study  treatment and by  [CONTACT_1570].
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by [CONTACT_5380] b y type of adverse event and treatment group.
Specific safety event categories (SECs) will be 
monitored during the study , consisting of one 
or more well-defined adverse events which are similar in nature and for which there is a 
specific clinical interest to epi[INVESTIGATOR_002] /TSC or the study  treatment. SECs of interest include for 
example CNS -related events, stomatitis/oral mucositis, infections, renal events and 
amenorrhea. This list is not exhaustive and all the principles guiding the definition and use of 
those categories will be further documented in the Report and Anal ysis Plan ( RAP ).
For each specified SEC, number and percentage of patients with at least one event that is part 
of the SEC will be rep orted.

[COMPANY_001] Confidential Page 127
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] Laboratory  abnormalities
For laboratory  tests covered by [CONTACT_15059] 
(CTCAE) version 4.03, the study ’s biostatistical and reporting team will grade laboratory  data 
accordingl y. Grade 0 will be assigned for all non-missing values not graded as 1 or higher. 
Grade 5 will not be used.
For laboratory  tests where grades are not defined by [CONTACT_3989], results will be graded by [CONTACT_15060]/normal/high classifications based on laboratory  normal ranges .
The following by-treatment summaries will be generated separately  for hematology , 
biochemistry  and urinary laboratory  tests:
frequency  table for newly  occurring on -treatment grades 3 or 4
shift tables using CTCAE grades to compare baseline to the worst on -treatment value
for laborat ory tests where CTCAE grades are not defined, shift t ables using the 
low/normal/high
classification to compare baseline to the worst on-treatment value
listing of all laboratory  data with values flagged to show the corresponding CTCAE 
grades and the classi fications relative to the laboratory  normal ranges.
In addition to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots might 
be specified in the RAP.
[IP_ADDRESS] Other safety  data
Neuropsy chological assessments
Changes from baseline in neurodevelopmental, neurobehavioral and neurocognitive 
assessments and tests of cognitive function will be listed and summarized descriptively  by 
[CONTACT_1570]. The instruments/questionnaires that will be used include:
Vineland Adaptive Behavior Scales 2ndEdition (VABS -II)
Wechsler Non- Verbal Scale of Ability
Vital signs
Definitions of notably  abnormal results will be defined in the RAP. Analy sis will consist of
shift table baseline to worst on-treatment result
table with descriptive statistics at baseline, one or several post -baseline time points and 
change from baseline to this/these post -baseline time points.
Columbia Suicide Severity Reporting Scale (C- SSRS)
C-SSRS data will be mapped to Columbia Classification Algorithm for Suicide Assessment 
(C-CASA) as per FDA guidance on suicidality  (Food and Drug Administration 2010). The 
proportion of patients who have compl eted suicide, suicide attempt, preparatory  actions 
toward imminent suicidal behavior, suicidal ideation, and self-injurious behavior without 

[COMPANY_001] Confidential Page 128
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
suicidal intent will be summarized by [CONTACT_1570]. The number of patients with SAEs 
referring to a positive suicidal evaluation will be summarized by  [CONTACT_1570].
Grow th Data
Growth data will only be analyzed as part of the long-term evaluation of everolimus among 
patients under the age of 18, i.e., using patients from the LTE Safet y Set who were under [ADDRESS_761026] deviation score (SDS, 
also called z -score) will be computed for each patient at each time point as:
(height -mean height for that age category) / SD of height for that age category .
The same approach will be used to compute height velocity  SDS, weight SDS and weight 
velocity  SDS.
Descriptive statistics of these endpoints will be presented by [CONTACT_356102] z-scores will 
allow identification of potential outliers. Growth velocity  during the trial will also be 
compared with growth velocity  at baseline (if sufficient pre -baseline data are available).
[IP_ADDRESS] Tolerability
Not appl icable for this study .
10.5.3 Pharmacokinetics
Biofluid concentrations will be expressed in mass per volume units. All concentrations below 
the lower limit of quantitation (LLOQ) or missing data will be reported as such in the 
concentration data listings. Concent rations below the limit of quantitation will be treated as 
zero in summary  statistics.
Validity  of PK samples will be confirmed by [CONTACT_579281].
Only  confirmed PK concentrations will be used in the anal yses.
Drug concentration s for each treatment group (for core phase only) and each visit will be 
summarized by [CONTACT_9086]. Descriptive statistics of drug concentration will include 
arithmetic and geometric mean, median, SD, coefficient of variation (CV), geometric CV, 
minimum and maximum. Zero concentrations will not be included in the geometric mean 
calculation.
To evaluate the effects of everolimus on exposure of AEDs descriptive statistics will be used
to compar ethe pre-dose concentrations of AEDs at Visits 1 and 2 (AED alone) with those at 
Visits 3 and 4 (AED plus everolimus).
To evaluate the impact of EIAED/CYP3A4 inducer and inhibitor on everolimus PK, a linear 
mixed model will be fitted to log -transformed C minconcentration at steady  state including log -
transformed dose, use of EIAED/CYP3A4 inducer and inhibitor and other factor sas 
appropriate as covariates.

[COMPANY_001] Confidential Page 129
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
To explore the relationship between everolimus Cminand the response rate as defined for the 
primary  analysis, a logistic regression model will be used to fit the response data using 
averaged Cminlevels in the maintenance period of the core phase, stratify ing by [CONTACT_579282].
The relationship between everolimus Cminand selected safet y endpoints will also be explored 
by [CONTACT_579283]- based approach.
10.5.4 Patient -reported outcomes
Quality  of life will be assessed using three age -specific questionnaires as follows:
Patients aged ≤ 10 years: Quality  of Life in Childhood Epi[INVESTIGATOR_002]  (QOLCE)
Patients aged 11 -17 years: Quality  of Life in Epi[INVESTIGATOR_579178] -48 
(QOLIE -AD-48)
Patients aged ≥ 18 y ears: Quality  of Life in Epi[INVESTIGATOR_122198] -31-Problems (QOLIE - 31-
P)
Descriptive statistics for the overall quality  (QOL )score and subscale scores will be presented 
by [CONTACT_579284].

[COMPANY_001] Confidential Page 130
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
 
10.7 Interim analy sis
No interim anal ysis is planned for this study .
10.8 Sample size calculation
The sample size was chosen to provide adequate power for the primary  objective comparing 
seizure frequency  between each everolimus arm and the placebo arm. The sample size 
calculation provided here is based exclusively  on response rate, the primary  endpoint used by 
[CONTACT_23357], but it is also expected to provide sufficient patients for the power of the FDA 
primary  endpoint, percentage reduction in seizure frequency . This is because response rate is 
a binary  transformation of percentage reduction in seizure frequency , and therefore likely  to 
be less sensitive owing to the loss of information going from a continuous variable to binary.
It was assumed that response rates would be 15% in the placebo arm and 35% in each of the 
two everolimus arms. That is, there was no a priori strong expectation that the higher targeted 
trough everolimus arm 9-15 ng/mL would deliver a higher response rate than the lower 
targeted trough everolimus arm 3-7 ng/mL , as better efficacy  may be mitigated by [CONTACT_579285] . For this reason, the testing strategy  was to simultaneousl y compare 
each pairwise 
comparison, splitting the significance level, rather than testing hierarchically  starting with the 
higher trough arm for example.
Using nQuery version 6.1 it was determined that a sample size of 355 patients would ensure 
90% power for each of the primary  comparisons of each everolimus arm versus placebo, 
assuming one
-sided 1.25% significance levels for each CMH chi-square test, and assuming 
balanced randomization (i.e., 115 patients per randomization arm) .
Table 10-2 Sample size and po wer for primary  objective
ComparisonOne-sided 
alphaResponse rates under 
alternative hy pothesis Sample Size Power
Everolimus 3 -7 ng/mL arm versus 
Placebo arm 1.25% 35% vs. 15% 230 
(115 vs. 115)90%
Everolimus 9 -15 ng/mL arm versus 
Placebo arm 1.25% 35% vs. 15% 230 
(115 vs. 115)90%
Approximately  [ADDRESS_761027] of this error on the study  power, it was noted 
that placebo patients would be unaffected, and in all likelihood, the majority  of patients in the 
everolimus 3 to 7 ng/ml arm would be expected to achieve everolimus concentr ations within
the targeted range. However, since few patients randomized to the everolimus 9 to 15 ng/ml 
arm would be expected to achieve adequate dosing, it was decided to increase the sample size 
in the everolimus 9 to 15 ng/ml arm by 10 patients .

[COMPANY_001] Confidential Page 131
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
The choice of [ADDRESS_761028] 
been on the everolimus 9 to 15 ng/ml arm. As a worst case, assume all 18 patients were under -
dosed and achieved everolimus concentrations in the 3-7 ng/ml range, and assume that this 
trough range is no better than placebo. Then at the end of the study , among the 115 planned 
patients 
on the everolimus 9 to 15 ng/ml arm, [ADDRESS_761029] a 15% chance of being 
responders (i.e., as placebo arm patients) and [ADDRESS_761030] a 35% chance. Overall this makes 
an expected response rate inthe everolimus 9 to 15 ng/ml arm of 31.9%, in which case the 
power for the comparison with the placebo armdrops to 78%. Other more realistic scenarios 
lead to a smaller loss in power, for example with [ADDRESS_761031] to 
placebo arm response rate, the power is 83%, with 6 patients it is 87%. The sample size 
increase was chosen to protect against loss in power for these more realistic scenarios, where 
the addition of 10 patients to the everolimus 9-15 ng/ml arm improves power to 85% for 12 
under -
dosed patients and to 88% for 6 under- dosed patients.
The sample size increase of 10 patients will be made by [CONTACT_4859] a number of blocks with 
randomization ratio of 1:1:2 in favor of the everolimus 9 to 15 ng/ml arm, with the planned 
sample size becoming 355 patients (115 on placebo arm, 115 patients on everolimus 3 to 7 
ng/ml arm and 125 patients oneverolimus 9 to 15 ng/ml arm; overall randomization ratio of 
1:1:1.09). The required modification of the randomization list will be overseen by [CONTACT_579286] , a [COMPANY_001] employ ee who is not part of the study  team.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulation s (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. A signed and dated statement that the 
protocol and informed consent have been approved by [CONTACT_1201]/IEC/REB must be given to 
[COMPANY_001] before study  initiation. Prior to study start, the investigator is required to sign a 
protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with 
these documents and all of the instructions and procedures found in this protocol and to give 
access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Clinical 
Quality  Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs/REBs and 
regulatory  authorities as required.

[COMPANY_001] Confidential Page 132
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent if incapable of 
doing so, after such consent has been provided by a legally  acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be 
informed about the study  to the extent possible given his/her understanding. If the patient is 
capable of doing so, he/she should indicate assent by  [CONTACT_230792] a separate assent form.
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the proced ures described in the protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a subject’s Informed 
Consent was actuall y obtained will be captured in their CRFs.
[COMPANY_001] will provide to investigators ,in a separate document , a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in 
Section 4.2.
11.5 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltria ls.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
11.[ADDRESS_761032] keepi[INVESTIGATOR_5324], in 
compliance with Section 
4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentialit y of subjects. As part of participating in a 
[COMPANY_001] -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by [CONTACT_1289], to copy) clinical 

[COMPANY_001] Confidential Page 133
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
records for the purposes ofqualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluatio n of the trial. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy  dispensing records, recor ded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and subject files 
and records kept at the pharmacy , at the laboratories, and medico- technical departments 
involved in the clinical trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report form (CRF) is the p rimary  data collection 
instrument for the study . The investigator should ensure the accuracy , completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported 
on the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF 
should be dated, initialed, and explained (if necessary ) and should not obscure the original 
entry . For electronic CRFs an audit trail will be maintained by [CONTACT_1190]. The investigator 
should retain records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
[CONTACT_64122]/or guidelines. The investigator/institution should take 
measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines
11.[ADDRESS_761033] ensure anon ymity of the patients; patients must not be identified by 
[CONTACT_64123]. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.9 Financial disclosures
Financial disclosures should be provided by [CONTACT_579287] -prior to study  start.

[COMPANY_001] Confidential Page 134
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[ADDRESS_761034] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/I EC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.[ADDRESS_761035] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. [LOCATION_006] requires the notification of 
urgent safet y measures within 3 days) but not later than 10 working day s.

[COMPANY_001] Confidential Page 135
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
13 References (available upon request)
Anon (2010) What is TSC? How many  people have TSC? Available f rom 
tsalliance.org/pages.aspx?content=2 (last accessed 17- Oct-2011).
Arulrajah S, Ertan G, Jordan L,et al (2009) Magnetic resonance imaging and diffusion -
weighted imaging of normal- appearing white matter in children and young adults with 
tuberous sclerosis complex. Neuroradiology ; 51(11):781 -
6.
Astrinidis A, Henske EP (2005) Tuberous sclerosis complex: linking growth and energy  
signaling pathways with human disease. Oncogene; 24: 7475-7481.
Baybis M, Yu J, L ee A, et al. (2004) mTOR cascade activation distinguishes tubers from focal 
cortical d ysplasia. Annals of Neurology  56: 478- 487.
Berg A (2006). Defining intractable epi[INVESTIGATOR_30989] y. Advances in Neurology ; 97: 5 -10.
Berg AT, Berkovic SF, Brodie MJ et al (2010) Revised terminology  and concepts for 
organizati on of the epi[INVESTIGATOR_31629]: Report of the Commission on Classification and Terminology . 
Epi[INVESTIGATOR_8330]; 51: 676 –685.
Bolton P, Park R, Higgins J, et al (2002) Neuro
-epi[INVESTIGATOR_579186]. Brain 125: [ADDRESS_761036] JC, Zonnenberg BA et al (2012). Everolimus therap y for 
angiom yolipoma in patients with tuberous sclerosis complex or sporadic 
lymphangioleiom yomatosis: Results from EXI ST-
2.J Clin Oncol; 30(suppl 5):356.
Bissler JJ et al (2013). E verolimus for angiom yolipoma associated with tuberous sclerosis 
complex or sporadic ly mphangioleiom yomatosis (EXI ST-2): a multicentre, randomised, 
double -blind, placebo -controlled trial. Lancet 381: 817 -824.
Chu-Shore CJ, Major P, Camposano S, et al (2010) The natural history  of epi[INVESTIGATOR_579187]. Epi[INVESTIGATOR_8330]; 5: 1236 –1241.
Ciccarelli O, Catani M, Johnansen -Berg H et al (2008) Diffusion
-based tractography  in 
neurological disorders: concepts, applications, and future developments. Lancet n eurology ; 
7(8):715-27.
Clopper C, Pearson S (1934) The use of confidence or fiducial limits illustrated in the case of 
the binomial. Biometrika 26: [ADDRESS_761037] J, et al (2006) Levetiracetam as adjunctive antiepi[INVESTIGATOR_392763] y 
for pa tients with tuberous sclerosis complex: a retrospective open -label trial. Journal of Child 
Neurology  21: 53-57.
Cramer et al (1999) Development of the Quality  of L ife in Epi[INVESTIGATOR_579178]: 
The QOLIE -AD
-48. Epi[INVESTIGATOR_8330]: 40 (8) 1114 -1121.
Cramer et al (2003) Maintenance of improvement in health -related quality  of life during long-
term treatment with levetiracetam: Epi[INVESTIGATOR_30989] y and Behavior 4 (2) 118-123.
Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med; 
355: 1345-56.
Crino PB (2010) The pathophy siology  of tuberous sclerosis complex. Epi[INVESTIGATOR_8330]; 51(s1):27 –29.

[COMPANY_001] Confidential Page 136
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Curatolo P, Verdecchia M, Bombardieri R (2002) Tuberous sclerosis complex: a review of 
neurological aspects. European Journal of Paediatric Neurology ; 6: 15-23.
Curatolo P, Bombardieri, R, Cerminara, C (2006) Current management for epi[INVESTIGATOR_579188]. Curr Opin Neurol; 19(2):119-23.
Dan H, Sun M, Yang L, et al (2002) Phosphatidy linositol 3 -kinase/Akt pathway  regulates 
tuberous sclerosis 
tumor suppressor complex by  [CONTACT_579288]. Journal of 
Biological Chemistry  277: [ZIP_CODE] -[ZIP_CODE].
Delakis I, Moore EM, Leach MO et al (2004) Developi[INVESTIGATOR_007] a quality  control protocol for 
diffusion imaging on a clinical MRI  system. Phy s Med Biol; 49(8):1409- 22.
de Vries PJ, Howe CJ (2007) The tuberous sclerosis complex proteins 
–a GRI PP on cognition 
and neurodevelopment. Trends Mol Med; 13: 319-326.
de Vries P.J. (2010) Targeted Treatments for Cognitive and Neurodevelopmental Disorders in 
Tuberous Scler osis Complex. Neurotherapeutics 7(3), 275-282.
DuBois D, DuBois EF (1916) A formula to estimate the approximate surface area if height
and weight be known. Arch Intern Medicine; 17: 863
-71.
Edwards AD, Arthurs OJ. Paediatric MRI under sedation: is it neces sary? What is the 
evidence for the alternatives? Pediatr Radiol;41(11):1353 -64
El-Hashemite N, Walker V, Zhang H, et al (2003) Loss of Tsc1 or Tsc2 induces vascular 
endothelial growth factor production through mammalian target of rapam ycin. Cancer 
Research 63: 5173 -5177.
Erlich S, Alexandrovich A, Shohami E, et al (2007) Rapam ycin is a neuroprotective treatment 
for traumatic brain injury. Neurobiology  of Disease 26: 86-93.
Ess KC (2006) The Neurobiology  of Tuberous Sclerosis Complex. Seminars in Child 
Neuro logy 13.
European Medicines Agency  (EMA) (2010). Committee for medicinal products for human 
use Guideline on clinical investigation of medicinal products in the treatment of epi[INVESTIGATOR_579189] .
Evans AC (2006) The NIH MRI  study  of normal brain development. Neuroimage; 30(1):184 -
202.
FDA (2010) Guidance for Industry  -Suicidality : Prospective assessment of occurrence in 
clinical trials .
Franz D, Tudor C, Leonard J (2000) Topi[INVESTIGATOR_579190] y for tuberous sclerosis complex -
associated seizures. Epi[INVESTIGATOR_8330] 41:
87.
Franz D, Leonard J, Tudor C, et al (2001) Oxcarbazepi[INVESTIGATOR_281099] y of epi[INVESTIGATOR_579191]. Journal of Child Neurology  16.
Franz D, Leonard J, C T, Chuck G, Egelhoff J (2001) Levetiracetam therapy of epi[INVESTIGATOR_30989] y in 
tuberous sclerosis. Journal of C hild Neurology  16: 679.
Franz D, Tudor C, Leonard J, et al. (2001) Lamotrigine therapy  of epi[INVESTIGATOR_579191]. Epi[INVESTIGATOR_8330] 42: 935 -940.

[COMPANY_001] Confidential Page 137
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Franz D, et al, (2013) Efficacy  and safet y of everolimus for subepend ymal giant cell 
astrocy tomas associated wi th tuberous sclerosis complex (EXI ST-1): a multicentre, 
randomised, placebo -controlled phase 3 trial. Lancet 381: 125-132.
Friedman L and Glover GH (2006a) Reducing interscanner variability of activation in a 
multicenter fMRI study: controlling for signal -to-fluctuation -noise -ratio (SFNR) differences. 
Neuroimage; 33(2):471 -81.
Friedman L and Glover GH (2006b) Report on a multicenter fMRI quality assurance protocol. 
J Magn Reson I maging; 23(6):827-39.
Garaci FG Floris R, Bozzao A et al (2004) Increased brain apparent diffusion coefficient in 
tuberous sclerosis. Radiology ; 232(2):461 -5.
Goh S, Butler W, Thiele EA (2004) Subepend ymal giant cell tumors in tuberous sclerosis 
complex. Neurology ; 63: 1457 -61.
Goh S, Kwiatkowski D, Dorer D et al (2005) Infantile spa sms and intellectual outcomes in 
children with tuberous sclerosis complex. Neurology  65: 235-238.
Gomez MR (1999) An overview the tuberous sclerosis complex. Gann Monograph on Cancer 
Research; 46: 17-25.
Goncharova E, Goncharov D, Eszterhas A, et al. (2002) Tuberin regulates p70 S6 kinase 
activation and ribosomal protein S6 phosphory lation. A role for the TSC2 tumor suppressor 
gene in pulmonary  lymphangioleiom yomatosis (LAM). Journal of Biological Chemistry  277: 
[ZIP_CODE]-[ZIP_CODE].
Gong R, Park CS, Abbassi NR, et 
al (2006) Roles of glutamate receptors and the mammalian 
target of rapam ycin (mTOR) signaling pathway in activity -dependent dendritic protein 
synthesis in hippocampal neurons. Journal of Biological Chemistry  281: [ZIP_CODE] -[ZIP_CODE].
Granata T, Marchi N, Carlton E , et. al. (2009) Management of the patient with medically  
refractory  epi[INVESTIGATOR_002] . Expert Rev. Neurother. 9(12): 1791-1802.
Holmes G, Stafstrom C (2007) The Tuberous Sclerosis Study  Group. Epi[INVESTIGATOR_8330]; 48(4): 617 –
630.
Huang J, Dibble C, Matsuzaki M, et al (2008) The TSC1 -TSC2 complex is required for 
proper activation of mTOR complex 2. Molecular and Cellular Biology  28: 4104 -4115.
Huang J, Manning B (2008) The TSC1-TSC2 complex: a molecular switchboard controlling 
cell growth. Biochemical Journal; 412: 179 -190.
Hunt A (1983) Tuberous sclerosis: A survey  of 97 cases I: Seizures, pertussis immunisation 
and handicap. Dev Med Child Neurol; 25:346-349.
Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC -mTOR pathway  in 
human disease. Nat Genet; 37: 19 -24.
Jansen F, van Huffelen AC, Algra A,(2007) Epi[INVESTIGATOR_579192]: A 
Systematic Review. Epi[INVESTIGATOR_8330]; 48(8) 1477-1484.
Jobst B (2009) Treatment algorithms in refractory partial epi[INVESTIGATOR_30989] y. Epi[INVESTIGATOR_8330] ; 50 (s8) : 51 -56.
Jansen FE, Vincken KL, et al (2008) Cognitive impairment in tuberous sclerosis complex is a 
multifactorial condition. Neurology ; 70(12):916 -23.

[COMPANY_001] Confidential Page 138
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Joinson C, O'Callaghan F, Osborne J, et al. (2003) Learning disabilit y and epi[INVESTIGATOR_579193]. Psychological 
Medicine 33: 335 -344.
Karian VE, Burrows PE et al (2002) The development of a pediatric radiology  sedation 
program. Pediatr Radiol; 32(5):348-53.
Keator DB Grethe JS, Marcus D et al (2008)
A national human neuroimaging collaboratory  
enabled b y the Biomedical I nformatics Research Network (BIRN). IEEE Trans Inf Technol 
Biomed; 12(2):162 -72.
Kenerson H, Dundon TA, Yeung RS (2005) Effects of rapam ycin in the Eker rat model of 
tuberous sclerosis complex. Pediatr Res; 57: 67 -75.
Kossoff E, Thiele E, Pfeifer H, et al (2005) Tuberous sclerosis complex and the ketogenic diet. 
Epi[INVESTIGATOR_8330]; 46: 1684-1686.
Krishnan ML, Commowick O, Jeste SS et al (2010) Diffusion features of white matter in 
tuberous sclerosis with tractograph y. Pediatric neurology ; 42(2):101-6.
Krueger DA, Care MM, Holland K, et al (2010) Everolimus for subepend ymal giant -cell 
astrocy tomas in tuberous sclerosis. N Eng J Med; 363:1801 -11.
Krueger DA, Wilfong AA, Holland- Bouley  K, et al (2013) Everolimus treatment of refractory  
epi[INVESTIGATOR_579194]. e publication .Kwan P, Brodie M (2010). 
Definition of refractory  epi[INVESTIGATOR_002] : defining the indefinable? Lancet Neurology ; 9: 27 -
29.
Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: a GAP at the crossroads of 
multiple signaling pathway s. Hum Mol Genet; 14 (suppl 2): R251 -8.
Kwon C -H, Luikart B, Powell CM, et al. (2006) Pten Regulates Neuronal Arborization and 
Social I nteraction in Mice. Neuron 50: 377-388.
Lenz G, Avruch J (2005) Glutamatergic reg ulation of the p70S6 kinase in primary  mouse 
neurons. Journal of Biological Chemistry  280: [ZIP_CODE] –[ZIP_CODE].
Levine NB, Collins J, Franz DN, et al (2006) Gradual formation of an operative corridor b y 
balloon dilation for resection of subependy mal giant cell ast
rocytomas in children with 
tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim I nvasive 
Neurosurg; 49: 317 -20.
Luat AF, Makki M, and Chugani HT (2007). Neuroimaging in tuberous sclerosis complex. 
Curr Opin Neurol; 20(2):142-50.
Ma L , Chen Z, Erdjument -Bromage H, et al(2005) Phosphory lation and Functional 
Inactivation of TSC2 by  [CONTACT_579289]: I mplications for Tuberous Sclerosis and Cancer Pathogenesis. 
Cell 121: 179-193.
Manning B, Tee A, Logsdon M, et al (2002) Identification of the t uberous sclerosis complex -
[ADDRESS_761038] tuberin as a target of the phosphoinositide 3 -kinase/akt 
pathway . Molecular Cell 10: 151 -162.
Marcotte L, Crino PB, (2006) The neurobiology  of the tuberous sclerosis complex. 
Neuromolecular Medicine ; 8 (4): 531 -546.

[COMPANY_001] Confidential Page 139
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Meikle L , Talos D, Onda H, et al. (2007) A mouse model of tuberous sclerosis: neuronal loss 
of Tsc1 causes d ysplastic and ectopic neurons, reduced m yelination, seizure activity, and 
limited survival. Journal of Neuroscience 27: 5546-5558.
Meikle L , Pollizzi K, Egnor A, et al (2008) Response of a neuronal model of tuberous 
sclerosis to mammalian target of rapam ycin (mTOR) inhibitors: effects on mTORC1 and Akt 
signaling lead to improved survival and function. J Neurosci; 28:5422- 5432.Mori S, Crain BJ, 
Chacko VP, et al (1999) Three -dimensional tracking of axonal projections in the brain by  
[CONTACT_9252]. Ann Neurol; 45(2):265-9.
Morrison PJ (2009) Tuberous Sclerosis: Epi[INVESTIGATOR_623] , Genetics and Progress towards 
Treatment. Neuroepid emiology ; 33(4):342-343
Nagy  Z, Weiskopf N, Alexander DC, et al (2007) A method for improving the performance of 
gradient s ystems for diffusion -weighted MRI. Magn Reson Med; 58(4):763-8.
Napolioni V, Moavero R, Curatolo P (2009) Recent advances in neurobiology  of Tuberous 
Sclerosis Complex. Brain & Development; 31:104 –113
Naray anan U, Nalavadi V, Nakamoto M, et al (2007) FMRP phosphory lation reveals an 
immediate -early signaling pathway  triggered by  [CONTACT_19313] I mGluR and mediated by  [CONTACT_23816]2A. 
Journal of Neur oscience 27: [ZIP_CODE]
-[ZIP_CODE].
Nock M, et al (2013) Prevalence, Correlates, and Treatment of Lifetime Suicidal Behavior 
Among Adolescents. JAMA Psy chiarty ; 70(3):300 -310.
Onda H, Lueck A, Marks PW, et al (1999) Tsc2(+/ -) mice develop tumors in multiple sites 
that express gelsolin and are influenced b y genetic background. J Clin I nvest; 104: 687 -95.
Orlova K, Crino P, (2010). The tuberous sclerosis complex. Annals of the [LOCATION_001] 
Academ y of Sciences; 1184: 87–105.
Osborne JP, Fry er A, Webb D (1991) Epi[INVESTIGATOR_579195]. Ann N Y Acad 
Sci ;615:125
-7
Peng T, Golub TR, Sabatini DM (2002) The immunosuppressant rapam ycin mimics a 
starvation -like signal distinct from amino acid and glucose deprivation. Molecular and 
Cellular Biology  22: 5575 -5584.
Peng SS, Lee WT, Wang YH, et al (2004) Cerebral diffusion tensor images in children with 
tuberous sclerosis: a preliminary  report. Pediatr Radiol; 34(5):387 -92.
Raab -Graham K, Haddick P, Jan Y, et al (2006) Activity -and mTOR -dependent suppression 
of Kv1.1 channel mRNA translation in dendrites. Science 314: 144-148.
Ruiz -Alzola J, Westin CF, Warfield SK et al (2002) Nonrigid registration of 3D tensor 
medical data. Med Image Anal; 6(2):143 -61.
Sabaz, et. Al (2003) Validation of the Quality  of Life in Childhood Epi[INVESTIGATOR_579196] y patients .Epi[INVESTIGATOR_579197]; 4, (6): 680-691.
Simao G, Ray baud C, Chuang S, et al (2010) Diffusion tensor imaging of commissural and 
projection white matter in tuberous sclerosis complex and correlation with tuber load. Am J 
Neuroradiol; 31(7):1273 -7.
Schulte -Uentrop L and Goepfert MS. Anaesthesia or sedation for MRI in children. Curr Opin 
Anaesthesiol.; 23(4):513 -7.

[COMPANY_001] Confidential Page 140
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Smith K, Jajodia S, Swarup V, et al (2004) Enabling the sharing of neuroimaging data through 
well-defined intermediate levels of visibility . Neuroimage; 22(4):1646 -56.
Sparagana S, Delgado M, Batchelor L, et al (2003) Seizure Remission and Antiepi[INVESTIGATOR_579198]. Arch Neurol. 2003;60:1286 -
1289.
Tsai Pand Sahin M. (2011). Mechanisms of neurocognitive d ysfunction and therapeutic 
considerations in tuberous sclerosis complex. Curr. Opin. Neurol; 24(2):106-13.
Tavazoie S, Alvarez V, Ridenour D, et al (2005) Regulation of neuronal morphology  and 
function b y the tumor suppressors Tsc1 and Tsc2. Nature Neuroscience 8: 1727 -1734.
Tillema JM. L each J L, Krueger DA, et al. (2012). Everolimus alters white matter diffusion in 
tuberous sclerosis complex. Neurology ; 78(8):526-31
Tischmey er W, Schicknick H, Kraus M, e t al. (2003) Rapam ycin-sensitive signalling in long -
term consolidation of auditory  cortex -dependent memory . European Journal of Neuroscience 
18: 942-950.
Tofts PS, L loyd D, Clark CA, et al (2000) Test liquids for quantitative MRI measurements of 
self-diffu sion coefficient in vivo. Magn Reson Med; 43(3):368 -74.
Uhlmann EJ, Wong M, Baldwin RL , et al (2002) Astrocy te-specific TSC1 conditional 
knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol; 52: 285-96.
Waltereit R, Welzl H, Dichgans J, et al. (2006) Enhanced epi[INVESTIGATOR_49564] -like memory  and kindling 
epi[INVESTIGATOR_579199] a rat model of tuberous sclerosis. Journal of Neurochemistry  96: 407 -413.
Waltereit R, Japs B, Schneider M, et al (2011) Epi[INVESTIGATOR_579200]2 haploinsuffici ency  lead to 
autistic -like social deficit behaviors in rats, Behavior Genetics; 41(3): 364- 372.
Widjaja E, Simao G, Mahmoodabadi SZ, et al (2010) Diffusion tensor imaging identifies 
changes in normal -appearing white matter within the epi[INVESTIGATOR_579201]. Epi[INVESTIGATOR_5612]; 89(2 -3):246-53.
Wiersma -Meems R, Van Minnen J, Sy ed N (2005) Sy napse formation and plasticity : The 
roles of local protein synthesis. Neuroscientist 11: 228 -237.
Wong M (2008). Mechanisms of epi[INVESTIGATOR_579202]. Epi[INVESTIGATOR_8330]; 
49(1):8-21.
Wong IY and Shortliffe LD (2009) The management of renal angiomy olipomas in a patient 
with tuberous sclerosis. Nat Clin Pract Urol; 6(3):168-172.
Wong M (2010) Mammalian target of rapam
ycin (mTOR) inhibition as a potential 
antiepi[INVESTIGATOR_579203]: From tuberous sclerosis to common acquired epi[INVESTIGATOR_31629]. Epi[INVESTIGATOR_8330]; 
51(1):27–36.
Zeng LH, Xu L, Gutmann DH, et al (2008) Rapamy cin prevents epi[INVESTIGATOR_30989] y in a mouse model of 
tuberous sclerosis complex. Annals of Neurology  63: 444 -453.
Zhang Y, Gao X, Saucedo L , et al. (2003) Rheb is a direct target of the tuberous sclerosis 
tumour suppressor proteins. Nature Cell 5: 578- 581.
Zhou Z and Liu BJ (2005) HI PAA compliant auditing s ystem for medical images. Comput 
Med I maging Graph; 29(2 -3):235-41.

[COMPANY_001] Confidential Page 141
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
Zou KH, Greve DN, Wang M, et al. (2005). Reproducibility  of functional MR imaging: 
preliminary  results of prospective multi -institutional study  performed b y Biomedical 
Informatics Research Network. Radiology ; 237(3):781 -9.
Zhu T,Hu R, Qiu X, et al (2011) Quantification of accuracy  and precision of multi -center DT I 
measurements: a diffusion phantom and human brain study . Neuroimage; 56(3):1398 -411.

[COMPANY_001] Confidential Page 142
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
14 Appendix A :Using Diffusion Tensor Imaging (DTI) w ith 
Tractography  to Measure the Treatment Effect of Everolimus 
in Tuberous Sclerosis Complex (TSC) Patients w ith Epi[INVESTIGATOR_002] : 
An EXIST -3 Sub -stud y
14.1 SUMMA RY OF DTI SUB -STUDY OBJECTIVES A ND RATIONA LE
Tuberous scler osis complex (TSC) is a genetic disorder with an incidence at birth of [ADDRESS_761039] common, occurring in 80-90% of patients, and often 
the seizures are severe, unremitting, and uncontrolled by [CONTACT_579290].
Strong preclinical evidence and more recent phase II human clinical trials reveal that 
treatment with the mTOR inhibitor everolimus can improve seizure control in TSC patients 
who are refractory  to conventional anticonvulsant treatments. EXIST -[ADDRESS_761040]. We propose to assess this hy pothesis through analy sis of 
white matter integrity and connectivity  using diffusion tensor imaging (DTI) with 
tractograph y and advanced EEG technology  in a subset of EXIST -3 participants through the 
following aims:
Asse ssthe hypothesis that DTI measures of white matter integrity improve after 
treatment with everolimus in epi[INVESTIGATOR_579204]. Regions of interest (ROI) 
will be determined and analy zed for before and after treatment changes in the everolimus 
and plac ebo arms. 
Assess the hypothesis that overall and specific tuber epi[INVESTIGATOR_579205]. 1 hour EEG utilizing a customized EEG protocol for 
recording high frequency oscillations (HFO) will be obtained at time points coinci ding 
with MRI  DTI studies. HFO measures (gamma, ripples, fast ripples) will be determined.
14.[ADDRESS_761041] demonstrated clear efficacy  and favorable clinical tolerability  of 
everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR) in the treatment of 
subepend ymal giant cell astrocy toma (SEGA) and angiom yolipoma (AML) in patients with 
tuberous sclerosis complex (TSC) (Bissler et al 2012;Franz et al 2012) .FDA approval for 
these indications occurred in 2010 and 2012, respectivel y.Relevant to the current proposal, 
improvement in seizure frequency  and other neurological and behavioral aspects of TSC has 
been seen in SEGA patients treated with everolimus (Krueger et al 2010) .We recentl y 
completed a phase II clinical trial confirming these earlier results in TSC epi[INVESTIGATOR_579206], in which seizure frequency  was reduced in 17 of 20 subjects (median 
reduc tion =73%)after 12 weeks of therapy  (clinicaltrials.gov: [STUDY_ID_REMOVED], Krueger et al 
2013). The current phase III double -blind randomized placebo control ledtrial (EXIST -3, 
CRAD001 M2304) is designed to confirm these earlier phase II results. This sub-study  of 

[COMPANY_001] Confidential Page 143
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
EXIST-3 subjects is designed to evaluate the value of diffusion tensor imaging (DTI) 
tractograph y accom panied by [CONTACT_579291] (HFO) EEG analysis as an 
exploratory  measure of clinical benefit in TSC patients with epi[INVESTIGATOR_579207].
As our understanding of TSC matures, it is becoming clear that non-tuber abnormalities, 
especiall yin the white matter (WM) and subcortical areas, are strongl y associated with 
neurological outcome (Wong 2008 ;Tsai 2011) . Diffusion tensor imaging (DTI), a specialized 
type of magnetic resonance imaging (MRI) of the brain that can be combined with 
tractog raphy to determine fascicle structures and connections in matching brain anatom y
(Ciccarelli et 
al 2008; Mori et al 1999), has been used to detect abnormities in TSC that 
appeared normal with conventional MRI  technique s (Garaci et al 2004; Peng et al 2004; Luat 
et 
al 2007; Arulrajah et al 2009; Krishnan et al 2010 ,Simao et al 2010 ; Widjaja et al 2010).
Furthermore, we have shown that DTI measures, such as fractional anisotropy  (FA), radial 
diffusivity  (RD), and mean diffusivity  (MD), improve 
in TSC patients with SEGA treated 
with everolimus (Tillema et al 2012 ). Comparing baseline val ues with those acquired after 12 -
18 months of treatment, a significant change in FA was observed in the corpus callosum, 
internal capsule, and geniculocalcarine region (p < 0.05). Mean change in FA was 0.04 (p < 
0.01), driven primarily  by a significant decrease in RD, and was independent of SEGA 
response to treatment. These findings suggest that WM integrit y can be improved with mTOR 
inhibition in TSC individuals and encourage systematic analy sis of the relationship between 
DTI and everolimus treatment resp onse in epi[INVESTIGATOR_579208].
Analy sis of DTI with tractography  in the current context can be further enhanced when 
accompanied with current state of the art advanced EEG analy sis that includes high frequenc y 
oscillations (HFO EEG). HFO EEG is a powe rful technique for examining the energy  in any 
single frequency  band as an indicator of oscillatory synchrony  and therefore local functional 
integration. In preliminary experiments, we examined HFO patterns in children with TSC and 
epi[INVESTIGATOR_579209] a particularl y high predictive value of 
epi[INVESTIGATOR_579210] 
(Wu, Bebin, unpublished). Specifically , traditional EEG demonstrated a sensitivity  of 83% 
and specifici ty of 50% (n=10), whereas HFO EEG was associated with 100% sensitivity  and 
specificit y (n=8)
EXIST-3 (C RAD001M2304) is a three -arm, randomized, double -blind, placebo- controlled 
study  to evaluate the efficacy  and safet y of two trough- ranges of everolimus given as 
adjunctive therap y in patients with TSC who have refractory  partial -onset seizures. The study  
consists of three phases (1) baseline observation period x 8 weeks; (2) core treatment phase 
from randomization to primary  endpoint x 18 weeks; and (3) extension phase from week [ADDRESS_761042] patient has completed the core phase. Target enrollment for the 
overall study  is approximately  355 subjects between ages 2 and 65(or 1 and 65 in Europe) , 
with partial -onset seizures refractory  to current medical therap y (failed 2 or more anti-
epi[INVESTIGATOR_579211]), and diagnosis of TSC. The study  will be conducted globall y, involving 
100-[ADDRESS_761043]-3 patients (about 15patients ) will be 
used to assess the bene fit of DTI tractograph y combined with HFO EEG analysis as an 
independent bi omarker of everolimus efficacy .
A number of important considerations must be accounted for in ensuring the successful 
acquisition of comparable data at multiple sites. These include logistical factors such as study 

[COMPANY_001] Confidential Page 144
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
protocol compliance, compliance with HIPAA regulations, and technical performance factors 
of imaging equipment (Smith et al 2004; Zhou and Liu 2005: Keator et al 2008). For MRI, 
differences in scanner make, model, field strength, field homogeneity , slew rates, and image 
reconstruction may influence data acquisition (Friedman and Glover 2006a ;Friedman and 
Glover 2006b). The quantitative assessment of acquired data may be influenced by [CONTACT_579292]- acquisition image analy sis, including approaches for identify ing 
and compensating for certain image artifacts. Recent publications have described successful 
multi- site diffusion imaging protocols, with effective assessment and management of inter-
site and intra-site variability  related to site-dependent and time-varying characteristics of 
imaging equipment (Zhu et al 2011; Evans 2006). Best practice for data quality  assessment is 
to estimate accuracy  with respect to a gold-standard phantom, and to characterize 
measurement precision via one of test-retest 
imaging, imaging with multiple replications, or 
bootstrap estimation.
It became clear during the [ADDRESS_761044] 12 months of existence, having been awarded more than $12.5M 
from the National Institutes of Health for clinical trials targeting epi[INVESTIGATOR_30989] y and a utism in TSC .
One of the current NIH
-funded clinical trials of the TSC-CRC includes sophisticated DTI 
imaging and advanced HFO EEG analy sis.As part of the study , the TSC-CRC alread y has 
identified personnel at each site familiar with acquisition and taske d specificall y to ensure 
quality  control. 3T MRI  scanners at each of the sites will be calibrated every  6 m onths using 
both the American College of Radiology  (ACR) and ‘live human’ (live volunteer who 
undergo repeated imaging at each site) phantoms to ensure DTI accuracy across all the sites
(Friedman 2006; Zhu et all 2011 ;Evans 2006; Nagy  et al 2007 ; Delakis et al 2004 ;Tofts et al 
2000; Zou et al 2005 ) .Similar standardization and quality  assurance procedures are in place at 
each location for HFO EEG. The advantage of utilizing TSC-CRC sites to conduct this DTI 
sub-study  in EXIST -[ADDRESS_761045]-3 if DTI sub- study  participation is declined.

[COMPANY_001] Confidential Page 145
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
14.3.[ADDRESS_761046]-3 will be eligible for participation in the DTI sub-study  and 
same inclusion/exclusion criteria for EXIST -3 will apply  for this DTI sub -study .
Inclusion criteria for participation in DTI  sub-study :
Meet allinclusion criteria for enrollment in EXI ST-3
Provide written, informed consent for participation in the optional DTI  sub-study  anal ysis
Exclusion criteria for participation in DTI  sub- study :
Ensure no exclusion criteria for enrollment in EXIST -3 apply
Contrai ndications to MRI scanning, such as metal implants/non -compatible medical 
devices or medical conditions
14.3.3 Sub-Study Procedures
[IP_ADDRESS] Overview
EXIST-[ADDRESS_761047] EEG 
and MRI  will be performed prior to randomization and study  
drug initiation (visit 2, week 0) and will serve as the baseline. The follow -up EEG and MRI 
will be performed at the end ofthe core phase (visit 11, week 18). Blinding rules in place for 
EXIST-[ADDRESS_761048] for the DTI sub-study  analysis (DTI investigators will remain 
blinded to treatment group of participating subjects until final unblinding and analysis of 
entire EXIST -3 dataset).
[IP_ADDRESS] Informed Consent
All prospective subjects and their families will have the DTI sub-study  explained by a 
member of the research team or a member of their staff. Participation in the DTI sub-study 
will be optional and not required for participation in EXIST -
3.The nature of sub-study  tests 
and procedures will be explained together with potential hazards and possible adverse 
reactions. The written informed consent, and patient assent with parental permission, if 
applicable, will be obtained prior to the performance of any screening evaluation, per each 
site’s I RB guidelines.
[IP_ADDRESS] DTI A cquisition
Both structural and diffusion images will be acquired. Sedation will be used if needed to limit 
motion artifact during image acquisition. DTI data will be pre-processed with alignment to 
T1-weighted MPRAGE images to help compensate for eddy currents and patient motion to 
ensure maximum data quality .
3-Telsa MRI  scanners will be used at all sites for all subject 
imaging in the DTI sub-study .Image acquisition protocols will be the same as those for the 
TACERN (TSC Autism Center of Excellence Network) study  conducted by [CONTACT_579293]-CRC, to 
minimize need for duplicative standardization, allow comparison of results across studies, and 
to provide recommended TSC clinical standard of care brain surveillance imaging. Specific 
sequences will include anatomical imaging, diffusion tensor imaging, functional imaging ,and 
post-gadolinium imaging .

[COMPANY_001] Confidential Page 146
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
[IP_ADDRESS] HFO EEG A cquisition
As for DTI, EEG acquisition and recording protocols will be the same as those for the 
TACERN study  conducted by  [CONTACT_579293] -CRC, to minimize need for duplicative standardization, 
allow comparison of results across studies, and to provide recommended TSC clinical 
standard of care EEG recording. One hour of recording is generall y sufficient for HFO 
analysis and negates the need for 24 -hour EEG used in previous TSC everolimus clinical trials.
Data will be acquired utilizing a 23 electrode enhanced version of the International 10-20 
System, with 9mm gold-disc electrodes to yield a frequency  resolu
tion of 0.5Hz. Sedation for 
EEG is not allowed and if performed on the same day as MRI  requiring sedation, EEG should 
be obtained prior to the MRI  or on a different day . Subjects should be sleep -deprived as much 
as tolerated and scheduled for early to mid-morning or around subjects’ usual nap times to 
increase the likelihood of both awake and sleep epochs being captured during the recording 
session.
[IP_ADDRESS] Data Transfer for Central A nalysis
Local sites will be able to review imaging and EEG studies for clinical and safet y purposes, 
where previous examinations will be available for comparison. For the DTI sub-study , 
imaging and EEG data will be transferred to  for centralized analysis.Prior to 
transfer, all data will be anony mized at the local site with the study  type, subject ID, and 
acquisition date as the only  identifiers. The local site will retain a copy  of the entire study  data 
(MRI  and EEG) until receipt by  [CONTACT_579294]. Standard redundancy  and backup 
procedures will be followed at  to ensure data is not lost or compromised until 
analysis is complete. TSC-CRC investigators involved in DTI and HFO EEG analy sis will be 
given secure access to  servers with the relevant anon ymized data sets necessary  for 
the anal yses ou tlined in Section [IP_ADDRESS].
14.3.4 Sub-Study Analysis and Statistical Considerations
[IP_ADDRESS] Analytical Methods
Specific, reproducible, regions of interest (ROI) will be determined, following known 
anatomy , to evalua te multiple white matter regions. These will include (i) the genu and 
splenium of the corpus callosum, (ii) anterior and posterior limb of the 
internal capsule, and 
(iii) the geniculocalcarine tract. The following four tensor parameters will be determined for 
each of the three ROIs: fractional anisotrop y, radial diffusivit y, axial diffusivity  and mean 
diffusivity , making a total of 12 different analyses. HFO EEG will be quantified in three 
frequency  bands, by  [CONTACT_579295] ,for gamma (30 -100Hz), 
ripple frequencies (100-250Hz), and fast ripple frequencies (250-500Hz). Data from the 
regions will be combined, providing three EEG parameters for gamma, ripple and fast ripple 
frequencies .
Change from baseline in the 12 DTI paramet ers and the 3 EEG parameters will be 
summarized using appropriate descriptive statistics between the pooled everolimus arms and
the placebo arm. Other endpoints include change from baseline in tuber burden, and change 
from baseline in number of regions of the brain with EEG abnormalities. 

[COMPANY_001] Confidential Page 147
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
The sample size of about1 5 patients in this sub-study  was chosen for practical reasons rather 
than on the basis of statistical power.
14.4 POTENTIA L BENEFITS, RISKS, A ND PRECA UTIONS
14.4.1 Potential Benefits of the DTI Sub- study
[IP_ADDRESS] Potential direct benefit to class
EXIST-3 is a randomized, placebo -controlled, double -blinded, phase III clinical trial using the 
investigational drug everolimus to evaluate its clinical effectiveness as a treatment of 
refractory  epi[INVESTIGATOR_30989] y in TSC. The DTI sub-study , using advanced non-invasive imaging and 
electroencephalograph y (EEG) technologies, provides additional objective assessment 
approaches to assess treatment 
efficacy  and safet y.The DTI sub-study  will do so without the 
need to involve the entire study population (n=15 vs n=[ADDRESS_761049]-3), improving study 
feasibility  and limiting patient time and effort within the group. The results of the DTI sub-
study  may further support IND application for FDA approval of everolimus for the treatment 
of refractory  epi[INVESTIGATOR_30989] y in this study  population by [CONTACT_579296]. It would also provide supporting evidence for the use of DTI and 
HFOEEG in the future as non-invasive, objective measures of everolimus treatment effect
should everolimus be approved for this indication .
[IP_ADDRESS] Potent ial direct benefit to subjects
TSC patients already undergo MRI  surveillance annually  to monitor for the emergence or 
progression of subependy mal giant cell astrocy toma (SEGA) (2012 International TSC 
Consensus Conference, manuscript in preparation). More frequent MRI  may be indicated if 
SEGA is present and being followed clinically before implementing medical or surgical 
intervention. In the process of DTI acquisition for the present study , MRI  obtained has the 
potential to identify  SEGA emergence or progression sooner than what would be realized 
otherwise. Like MRI, convent ional EEG in TSC is recommended -at time of diagnosis and 
periodicall y thereafter according to clinical need in refractory  epi[INVESTIGATOR_30989] y patients. The purpose 
of conventional EEG is to assess for epi[INVESTIGATOR_579212], both 
of which will be frequent 
in patients participating in EXIST-3.Participation in the DTI sub-
study  will provide such patients 
two opportunities to non-invasively  assess for these findings 
that in turn may have important secondary  impact on development, cognitive function, and 
behavior that can directl y influence medical decision -making for the same.
Participants also will have potential for benefit after DTI and HFO analysis is completed. The 
previously  discussed Phase II Everolimus for SEGA in TSC clinical trial is now in extension 
phase, with patients treated now out to 5+ years.At the time of most recent analy sis, in which 
all patients 
were treated at least 2 years, patient -reported seizure frequency  demonstrated 
improvement at 12 and 24 months that was not evident in all participants at the conclusion of 
the main study  phase (6 months) ( Krueger et al 2013 ). In fact, improvement seems to be more 
evident the longer treatment is continued (Krueger et 
al 2013). Thus evidence of DTI or HFO 
EEG improvement within individual study  participants could provide compelling evidence to 
pursue continued treatment with everolimus on a clinical basis even if clear improvement in 
seizure frequency  isnotimmediately  evident .

[COMPANY_001] Confidential Page 148
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
14.4.[ADDRESS_761050] agent 
(gadolinium) can rarely cause hypersensitivity  or skin reactions in susceptible individuals and 
individuals with severely compromised renal clearance. In both instances (incompatib le 
medical devices or medical conditions), such patients are excluded from participation in the 
EXIST-[ADDRESS_761051], MRI  in TSC refractory  epi[INVESTIGATOR_579213]
(Curatolo et al 2002; Jansen et al 2008 ).This is particularl y true for DTI acquisition, which is 
additio nally  susceptible to motion artifact and eddy  currents and other distortions.
Complications with sedation are rare
(Karian et al 2002), but include risk of over-sedation, 
respi[INVESTIGATOR_2477], and post-sedation effects on mental status, behavior, and cognitive 
performance (Schulte -Uentrop and Goepfert 2010 ; Edwards and Arthurs 2011 ).
14.4.[ADDRESS_761052]-3 participation is considered to be of 
more than minimal risk with potential for direc t patient benefit. The only additional risk of 
DTI sub-study  participation is encountered with sedation required for MRI  during the 
acquisition of DTI. This risk is countered by [CONTACT_579297]-study ’s potential to provide an 
objective measures to treatment effect and establish evidence for everolimus mechanism of 
action in treating epi[INVESTIGATOR_579214] 149
Amended Protocol Version 03 (Clean) Protocol No. CRAD001M2304
subjects needed for the analysis (direct benefit to overall study  and indirect benefit to 
subjects). Direct benefit to DTI sub-study  participants is also possible through heightened 
MRI  surveillance for SEGA emergence/progression and 
EEG monitoring for epi[INVESTIGATOR_579215]. DTI and HFO analysis may also provide direct evidence of treatment 
benefit onan individual basis that may prove useful for future treatment decisions involving 
patient care with everolimus after completion of EXI ST-3.Altogether, both EXIST-[ADDRESS_761053] patient benefits.
